WO2012168162A1 - Benzocycloheptene acetic acids - Google Patents

Benzocycloheptene acetic acids Download PDF

Info

Publication number
WO2012168162A1
WO2012168162A1 PCT/EP2012/060455 EP2012060455W WO2012168162A1 WO 2012168162 A1 WO2012168162 A1 WO 2012168162A1 EP 2012060455 W EP2012060455 W EP 2012060455W WO 2012168162 A1 WO2012168162 A1 WO 2012168162A1
Authority
WO
WIPO (PCT)
Prior art keywords
tetrahydro
yloxy
benzocyclohepten
acetic acid
methyl
Prior art date
Application number
PCT/EP2012/060455
Other languages
French (fr)
Inventor
Fariborz Firooznia
Paul Gillespie
Tai-An Lin
Sung-Sau So
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Priority to JP2014514009A priority Critical patent/JP2014522407A/en
Priority to CA2837146A priority patent/CA2837146A1/en
Priority to EP12725741.8A priority patent/EP2718264B1/en
Priority to MX2013013849A priority patent/MX2013013849A/en
Priority to CN201280027840.6A priority patent/CN103596925A/en
Priority to RU2013154733/04A priority patent/RU2013154733A/en
Priority to KR1020137034448A priority patent/KR20140041589A/en
Priority to BR112013030264A priority patent/BR112013030264A2/en
Publication of WO2012168162A1 publication Critical patent/WO2012168162A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/67—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfonamide groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/32—Sulfur atoms
    • C07D213/34—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/12—One of the condensed rings being a six-membered aromatic ring the other ring being at least seven-membered

Definitions

  • the present invention relates to organic compounds useful for therapy and/or prophylaxis in a mammal of an inflammatory disease or disorder, and in particular to arylsulfonylamino-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy-acetic acids, their manufacture, pharmaceutical compositions containing them and their use as CRTH2 antagonists.
  • Prostaglandin D 2 is the major prostanoid produced by activated mast cells and has been implicated in the pathogenesis of allergic diseases such as allergic asthma and atopic dermatitis.
  • Chemoattractant Receptor-homologous molecule expressed on T-helper type cells is one of the prostaglandin D 2 receptors and is expressed on the effector cells involved in allergic inflammation such as T helper type 2 (Th2) cells, eosinophils, and basophils (Nagata, K. et al. FEBS Lett. 1999, 459, 195-199).
  • CRTH2 plays a proinflammatory role in allergic diseases. Therefore, antagonists of CRTH2 are believed to be useful for treating disorders such as asthma, allergic inflammation, chronic obstructive pulmonary disease (COPD), allergic rhinitis, and atopic dermatitis.
  • COPD chronic obstructive pulmonary disease
  • Ar is: -phenyl, unsubstituted or mono- or bi-substituted independently with halogen, lower alkyl, -CF 3 , -SO 2 CH 3 , alkoxy, -C(0)CH 3 , unsubstituted heteroaryl or heteroaryl substituted with lower alkyl;
  • -biphenyl unsubstituted or mono- or bi-substituted independently with -OH, lower alkyl, -SCH 3 or -S0 2 CH 3 ; or
  • R is hydrogen or lower alkyl
  • a pharmaceutical composition comprising a therapeutically effective amount of a compound according to formula (I) and a therapeutically inert carrier.
  • a method for the treatment or prophylaxis of asthma or COPD comprises the step of administering a therapeutically effective amount of a compound according to formula (I) to a patient in need thereof.
  • alkyl refers to a branched or straight-chain monovalent saturated aliphatic hydrocarbon radical of one to twenty carbon atoms, preferably one to sixteen carbon atoms, more preferably one to ten carbon atoms.
  • lower alkyl alone or in combination with other groups, refers to a branched or straight-chain alkyl radical of one to nine carbon atoms, preferably one to six carbon atoms, more preferably one to four carbon atoms.
  • This term is further exemplified by radicals such as methyl, ethyl, n-propyl, isopropyl, w-butyl, s-butyl, isobutyl, f-butyl, H-pentyl, 3-methylbutyl, H-hexyl, 2-ethylbutyl and the like.
  • cycloalkyl refers to a monovalent mono- or polycarbocyclic radical of three to ten, preferably three to six carbon atoms. This term is further exemplified by radicals such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, norbornyl, adamantyl and the like.
  • the "cycloalkyl” moieties can optionally be substituted with one, two, three or four substituents, with the understanding that said substituents are not, in turn, substituted further.
  • cycloalkyl moieties include, but are not limited to, optionally substituted cyclopropyl, optionally substituted cyclobutyl, optionally substituted cyclopentyl, optionally substituted cyclopentenyl, optionally substituted cyclohexyl, optionally substituted cyclohexylene, optionally substituted cycloheptyl, and the like or those which are specifically exemplified herein.
  • heterocycloalkyl denotes a mono- or polycyclic alkyl ring, wherein one, two or three of the carbon ring atoms is replaced by a heteroatom such as N, O or S.
  • heterocycloalkyl groups include, but are not limited to, morpholinyl, thiomorpholinyl, piperazinyl, piperidinyl, pyrrolidinyl, tetrahydropyranyl,
  • heterocycloalkyl groups may be unsubstituted or substituted and attachment may be through their carbon frame or through their heteroatom(s) where appropriate, with the understanding that said substituents are not, in turn, substituted further.
  • aryl refers to an aromatic mono- or polycarbocyclic radical of 6 to 12 carbon atoms having at least one aromatic ring.
  • groups include, but are not limited to, phenyl, naphthyl, 1,2,3,4-tetrahydronaphthalene, 1,2- dihydronaphthalene, indanyl, lH-indenyl and the like.
  • heteroaryl refers to an aromatic mono- or polycyclic radical of 5 to 12 atoms having at least one aromatic ring containing one, two, or three ring heteroatoms selected from N, O, and S, with the remaining ring atoms being C.
  • groups include, but are not limited to, pyridine, thiazole and pyranyl.
  • alkyl, lower alkyl, aryl and heteroaryl groups described above may be substituted independently with one, two, or three substituents, with the understanding that said substituents are not, in turn, substituted further.
  • Substituents may include, for example, halogen, lower alkyl, -CF 3 , -S0 2 CH 3 , alkoxy, -C(0)CH 3 , -OH, -SCH 3 and - CH 2 CH 2 OH.
  • alkoxy means alkyl-O-; and "alkoyl” means alkyl-CO-.
  • Alkoxy substituent groups or alkoxy-containing substituent groups may be substituted by, for example, one or more alkyl groups, with the understanding that said substituents are not, in turn, substituted further.
  • halogen means a fluorine, chlorine, bromine or iodine radical, preferably a fluorine, chlorine or bromine radical, and more preferably a fluorine or chlorine radical.
  • Compounds of formula I can have one or more asymmetric carbon atoms and can exist in the form of optically pure enantiomers, mixtures of enantiomers such as, for example, racemates, optically pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates or mixtures of diastereoisomeric racemates.
  • the optically active forms can be obtained for example by resolution of the racemates, by asymmetric synthesis or asymmetric chromatography (chromatography with a chiral adsorbents or eluant).
  • the invention embraces all of these forms.
  • the term "pharmaceutically acceptable salt” means any of pharmaceutically acceptable salt.
  • Salts may be prepared from pharmaceutically acceptable non-toxic acids and bases including inorganic and organic acids and bases.
  • acids include, for example, acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethenesulfonic, dichloro acetic, formic, fumaric, gluconic, glutamic, hippuric, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, oxalic, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, oxalic, p-toluenesulfonic and the like.
  • Acceptable base salts include alkali metal (e.g. sodium, potassium), alkaline earth metal (e.g. calcium, magnesium) and aluminum salts.
  • an effective amount of any one of the compounds of this invention or a combination of any of the compounds of this invention or a pharmaceutically acceptable salt thereof is administered via any of the usual and acceptable methods known in the art, either singly or in combination.
  • the compounds or compositions can thus be administered orally (e.g., buccal cavity), sublingually, parenterally (e.g., intramuscularly, intravenously, or subcutaneously), rectally (e.g., by suppositories or washings), transdermally (e.g., skin electroporation) or by inhalation (e.g., by aerosol), and in the form or solid, liquid or gaseous dosages, including tablets and suspensions.
  • buccal cavity e.g., buccal cavity
  • parenterally e.g., intramuscularly, intravenously, or subcutaneously
  • rectally e.g., by suppositories or washings
  • transdermally e.g., skin electroporation
  • the administration can be conducted in a single unit dosage form with continuous therapy or in a single dose therapy ad libitum.
  • the therapeutic composition can also be in the form of an oil emulsion or dispersion in conjunction with a lipophilic salt such as pamoic acid, or in the form of a
  • biodegradable sustained-release composition for subcutaneous or intramuscular administration.
  • compositions hereof can be solids, liquids or gases.
  • the compositions can take the form of tablets, pills, capsules, suppositories, powders, enterically coated or other protected formulations (e.g. binding on ion-exchange resins or packaging in lipid-protein vesicles), sustained release formulations, solutions, suspensions, elixirs, aerosols, and the like.
  • the carrier can be selected from the various oils including those of petroleum, animal, vegetable or synthetic origin, e.g., peanut oil, soybean oil, mineral oil, sesame oil, and the like.
  • formulations for intravenous administration comprise sterile aqueous solutions of the active ingredient(s) which are prepared by dissolving solid active ingredient(s) in water to produce an aqueous solution, and rendering the solution sterile.
  • compositions include starch, cellulose, talc, glucose, lactose, talc, gelatin, malt, rice, flour, chalk, silica, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk, glycerol, propylene glycol, water, ethanol, and the like.
  • the compositions may be subjected to conventional
  • compositions will, in any event, contain an effective amount of the active compound together with a suitable carrier so as to prepare the proper dosage form for proper administration to the recipient.
  • the dose of a compound of the present invention depends on a number of factors, such as, for example, the manner of administration, the age and the body weight of the subject, and the condition of the subject to be treated, and ultimately will be decided by the attending physician or veterinarian.
  • Such an amount of the active compound as determined by the attending physician or veterinarian is referred to herein, and in the claims, as a "therapeutically effective amount".
  • the dose of a compound of the present invention is typically in the range of about 1 to about 1000 mg per day.
  • the therapeutically effective amount is in an amount of from about 1 mg to about 500 mg per day.
  • the present invention provides compounds having the general formula (I):
  • Ar is: -phenyl, unsubstituted or mono- or bi-substituted independently with halogen, lower alkyl, -CF 3 , -SO 2 CH 3 , alkoxy, -C(0)CH 3 , unsubstituted heteroaryl or heteroaryl substituted with lower alkyl;
  • -biphenyl unsubstituted or mono- or bi-substituted independently with -OH, lower alkyl, -SCH 3 or -S0 2 CH 3 ; or -pyridine, unsubstituted or substituted independently with unsubstituted phenyl or phenyl mono- or bi-substituted independently with lower alkyl, -CF 3 or - CH 2 CH 2 OH; and
  • R 1 is hydrogen or lower alkyl
  • Particular compounds of formula (I) include the following:
  • composition comprising a therapeutically effective amount of a compound of formula (I) and a therapeutically inert carrier.
  • a compound according to formula (I) for the treatment or prophylaxis of asthma or COPD.
  • a compound according to formula (I) for the treatment or prophylaxis of asthma or COPD is provided.
  • a method for the treatment or prophylaxis of asthma or COPD comprises the step of administering a therapeutically effective amount of a compound of formula (I) to a patient in need thereof.
  • the compounds of general formula I in this invention may be derivatized at functional groups to provide derivatives which are capable of conversion back to the parent compound in vivo.
  • Physiologically acceptable and metabolically labile derivatives, which are capable of producing the parent compounds of general formula I in vivo are also within the scope of this invention.
  • Chromatography supplies and equipment may be purchased from such companies as for example AnaLogix, Inc, Burlington, WI; Biotage AB, Charlottesville, VA;
  • the present invention is also directed to the administration of a therapeutically effective amount of a compound of formula I in combination or association with other drugs or active agents for the treatment of inflammatory or allergic diseases and disorders.
  • the present invention relates to a method for the treatment and/or prevention of such diseases or disorders comprising administering to a human or animal simultaneously, sequentially, or separately, a therapeutically effective amount of a compound of formula I and another drug or active agent (such as another anti-inflammatory or anti-allergic drug or agent).
  • Another drug or active agent such as another anti-inflammatory or anti-allergic drug or agent.
  • Suitable other drugs or active agents may include, but are not limited to: Beta2- adrenergic agonists such as albuterol or salmeterol; corticosteroids such as dexamethasone or fluticasone; antihistamines such as loratidine; leukotriene antagonists such as montelukast or zafirlukast; anti-IgE antibody therapies such as omalizumab; anti-infectives such as fusidic acid (particularly for the treatment of atopic dermatitis); anti-fungals such as clotrimazole (particularly for the treatment of atopic dermatitis); immunosuppressants such as tacrolimus and pimecrolimus; other antagonists of PGD2 acting at other receptors such as DP antagonists; inhibitors of phosphodiesterase type 4 such as cilomilast; drugs that modulate cytokine production such as inhibitors of TNF-alpha converting enzyme (TACE); drugs that modulate the activity of Th2
  • the compounds of the present invention can be prepared by any conventional means. Suitable processes for synthesizing these compounds are provided in the examples. Generally, compounds of formula I can be prepared according to the schemes illustrated below. For example, certain compounds of the invention may be made using the approach outlined in Scheme 1.
  • benzosuberone the compound of formula 2 (which may be purchased from suppliers such as Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA and TCI America, 9211 N. Harborgate Street, Portland, OR 97203, USA) is brominated to give the bromo-derivative of formula 3.
  • the compound of formula 3 is then subjected to a palladium-catalyzed hydroxylation reaction to give the compound of formula 4 which is alkylated to give the compound of formula 5.
  • Reductive animation of the ketone then gives the amine of formula 6, which is reacted with an aryl-sulfonyl chloride of formula 34 to give the compound of formula 7.
  • the bromination of the compound of benzosuberone (the compound of formula 2) is a known reaction and the reaction may be carried out using the conditions reported in the literature, or using such modifications of these conditions as are obvious to one skilled in the art of organic synthesis.
  • the reaction may be carried out by heating the compound of formula 2 with bromine in the presence of aluminum chloride at a temperature of about 75-80 °C to give a mixture of the desired compound, l-bromo-6,7,8,9-tetrahydro-benzocyclohepten-5-one; the isomeric compound, 3- bromo-6,7,8,9-tetrahydro-benzocyclohepten-5-one; and the disubstituted compound, l,3-dibromo-6,7,8,9-tetrahydro-benzocyclohepten-5-one.
  • the compound of formula 3 may be prepared by the cyclization of 5- (2- bromo-phenyl)-pentanoic acid using polyphosphoric acid at a temperature of about 150 °C as described by Gruber, R. et al. Bull. Chem. Soc. France 1983, 96-104.
  • the conversion of the compound of formula 3 to the phenol of formula 4 may conveniently be carried out using a palladium-catalyzed hydroxylation reaction.
  • the reaction may be carried out by heating the compound of formula 3 with potassium hydroxide in the presence of tris(dibenzylideneacetone)dipalladium(0) (which may be purchased from suppliers such as Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA; Alfa Aesar, 26 Parkridge Road, Ward Hill, MA 01835, USA; and TCI America, 9211 N.
  • tris(dibenzylideneacetone)dipalladium(0) which may be purchased from suppliers such as Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA; Alfa Aesar, 26 Parkridge Road, Ward Hill, MA 01835, USA; and TCI America, 9211 N.
  • the compound of formula 3 may be made using the procedure described in Ito, F. et al. JP 2006063064 where l-methoxy-6,7,8,9-tetrahydrobenzocyclohepten- 5-one may be hydrolyzed by heating in a mixture of acetic acid and 48% aqueous hydrobromic acid at reflux.
  • the multi-step preparation of l-methoxy-6,7,8,9- tetrahydrobenzocyclohepten-5-one is described in da Conceicao, C. M. M. et al. J. Chem. Res. 1995, 347.
  • the alkylation of the phenol of formula 4 may be carried out using any conventional means.
  • the reaction may conveniently be effected by treating the phenol with tert-butyl bromoacetate in the presence of an inorganic base such as CS 2 CO 3 or K 2 CO 3 in an inert solvent such as DMF or CH 3 CN or acetone or 2-butanone at a temperature between about 20 °C and about 80 °C.
  • an inorganic base such as CS 2 CO 3 or K 2 CO 3
  • an inert solvent such as DMF or CH 3 CN or acetone or 2-butanone
  • the reductive amination of the ketone of formula 5 may be carried out using any of a number of reactions that are familiar to one of average skill in the art of organic synthesis.
  • the reaction may be conveniently carried out by treating the ketone of formula 5 with an acid addition salt of ammonia such as ammonium acetate in the presence of a reducing agent such as sodium triacetoxyborohydride or sodium cyanoborohydride in an inert solvent such as methanol or ethanol at about room temperature.
  • a reducing agent such as sodium triacetoxyborohydride or sodium cyanoborohydride
  • an inert solvent such as methanol or ethanol
  • the ketone of formula 5 may be converted to the corresponding oxime by heating with hydroxylamine hydrochloride in MeOH or EtOH at reflux in the presence of an organic base such as triethylamine or diisopropylethylamine or sodium acetate followed by treatment of the oxime under dissolving metal conditions such as by treatment with sodium metal in propanol at reflux to give the amine of formula 6. Examples of specific conditions useful for this reaction may be found in the literature, for example in Bhandari, K. et al. Bioorg. Med. Chem. 2004, 12, 4189- 4196.
  • the ketone of formula 5 may be treated with O- methylhydroxylamine hydrochloride in MeOH at room temperature, followed by treatment of the resulting oxime ether with borane-THF complex in THF at about
  • amine of formula 6 60 °C to give the amine of formula 6.
  • specific conditions useful for this reaction may be found in the literature, for example in S0rensen, U. S. et al. US 7,737,167.
  • the sulfonylation of a compound of formula 6 can be effected using procedures that are well known in the field of organic synthesis.
  • the compound of formula 6 may be treated with an arylsulfonyl chloride in the presence of an appropriate base for example pyridine, which may also be used as solvent.
  • the reaction may also be performed by using a tertiary amine as the base, in the presence of an inert solvent such as tetrahydrofuran or dichloromethane; or in aqueous solution using an alkali metal hydroxide such as sodium hydroxide as the base.
  • the reaction is conveniently carried out at a temperature of between about room temperature and about 80 °C, preferably at about room temperature. Examples of conditions suitable for carrying out this reaction may be found in the literature, for example in Gillespie, J. et al. WO 2009147167; in Allerton, C. M. M. WO 2007057775; in Firooznia, F. et al. US 20100041713; and in Guianvarc'h, D. et al. J. Med. Chem. 2004, 47, 2365-2374.
  • Removal of the tert-butyl group from a compound of formula 7 to give a compound of the invention of formula 8 may be accomplished using a variety of conditions that are well known to one of average skill in the art of organic synthesis. For example, many conditions for effecting such a transformation are outlined in "Protective Groups in Organic Synthesis" [T. W. Greene and P. G. M. Wuts, 2nd Edition, John Wiley & Sons, N.Y. 1991].
  • the compound of formula 7 may be treated with a strong organic acid (preferably trifluoroacetic acid) in an inert solvent such as a halogenated hydrocarbon (preferably dichloromethane or chloroform) at a temperature about room temperature.
  • a strong organic acid preferably trifluoroacetic acid
  • an inert solvent such as a halogenated hydrocarbon (preferably dichloromethane or chloroform)
  • reaction may be effected by heating the compound of formula 7 in 2,2,2-trifluoroethanol or hexafluoroisopropanol at a temperature between about 100 °C and about 150 °C with or without microwave irradiation (for an example of conditions, see Choi, J. C.-C. et al.
  • the reaction can be accomplished by treating the compound of formula 7 with an excess of an alkali metal hydroxide such as lithium hydroxide or preferably sodium hydroxide in an inert solvent such as a mixture of tetrahydrofuran and water at about room temperature.
  • an alkali metal hydroxide such as lithium hydroxide or preferably sodium hydroxide
  • an inert solvent such as a mixture of tetrahydrofuran and water
  • Methylation of a compound of formula 7 to give a compound of formula 9 may be accomplished using any conventional means.
  • the reaction may be conveniently carried out by treating the compound of formula 7 with a methylating agent such as methyl iodide or dimethyl sulfate in the presence of a base such as potassium carbonate or cesium carbonate or sodium hydride in an inert solvent such as DMF or tetrahydrofuran at a temperature between about 0 °C and about room temperature, preferably at about room temperature.
  • a methylating agent such as methyl iodide or dimethyl sulfate
  • a base such as potassium carbonate or cesium carbonate or sodium hydride
  • an inert solvent such as DMF or tetrahydrofuran
  • Removal of the tert-butyl group from a compound of formula 9 to give a compound of the invention of formula 10 may be accomplished using any of the conditions described above for the removal of the tert-butyl group from a compound of formula 7 to give a compound of the invention of formula 8.
  • the compound of formula 6, which may be prepared as outlined in Scheme 1, is reacted with an aryl-sulfonyl chloride to give the compound of formula 11, in which Y represents a group such as bromo or iodo that can act as a leaving group in a noble metal-catalyzed coupling reaction such as a Suzuki reaction, a Stille reaction, or a Negishi reaction.
  • the compound of formula 11 then undergoes a noble metal-catalyzed reaction to give a biaryl of formula 12, which may be hydrolyzed to give the compound of the invention of formula 13, or methylated and then hydrolyzed to give the compound of the invention of formula 15.
  • the sulfonylation of a compound of formula 6 to give a compound of formula 11 where X is N or CH and Y is a group which is commonly used in a Suzuki, Stille, or Negishi reaction, such as bromine, iodine, or trifluoromethanesulfonyl, may be effected using the conditions described above for the sulfonylation of a compound of formula 6 to give a compound of formula 7.
  • the reaction of a compound of formula 11 to give a biaryl derivative of formula 12 may be accomplished using reactions that are well known to one of average skill in the art of organic synthesis.
  • the reaction may be accomplished using one of a set of reactions which use noble metal catalysis, and which include the Suzuki reaction, the Stille reaction, and the Negishi reaction.
  • the reaction can be conveniently carried out by reacting a compound of formula 11 with a compound of formula 44 where V represents B(OH) 2 or the pinacol ester thereof, in a convenient inert solvent such as a polar aprotic solvent (e.g., ⁇ , ⁇ -dimethylformamide) or an ether (e.g., dioxane) or water, or indeed in a mixture of such solvents, in the presence of a catalytic amount of a compound that can be reduced in situ to give palladium(O) (for example, palladium(II) acetate or bis(triphenylphosphine)palladium(II) chloride), in the optional additional presence of a catalytic amount of a phosphine ligand, for example tri-o-tolylphosphine or tri
  • Suzuki reaction is familiar to one of ordinary skill in the art of organic synthesis, and has been reviewed several times, notably in Miyaura, N.; Suzuki, A. Chem. Rev. 1995, 95, 2457-2483 and, more recently, in Alonso, F.;
  • Stille coupling is well known to one of average skill in the field of organic synthesis, and may be used as an alternative to the Suzuki coupling, examples of conditions for which have been provided above. Stille coupling has been reviewed, including in Farina, V. et al. Org. Reactions 1997, 50, 1-652. Examples of specific conditions that have been used for Stille coupling may be found in the literature, for example in Littke, A. F. et al. /. Am. Chem. Soc. 2002, 124, 5343-6348; in Alberati-Giani, D. et al. US 7,462,617; and in Robl, J. A. US 5,072,023.
  • Removal of the tert-butyl group from a compound of formula 12 to give a compound of the invention of formula 13 may be accomplished using any of the conditions described above for the removal of the tert-butyl group from a compound of formula 7 to give a compound of the invention of formula 8.
  • Methylation of a compound of formula 12 to give a compound of formula 14 may be accomplished using the conditions outlined above for the conversion of a compound of formula 7 to a compound of formula 9.
  • Removal of the tert-butyl group from a compound of formula 14 to give a compound of the invention of formula 15 may be accomplished using any of the conditions described above for the removal of the tert-butyl group from a compound of formula 7 to give a compound of the invention of formula 8.
  • the compound of formula 6, which may be prepared as outlined in Scheme 1, is reacted with 3-fluoro-5-(trifluoromethyl)benzenesulfonyl chloride (which may be purchased from Alfa Aesar, 26 Parkridge Road, Ward Hill, MA 01835, USA) to give the sulfonamide of formula 16.
  • This compound may be reacted with the sodium salt of a lower alcohol to effect simultaneous substitution of the fluorine and hydrolysis of the tert-butyl protective group to give the compound of the invention of formula 17.
  • the sulfonamide of formula 16 may be methylated to give the compound of formula 18, and then reacted with the sodium salt of a lower alcohol to effect simultaneous substitution of the fluorine and hydrolysis of the tert-butyl protective group to give the compound of the invention of formula 19.
  • the sulfonylation of a compound of formula 6 to give a compound of formula 16 may be effected using the conditions described above for the sulfonylation of a compound of formula 6 to give a compound of formula 7.
  • the conversion of a compound of formula 16 to give a compound of formula 17 may be effected by treating the compound of formula 16 with the sodium salt of a lower alcohol in an inert solvent such as the same lower alcohol or a mixture of the lower alcohol and DMF at a temperature between about the reflux temperature of the solvent and about 150 °C, with or without microwave irradiation.
  • an inert solvent such as the same lower alcohol or a mixture of the lower alcohol and DMF
  • the tert-butyl protective group may be deprotected during the course of the reaction giving directly the compound of the invention of formula 17.
  • the tert-butyl group is not cleaved during the nucleophilic substitution reaction, the it can be removed using any of the conditions described above for the removal of the tert-butyl group from a compound of formula 7 to give a compound of the invention of formula 8.
  • Methylation of a compound of formula 16 to give a compound of formula 18 may be accomplished using the conditions outlined above for the conversion of a compound of formula 7 to a compound of formula 9.
  • the conversion of a compound of formula 18 to give a compound of the invention of formula 19 may be effected using the conditions outlined above for the conversion of a compound of formula 16 to a compound of formula 17.
  • the compound of formula 6, which may be prepared as outlined in Scheme 1, is reacted with a 3-bromo- substituted benzenesulfonyl chloride to give the sulfonamide of formula 20.
  • This compound may be reacted with a tributyl(l-ethoxyvinyl)tin derivative under Stille coupling conditions to give the ketone of formula 21, which may be hydrolyzed to give the compound of the invention of formula 22, or methylated and then hydrolyzed to give the compound of the invention of formula 24.
  • the sulfonylation of a compound of formula 6 to give a compound of formula 20 may be effected using the conditions described above for the sulfonylation of a compound of formula 6 to give a compound of formula 7.
  • the conversion of a compound of formula 20 to give a compound of formula 21 can be conveniently carried out by subjecting the compound of formula 20 to a Stille coupling reaction to give a vinyl ether which is then hydrolyzed to give the ketone. Accordingly, the compound of formula 20 is treated with a tributyl(l-ethoxyvinyl)tin derivative in the presence of a catalytic amount of a compound that can be reduced in situ to give palladium(O) (for example, palladium(II) acetate or
  • bis(triphenylphosphine)palladium(II) chloride) in the optional additional presence of a catalytic amount of a phosphine ligand, for example tri-o-tolylphosphine or tri-tert- butylphosphine or triphenylarsine, or alternatively in the presence of a preformed complex of palladium(O) with a phosphine ligand such as bis(tri- cyclohexylphosphine)palladium, tetrakis(triphenylphosphine)-palladium(0) or [1,1- bis(diphenylphosphino)ferrocene]dichloropalladium(II)), in an inert solvent such as DMF or dioxane at a temperature between about room temperature and about 100 °C, and preferably at about 100 °C.
  • a phosphine ligand for example tri-o-tolylphosphine or tri
  • Removal of the tert-butyl group from a compound of formula 21 to give a compound of the invention of formula 22 may be accomplished using any of the conditions described above for the removal of the tert-butyl group from a compound of formula 7 to give a compound of the invention of formula 8.
  • Methylation of a compound of formula 21 to give a compound of formula 23 may be accomplished using the conditions outlined above for the conversion of a compound of formula 7 to a compound of formula 9.
  • Removal of the tert-butyl group from a compound of formula 23 to give a compound of the invention of formula 24 may be accomplished using any of the conditions described above for the removal of the tert-butyl group from a compound of formula 7 to give a compound of the invention of formula 8.
  • the compound of formula 20 which may be prepared as outlined in Scheme 4, is reacted with a lower alkylsulfinic acid to give the sulfone of formula 25.
  • This compound may be hydrolyzed to give the compound of the invention of formula 26, or methylated and then hydrolyzed to give the compound of the invention of formula 28.
  • Removal of the tert-butyl group from a compound of formula 25 to give a compound of the invention of formula 26 may be accomplished using any of the conditions described above for the removal of the tert-butyl group from a compound of formula 7 to give a compound of the invention of formula 8.
  • Methylation of a compound of formula 25 to give a compound of formula 27 may be accomplished using the conditions outlined above for the conversion of a compound of formula 7 to a compound of formula 9.
  • Removal of the tert-butyl group from a compound of formula 27 to give a compound of the invention of formula 28 may be accomplished using any of the conditions described above for the removal of the tert-butyl group from a compound of formula 7 to give a compound of the invention of formula 8.
  • the conversion of the compound of formula 20 to the compound of formula 29 may be conveniently carried out by subjecting the compound of formula 20 to a Suzuki coupling reaction with a vinylboronic acid or the ester of a vinylboronic acid in a convenient inert solvent such as a polar aprotic solvent (e.g., N,N-dimethylformamide) or an ether (e.g., dioxane) or water, or indeed in a mixture of such solvents, in the presence of a catalytic amount of a compound that can be reduced in situ to give palladium(O) (for example, palladium(II) acetate or
  • phosphine ligand for example tri-o-tolylphosphine or tri-tert- butylphosphine, or alternatively in the presence of a preformed complex of
  • phosphine ligand such as bis(tri-cyclohexylphosphine)palladium, tetrakis(triphenylphosphine)-palladium(0) or [1,1- bis(diphenylphosphino)ferrocene]dichloropalladium(II)
  • an inorganic base for example, an alkali metal carbonate, bicarbonate or phosphate (e.g., potassium phosphate or sodium carbonate) at a temperature between about room temperature and about 100 degrees, and preferably between about room temperature and about 50 degrees.
  • Suzuki reaction is familiar to one of ordinary skill in the art of organic synthesis, and has been reviewed several times, notably in Miyaura, N.; Suzuki, A. Chem. Rev. 1995, 95, 2457-2483 and, more recently, in Alonso, F.;
  • the conversion of the compound of formula 29 to the compound of formula 30 may be carried out by treating the compound of formula 29 with hydrogen gas at ambient pressure or at a pressure of up to approximately 50 pounds per square inch in an inert solvent such as ethanol or ethyl acetate at about room temperature.
  • an inert solvent such as ethanol or ethyl acetate at about room temperature.
  • Removal of the tert-butyl group from a compound of formula 30 to give a compound of the invention of formula 31 may be accomplished using any of the conditions described above for the removal of the tert-butyl group from a compound of formula 7 to give a compound of the invention of formula 8.
  • Methylation of a compound of formula 30 to give a compound of formula 32 may be accomplished using the conditions outlined above for the conversion of a compound of formula 7 to a compound of formula 9.
  • Removal of the tert-butyl group from a compound of formula 32 to give a compound of the invention of formula 33 may be accomplished using any of the conditions described above for the removal of the tert-butyl group from a compound of formula 7 to give a compound of the invention of formula 8.
  • Sulfonyl chlorides of formula 34 can also be made by reactions that are well known in the field of organic synthesis, such as those outlined below.
  • a sulfonyl chloride of formula 34 can be made from a sulfonic acid of formula 35 as shown in Scheme 7.
  • the chlorination of an arylsulfonic acid, or a salt thereof, of formula 35 can be accomplished conveniently by treating it with a chlorinating agent such as thionyl chloride or phosphorus oxychloride or phosphorus pentachloride, in the optional additional presence of a catalytic amount of N,N- dimethylformamide, at a temperature between about 0 °C and about 120 °C depending on the reactivity of the chlorinating agent. Examples of specific conditions useful for this reaction may be found in the literature, for example in Morikawa, A. et al. /. Med. Chem.
  • Sulfonyl chlorides of formula 34 can be made by electrophilic aromatic substitution of an aromatic compound of formula 36 as shown in Scheme 8. As is known to one of average skill in the art, this process is suitable for the preparation of arylsulfonyl chlorides with particular substitution patterns, such as for example where there is an ortho/para directing substituent in a benzene ring ortho or para to the site of introduction of the sulfonyl group.
  • the reaction is conveniently carried out by treating the aromatic compound of formula 36 with chloro sulfonic acid in the absence of solvent and then heating the mixture at a temperature between about 70 °C and about 100 °C. Examples of specific conditions useful for this reaction may be found in the literature, for example in Arduini, A. et al.
  • Sulfonyl chlorides of formula 34 can also be made from anilines of formula 37 by a diazotization/sulfonylation reaction sequence as shown in Scheme 9.
  • diazotization reaction is conveniently carried out by treating the aniline of formula 37 or an acid addition salt thereof (such as the hydrochloride salt) in aqueous solution in the presence of a mineral acid such as hydrochloric acid or sulfuric acid with an alkali metal nitrite salt such as sodium nitrite at a temperature less than 10 °C, preferably around 0 °C.
  • a mineral acid such as hydrochloric acid or sulfuric acid
  • an alkali metal nitrite salt such as sodium nitrite
  • Suitable reagents include sulfur dioxide and copper(I) chloride or copper(II) chloride in acetic acid/water, or thionyl chloride and copper(I) chloride or copper(II) chloride in water, according to the procedure of P. J. Hogan (US 6,531,605).
  • the sulfonylation reaction can be carried out by adding the solution of the diazonium salt, prepared as described above, to a mixture of sulfur dioxide and copper(II) chloride in a suitable inert solvent, such as glacial acetic acid, at a temperature around 0 °C. Examples of specific conditions useful for this reaction may be found in the literature, for example in N. Ikemoto, N. et al.
  • a sulfonyl chloride of formula 34 can also be made from an aryl benzyl sulfide of formula 38 by an oxidative chlorination reaction as shown in Scheme 10.
  • the reaction is conveniently carried out by bubbling chlorine gas into a solution or suspension of the aryl benzyl sulfide of formula 38 in a suitable inert solvent such as a mixture of acetic acid and water at a temperature around room temperature. Examples of specific conditions useful for this reaction may be found in the literature, for example in Andrews, S. P. and Ladlow, M. /. Org. Chem. 2003, 68, 5525-5533; in Baker, R. H. et al. /. Am. Chem. Soc.
  • Sulfonyl chlorides of formula 34 can also be made as shown in Scheme 11 from an aryl bromide of formula 39 by metal-halogen exchange, followed by reaction of the organometallic intermediate with sulfur dioxide to give an arylsulfonate salt, followed by reaction with sulfuryl chloride to give the arylsulfonyl chloride.
  • the reaction can be carried out by treating the aryl bromide with an organometallic reagent such as n- butyl lithium or preferably sec-butyl lithium, in the optional additional presence of tetramethylethylenediamine (TMEDA) in a suitable inert solvent such as
  • organometallic reagent such as n- butyl lithium or preferably sec-butyl lithium
  • tetrahydrofuran (THF) or diethyl ether at low temperature for example, around - 78 °C
  • THF tetrahydrofuran
  • diethyl ether at low temperature (for example, around - 78 °C)
  • This can then be reacted, without isolation, with a mixture of sulfur dioxide and a solvent such as diethyl ether, again at low temperature, such as for example between about -78 °C and about -60 °C.
  • the resulting arylsulfonate salt can then be converted to the arylsulfonyl chloride, again without isolation of the intermediate, by treatment with sulfuryl chloride at a temperature around 0 °C. Examples of specific conditions useful for this reaction may be found in the literature, for example in Chan, M. F. et al. Bioorg. Med.
  • Sulfonyl chlorides of formula 34 can be made from an aryl thiol of formula 40 by oxidation using chlorine as shown in Scheme 12.
  • the reaction can be carried out by treating the aryl thiol of formula 40 with a solution of chlorine in an inert solvent such as glacial acetic acid at a temperature around 0 °C; or by treating the aryl thiol of formula 40 with N-chlorosuccinimide in a mixture of aqueous hydrochloric acid and acetonitrile at a temperature below about 20 °C.
  • Examples of specific conditions useful for this reaction may be found in the literature, for example in Curran, W. V. et al. US 3,932,440; in Crich, D.
  • aryl thiol of formula 40 that is particularly useful for the preparation of certain compounds of the invention is 5- bromo-pyridine-2-thiol. This compound is commercially available from a number of different vendors including Combi-Blocks Inc., 7949 Silverton Avenue, Suite 915,
  • 5-Bromo-pyridine-2-thiol may also be synthesized according to the procedure disclosed in Fuchss, T. et al. WO 2007039578 or according to the procedure disclosed in Raeth, C. Liebigs Ann. Chem. 1931, 487, 105-119.
  • Sulfonyl chlorides of formula 34 can be made from phenols of formula 41 through a sequence of reactions outlined in Scheme 13.
  • the phenol of formula 41 can be converted to the 0-aryl-N,N'-dialkylthiocarbamate of formula 42 by reaction with an ⁇ , ⁇ '-dialkylthiocarbamoyl chloride in an inert solvent in the presence of a base.
  • the resulting 0-aryl-N,N'-dialkylthiocarbamate of formula 42 can be rearranged to the S- aryl-N,N'-dialkylthiocarbamate of formula 43 by heating neat at high temperature such as at around 250 °C.
  • the S-aryl-N,N'-dialkylthiocarbamate of formula 43 can then be converted to the sulfonyl chloride of formula 34 by oxidation using chlorine in a suitable inert solvent such as a mixture of formic acid and water at a temperature around 0 °C.
  • suitable inert solvent such as a mixture of formic acid and water at a temperature around 0 °C. Examples of specific conditions useful for this reaction may be found in the literature, for example in Percec, V. et al. J. Org. Chem. 2001, 66, 2104-2117; in Allison, B. D. et al. WO 2008124524; and in Deng, X. et al. US 7,288,651.
  • sulfonyl chlorides of formula 34 which are particularly useful for the preparation of sulfonamides of formula 11 in Scheme 2 are commercially available: 4- iodobenzenesulfonyl chloride (available from Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA; Alfa Aesar, 26 Parkridge Road, Ward Hill, MA 01835, USA; and TCI America, 9211 N.
  • the following compounds are available from the suppliers indicated below. These examples of commercially available compounds are provided for the purposes of illustration and are not intended to limit the invention. The suppliers indicated are not necessarily the only suppliers of these reagents, and these and other suppliers also provide other building blocks useful for the preparation of compounds of the invention.
  • hydrochloride salt 3-(chloromethyl)benzeneboronic acid; 3-(difluoromethoxy)- benzeneboronic acid; 3-(hydrazinecarbonyl)benzeneboronic acid; 3- (methoxymethoxy)phenylboronic acid; 3-(methylsulfonyl)phenylboronic acid; 3- (N,N-dimethylamino)phenylboronic acid; 3-(N-methylaminocarbonyl)phenylboronic acid; 3,4,5-trichlorophenylboronic acid; 3,4-dichloro-2-methylbenzeneboronic acid;
  • hydrochloride salt 5-(methylsulphonyl)pyridine-3-boronic acid; 5- (methylthio)pyridine-3-boronic acid; 5-acetyl-2-chlorophenylboronic acid; 5-acetyl-2- fluorophenylboronic acid; 5-carbamoyl-2-chlorophenylboronic acid; 5-carbamoyl-2- fluorobenzeneboronic acid; 5-chloro-2-cyanophenylboronic acid; 5-chloro-2- ethoxyphenylboromc acid; 5-chloro-2-ethoxypyridine-3-boronic acid; 5-chloro-2- fluoro-4-methoxyphenylboronic acid; 5-chloro-2-fluoro-4-methylphenylboronic acid; 5-chloro-2-fluoropyridine-3-boronic acid; 5-chloro-2-methoxyphenylboronic acid; 5- chloro-2-nitrophenylboronic acid; 5-chloro-4-methoxyphen
  • a compound of this type can conveniently be synthesized according to Scheme 14 from a compound of formula 45, in which X represents bromine or iodine, by treatment with an alkyllithium (e.g., n-butyllithium) or magnesium (to form the Grignard reagent) in a suitable inert solvent such as an ether (such as tetrahydrofuran or diethyl ether) at a temperature appropriate for the reaction (for example, at approximately -78 degrees for reaction with an alkyllithium, or at approximately room temperature for reaction with magnesium), followed by treatment with a trialkyl borate and then with dilute acid to form the compound of formula 46.
  • an alkyllithium e.g., n-butyllithium
  • magnesium to form the Grignard reagent
  • a suitable inert solvent such as an ether (such as tetrahydrofuran or diethyl ether)
  • a temperature appropriate for the reaction for example, at approximately -78
  • a compound of this type can conveniently be synthesized according to Scheme 15 from a compound of formula 45, in which X represents bromine or iodine or trifluoromethanesulfonate.
  • a compound of formula 47 may be conveniently prepared according to this procedure by treating the compound of formula 45 with bis(pinacolato)diboron (which is commercially available from many vendors including Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue,
  • a palladium catalyst such as dichloro[l,l'- bis(diphenylphosphino)ferrocene]-palladium(II) or the dichloromethane adduct thereof in the presence of a base such as potassium acetate in an inert solvent such as 1 ,4-dioxane or dimethylsulfoxide or N,N-dimethylformamide at a temperature between about 80 °C and about 100 °C.
  • the reaction may be advantageously carried out under an inert atmosphere. Examples of specific conditions that may be used for this reaction can be found in the literature, for example in Goodacre, S. C. et al. J. Med. Chem.
  • a compound of formula 47 may also be conveniently prepared according to Scheme 15 by treating the compound of formula 45 with pinacolborane (which is
  • a palladium catalyst such as dichloro[l,l'- bis(diphenylphosphino)ferrocene]-palladium(II) or the dichloromethane adduct thereof or dichlorobis(triphenylphosphine)palladium(II), or else a mixture of a palladium catalyst such as palladium(II) acetate in the presence of a ligand such as 2- dicyclohexylphosphino-l,l'-biphenyl, in an inert solvent such as 1,4-dioxane at a temperature between about 80 °C and about 100 °C.
  • a ligand such as 2- dicyclohexylphosphino-l,l'-biphenyl
  • a compound of this type can conveniently be synthesized according to Scheme 16 from a compound of formula 45, in which X represents bromine or iodine.
  • a compound of formula 47 may be conveniently prepared according to this procedure by treating the compound of formula 45 with tert-butyllithium or n-butyllithium in an inert solvent such as tetrahydrofuran or diethyl ether at -78 °C, adding trimethyltin chloride or tributyltin chloride, and allowing the reaction to proceed at room temperature. Examples of specific conditions that may be used for this reaction can be found in the literature, for example in John, V. et al. US 20090270367; in Halbert, S. M. et al.
  • a compound of formula 48 may also be conveniently prepared according to Scheme 16 by treating the compound of formula 45 with hexamethyldistannane (which is commercially available from several vendors including Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA) or
  • hexabutyldistannane (which is commercially available from several vendors including Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA) (to give the compounds of formula 48 where R represents methyl or butyl, respectively) in the optional presence of lithium chloride, a palladium catalyst such as tetrakis(triphenylphosphine)palladfum(0) (which is commercially available from several vendors including Aldrich Chemical Company, Inc., 1001 West Saint
  • the compounds of the present invention can be prepared using appropriate starting materials according to the methods described generally herein and/or by methods available to one of ordinary skill in the art.
  • Flash chromatography was performed using (1) the Biotage SP1TM system and the Quad 12/25 Cartridge module from Biotage AB) or (2) the ISCO CombiFlash ®
  • silica gel brand and pore size utilized were: (1) KP-SILTM 60 A, particle size: 40-60 micron (from Biotage AB); (2) Silica Gel CAS registry No: 63231-67-4, particle size: 47-60 micron; or (3) ZCX from Qingdao Haiyang Chemical Co., Ltd, pore size: 200- 300 mesh or 300-400 mesh.
  • Preparative HPLC was performed on a reversed phase column using an XbridgeTM Prep C 18 (5 m, OBDTM 30 x 100 mm) column (from Waters Corporation), a SunFireTM Prep Ci 8 (5 m, OBDTM 30 x 100 mm) column (from Waters Corporation), or a Varian Pursuit ® C-18 column 20 X 150 mm (from Varian, Inc.).
  • Mass spectrometry (MS) or high resolution mass spectrometry (HRMS) was performed using a Waters ® ZQTM 4000 (from Waters Corporation), a Waters ®
  • Mass spectra data generally only indicates the parent ions unless otherwise stated. MS or HRMS data is provided for a particular intermediate or compound where indicated.
  • Nuclear magnetic resonance spectroscopy was performed using a Varian ® Mercury300 NMR spectrometer (for the HNMR spectrum acquired at 300 MHz) and a Varian ® Inova400 NMR spectrometer (for the HNMR spectrum acquired at 400 MHz) both from Varian Inc. NMR data is provided for a particular intermediate or compound where indicated.
  • Microwave assisted reactions were carried out in a Biotage InitiatorTM Sixty (or earlier models) (from Biotage AB) or by a CEM Discover ® model (with gas addition accessory) (from CEM Corporation).
  • Methyl iodide (2 equivalents) was added to a mixture of the 5-arylsulfonylamino- 6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy]-acetic acid tert-butyl ester (1 equivalent) and K 2 CO 3 (2 equivalents) in DMF (20 mL/mmol) at room temperature under nitrogen. The mixture was stirred overnight at room temperature, then diluted with water and extracted with ethyl acetate (3 x 50 mL/mmol).
  • the titled compound was prepared using conditions similar to those described in Cornelius, L. A. M. and Combs, D. W. Synth. Commun. 1994, 24, 2777-2788.
  • Aluminum chloride (17.18 g, 0.129 mol) was placed in a 250 mL, three-necked round- bottomed flask under argon. The flask was fitted with a condenser, overhead stirrer, and rubber septum; and 1-benzosuberone (available from Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA; approx. 7.6 mL; approx. 0.05 mol) was added slowly over 3 min. The mixture was stirred for 5 min, and then bromine (approx.
  • KOH pellets (632 mg, 11.3 mmol) were placed in a 25 mL round-bottomed flask and tris(dibenzylideneacetone)dipalladium(0) (available from Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA; 101 mg, 0.11 mmol) and 2-di-tert-butyl-phosphino-2',4',6'-triisopropylbiphenyl (available from Strem
  • the reaction mixture was concentrated, and the pH was adjusted to ⁇ 7 by the addition of aqueous saturated Na 2 C0 3 .
  • the mixture was extracted with EtOAc (3 x 100 mL). The combined organic extracts were dried over anhydrous Na 2 S0 4 , filtered, and evaporated. The residue was purified by silica gel chromatography, using 2-5%
  • 5-Bromo-pyridine-2-sulfonyl chloride A suspension of 5-bromo-pyridine-2-thiol (which may be prepared as described for Intermediate 1.05; 2 g, 10.5 mmol) in carbon tetrachloride (40 mL) and water (8 mL) was cooled to ⁇ 0 °C using an ice-bath. Chlorine gas was bubbled through the reaction mixture for 20 min and then CH 2 CI 2 (100 mL) was added. The mixture was washed with brine.
  • reaction mixture was stirred at this temperature for 15 min and then a solution of bis-(3,5-trifluoromethyl)benzenesulfonyl chloride (available from Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA; 0.129 g, 0.41 mmol) was added.
  • the reaction mixture was stirred at room temperature overnight and then concentrated. EtOAc was added and the mixture was washed with water.
  • Biphenyl-4-sulfonyl chloride (available from Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA; 0.26 g, 1.03 mmol), and diisopropylethylamine (0.35 mL, 2.0 mmol) were added to a ⁇ 0°C solution of (5- amino-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy)-acetic acid tert-butyl ester (which may be prepared as described for Intermediate 1.04; 0.25 g, 0.86 mmol) in CH 2 CI 2 (5 mL) under nitrogen. The mixture was stirred at room temperature for 5 h and then water (5 mL) was added.
  • aqueous layer was acidified with 1 N HCl and extracted with ethyl acetate.
  • EtOAc extracts were combined, washed with water and brine, dried over anhydrous Na 2 S0 4 , filtered, and evaporated to give ⁇ 5-[(3-methoxy-5-trifluoromethyl- benzenesulfonyl)-methyl-amino]-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy ⁇ - acetic acid (20 mg, 36%).
  • Lithium hydroxide monohydrate (8 mg, 0.19 mmol) was added to a mixture of [5-(3- isopropyl-5-trifluoromethyl-benzenesulfonylamino)-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy] -acetic acid tert-butyl ester (which may be prepared as described for Intermediate 2.24; 30 mg, 0.06 mmol), THF (4 mL), MeOH (1 mL) and water (1 mL). The mixture was stirred for 16 h, then concentrated and diluted with water (10 mL). The pH of the mixture was adjusted to ⁇ 4 by adding 2N HC1 and the mixture was then extracted with EtOAc.
  • a whole cell receptor binding assay using [ 3 H]ramatroban as the competing radioactive ligand was employed to evaluate the compound binding activity to human CRTH2.
  • the radioactive ligand [ 3 H]ramatroban was synthesized according to Sugimoto et. al. ⁇ Eur. J. Pharmacol. 2005, 524, 30-37) to a specific activity of 42 Ci/mmol.
  • a cell line stably expressing human CRTH2 was established by transfecting CHO-K1 cells with two mammalian expression vectors that harbored human CRTH2 and G- alphal6 cDNAs, respectively, using FuGene ® 6 transfection reagent (from Roche). Stable clones expressing CRTH2 were selected by staining each clone with BM16 (BD PharmingenTM from BD Biosciences, a division of Becton, Dickinson and Company), which is a rat monoclonal antibody to human CRTH2.
  • BM16 BD PharmingenTM from BD Biosciences, a division of Becton, Dickinson and Company
  • the cells were maintained as monolayer cultures in Ham's F-12 medium containing 10% fetal bovine serum, 100 units/mL penicillin, 100 ⁇ g/mL streptomycin, 2 mM glutamine, 0.5 mg/mL G418 (geneticin) for CRTH2, and 0.2 mg/mL hygromycin-B (for G-alpha 16).
  • the monolayer cells were rinsed once with PBS (phosphate buffered saline), dissociated using ethylenediaminetetraacetate (VerseneTM EDTA from Lonza Inc.), and suspended in PBS containing 10 mM MgCl 2 and 0.06% BSA (bovine serum albumin) at 1.5 x 10 6 cells/mL.
  • PBS phosphate buffered saline
  • BSA bovine serum albumin
  • the binding reactions (0.2 mL) were performed in 96-well plates at room temperature in PBS containing 1.5 x 10 s cells, 10 mM MgCl 2 , 0.06% BSA, 20 nM [ 3 H]ramatroban, and test compound at various concentrations. After 1 hour of binding reactions, the cells were harvested on GFTM/B filter microplates (microtiter plates with embedded glass fiber from PerkinElmer, Inc.) and washed 5 times with PBS using a FiltermateTM Harvester (a cell harvester that harvests and washes cells from microplates from PerkinElmer, Inc.).
  • the radioactivities bound to the cells were determined using a microplate scintillation counter (TopCount ® NXT, from PerkinElmer, Inc.) after adding 50 ⁇ ⁇ of MicroscintTM 20 scintillation fluid (from PerkinElmer, Inc.) to each well of the filter plates.
  • the radioactivity from non-specific binding was determined by replacing compound with 10 ⁇ of 15(R)-15-methyl PGD 2 (from Cayman
  • the IC 50 value is defined as the concentration of the tested compound that is required for 50% inhibition of total specific binding.
  • the percent inhibition data were determined for 7 concentrations for each compound.
  • the percent inhibition for a compound at each concentration was calculated according to the following formula, [1 -(specific binding in the presence of compound)/(total specific binding)]xl00.
  • the IC 50 value was then obtained by fitting the percent inhibition data to a sigmoidal dose-response (4 parameter logistic) model in the
  • CHO-K1 cells previously transfected with G-alpha 16 were subsequently transfected with the human CRTH2 receptor and the neomycin resistance gene.
  • individual clones were assayed for their receptor expression based on staining with an anti human CRTH2 IgG, followed by assaying for their response to 13, 14-dihydro- 15-keto Prostaglandin D 2 (DK-PDG 2 ) (ligand) in the Ca 2+ Flux assay. Positive clones were then cloned by limiting dilution cloning.
  • the transfected cells were cultured in Ham's F- 12 medium supplemented with 10% fetal bovine serum, 2 mM glutamine , 100 U/mL penicillin/ 100 ⁇ g/mL streptomycin, 200 ⁇ g/mL hygromycin B, and 800 ⁇ g/mL G418 (geneticin).
  • Cells were harvested with trypsin-EDTA (trypsin-ethylenediaminetetraacetic acid) and counted using ViaCount ® reagent (from Guava Technologies, Inc. which contains two DNA-binding dyes that enable the reagent user to distinguish between viable and nonviable cells).
  • the cell suspension volume was adjusted to 2.5 xlO 5 cells /mL with complete growth media.
  • Molecular Devices a division of MDS Analytical Technologies and MDS Inc. was prepared by dissolving the contents of one bottle into 200 mL Hank' s Balanced Salt Solution containing 20 mM HEPES (4-(2-hydroxyethyl)-l-piperazineethanesulfonic acid) and 2.5 mM probenecid. Growth media was removed from the cell plates and 25 ⁇ . of Hank' s Balanced Salt Solution (HBSS) containing 20 mM HEPES, 0.05% BSA and 2.5 mM probenecid was added to each well followed by 25 ⁇ L ⁇ of diluted dye using a Multidrop dispenser. The plates were then incubated for 1 hour at 37 C.
  • HEPES 4-(2-hydroxyethyl)-l-piperazineethanesulfonic acid
  • test compound plates were prepared by adding 90 ⁇ L ⁇ of HBSS/20 mM HEPES/0.005% BSA buffer to the 2 ⁇ , of serial diluted compounds.
  • serial diluted compounds 20 mM stocks of compounds were dissolved in 100% DMSO.
  • the compound dilution plate was set up as follows: well # 1 received 5 ⁇ L of compound plus 10 ⁇ L ⁇ of DMSO.
  • Wells 2-10 received 10 ⁇ L of DMSO.
  • 5 ⁇ L ⁇ was mixed and transferred from well #1 into well #2. 1:3 serial dilutions were continued out 10 steps. 2 pL of diluted compound was transferred into duplicate wells of a 384 well "assay plate" and then 90 ⁇ L ⁇ of buffer was added.
  • both the cell and "assay plate” plates were brought to the fhiorometric imaging plate reader (FLIPR ® ) and 20 ⁇ . of the diluted compounds were transferred to the cell plates by the FLIPR ® . Plates were then incubated for 1 hour at room temperature. After the 1 hour incubation, plates were returned to the FLIPR ® and 20 ⁇ L ⁇ of 4.5X concentrated ligand was added to the cell plates.
  • fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 ⁇ L ⁇ of sample was rapidly (30 ⁇ L/sec) and simultaneously added to each well of the cell plate.
  • the fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds. Responses (increase in peak fluorescence) in each well following agonist addition were determined. The initial fluorescence reading from each well, prior to ligand stimulation, was used as a zero baseline value for the data from that well. The responses were expressed as % inhibition of the buffer control.
  • Specific representative compounds tested in the binding assay were tested using the above FLIPR ® assay. For instance, the following table shows the specific IC 50 values for these compounds: Human CRTH2 FLIPR ®
  • PBMC Peripheral blood mononuclear cells
  • the CD4 + T cells were then differentiated to Th2 cells by culturing the cells in X-VIVO 15 ® medium (from Cambrex BioScience Walkersville Inc.) containing 10% human AB serum (serum of blood type AB from Invitrogen Corporation), 50 U/mL of recombinant human interleukin-2 (rhIL-2) (from PeproTech Inc.) and 100 ng/mL of recombinant human interleukin-4 (rhIL-4) (from PeproTech Inc.) for 7 days.
  • X-VIVO 15 ® medium from Cambrex BioScience Walkersville Inc.
  • human AB serum serum of blood type AB from Invitrogen Corporation
  • rhIL-2 recombinant human interleukin-2
  • rhIL-4 recombinant human interleukin-4
  • the Th2 cells were isolated using a CD294 (CRTH2) MicroBead Kit (from Miltenyi Biotec Inc.) and amplified in X-VIVO 15 ® medium containing 10% human AB serum and 50 U/mL of rhIL-2 for 2 to 5 weeks.
  • CRTH294 CD294
  • X-VIVO 15 ® medium containing 10% human AB serum and 50 U/mL of rhIL-2 for 2 to 5 weeks.
  • 70% to 80% of the Th2 cells used in the assay are CRTH2-positive when analyzed by fluorescence- activated cell sorting using the BM16 antibody (as previously described) conjugated to phycoerythrin (PE).
  • the percent inhibition of interleukin 13 (IL-13) production for a compound at various concentrations was calculated according to the following formula, [1 -(IL-13 production in the presence of compound)/(IL-13 production in the presence of 0.15% DMSO)]xl00.
  • Representative compounds tested in the binding assay were tested using the foregoing DK-PGD 2 -induced IL-13 production assay (examples 1-1 to 1-9, 2-1, 3-1 to 3-3, 4-1 to 4-3, 5-1, 6-1, 7-1, 8-1, 9-1 to 9-3, 10-2, 10-5, and 10-6).
  • the results of the DK- PGD 2 -induced IL-13 production assay showed that, with the exception of examples 1- 8 and 1-9 (which exhibited IC 50 values greater than 10), the compounds tested in this assay exhibited activity in inhibiting IL-13 production, with IC 50 values ranging from 0.0032 ⁇ to 6.428 ⁇ .
  • the compounds of the present invention possess a specific, substantial and credible utility since the compounds tested show some activity in at least one of the above three assays (i.e., binding at the CRTH2 receptor), and therefore may be useful as antagonists in treating diseases and disorders associated with this receptor such as asthma.
  • thromboxane A2 Receptor Binding Assay The thromboxane A2 receptor (TP) plays a key role in hemostasis as its abnormality leads to bleeding disorders. To avoid the potential liability of bleeding disorders, the binding activity of certain compounds of the present invention against TP was monitored by a receptor binding assay using human platelets as the source of the receptor and [ 3 H]SQ29548 (generically named (5Z)-[5,6- 3 H]-7-[(lS,2R,3R,4R)-3-[[2- [(phenylamino)carbonyl]hydrazinyl]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5- heptenoic acid, from PerkinElmer Inc.) as the competing radioactive ligand.
  • 5Z 5-Z-[5,6- 3 H]-7-[(lS,2R,3R,4R)-3-[[2- [(phenylamino)carbonyl]hydrazinyl]
  • the TP binding reactions (0.2 mL) were performed in 96-well plates at room temperature in PBS containing 5 x 10 7 platelets, 10 mM MgCl 2 , 0.06% BSA, 10 nM [ 3 H]SQ29548, and the test compound at various concentrations. After 1 hour of binding reactions, the platelets were harvested on GF/B filter plates (as previously described from PerkinElmer Inc.) and washed 5 times with PBS using a FiltermateTM Harvester (as previously described from PerkinElmer Inc.).
  • the radioactivities bound to the platelets were determined using a microplate scintillation counter (TopCount ® NXT, from PerkinElmer Inc.) after adding 50 of Micro scintTM 20 scintillation fluid (from PerkinElmer Inc.) to each well of the filter plates.
  • the radioactivity from nonspecific binding was determined by replacing the compound with 10 ⁇ of ramatroban (BAY-u3405, from Cayman Chemical Company) in the reaction mixtures.
  • the radioactivity bound to the platelets in the absence of compound (total binding) was determined by replacing the compound with 0.25% of DMSO in the reaction mixture. Specific binding data were obtained by subtracting the radioactivity of nonspecific binding from each binding data.
  • the IC 50 value is defined as the concentration of the tested compound that is required for 50% inhibition of total specific binding.
  • the percent inhibition data were determined for 7 concentrations for each compound.
  • the percent inhibition for a compound at each concentration was calculated according to the following formula, [1 -(specific binding in the presence of compound)/(total specific binding)]xl00.
  • the IC 50 value was then obtained by fitting the percent inhibition data to a sigmoidal dose-response (4 parameter logistic) model in the

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)

Abstract

Provided herein are compounds of the formula (I) as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of inflammatory diseases and disorders such as, for example, asthma and COPD.

Description

BENZOCYCLOHEPTENE ACETIC ACIDS
The present invention relates to organic compounds useful for therapy and/or prophylaxis in a mammal of an inflammatory disease or disorder, and in particular to arylsulfonylamino-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy-acetic acids, their manufacture, pharmaceutical compositions containing them and their use as CRTH2 antagonists.
Prostaglandin D2 (PGD2) is the major prostanoid produced by activated mast cells and has been implicated in the pathogenesis of allergic diseases such as allergic asthma and atopic dermatitis. Chemoattractant Receptor-homologous molecule expressed on T-helper type cells (CRTH2) is one of the prostaglandin D2 receptors and is expressed on the effector cells involved in allergic inflammation such as T helper type 2 (Th2) cells, eosinophils, and basophils (Nagata, K. et al. FEBS Lett. 1999, 459, 195-199). It has been shown to mediate PGD2- stimulated chemotaxis of Th2 cells, eosinophils, and basophils (Hirai, H. et al. . Exp. Med. 2001, 193, 255-261). Moreover, CRTH2 mediates the respiratory burst and de granulation of eosinophils (Gervais, F. G. /. Allergy Clin. Immunol. 2001, 108, 982-988), induces the production of
proinflammatory cytokines in Th2 cells (Xue, L. et al. J. Immunol. 2005, 175, 6531- 6536), and enhances the release of histamine from basophils (Yoshimura-Uchiyama, C. et al. Clin. Exp. Allergy 2004, 34, 1283-1290). Sequence variants of the gene encoding CRTH2, which differentially influence its mRNA stability, are shown to be associated with asthma (Huang, J.-L. et al. Hum. Mol. Genet. 2004, 13, 2691-2697). Increased numbers of circulating T cells expressing CRTH2 have also been correlated with severity of atopic dermatitis (Cosmi, L. et al. Eur J Immunol 2000, 30, 2972- 2979). These findings suggest that CRTH2 plays a proinflammatory role in allergic diseases. Therefore, antagonists of CRTH2 are believed to be useful for treating disorders such as asthma, allergic inflammation, chronic obstructive pulmonary disease (COPD), allergic rhinitis, and atopic dermatitis.
In an embodiment of the present invention, provided are compounds of general formula (I):
Figure imgf000004_0001
wherein:
Ar is: -phenyl, unsubstituted or mono- or bi-substituted independently with halogen, lower alkyl, -CF3, -SO2CH3, alkoxy, -C(0)CH3, unsubstituted heteroaryl or heteroaryl substituted with lower alkyl;
-biphenyl, unsubstituted or mono- or bi-substituted independently with -OH, lower alkyl, -SCH3 or -S02CH3; or
-pyridine, unsubstituted or substituted independently with unsubstituted phenyl or phenyl mono- or bi-substituted independently with lower alkyl, -CF3 or - CH2CH2OH; and
R is hydrogen or lower alkyl,
or a pharmaceutically acceptable salt thereof.
In a further embodiment of the invention, provided is a pharmaceutical composition comprising a therapeutically effective amount of a compound according to formula (I) and a therapeutically inert carrier.
In a still further embodiment of the invention, provided is a method for the treatment or prophylaxis of asthma or COPD, which method comprises the step of administering a therapeutically effective amount of a compound according to formula (I) to a patient in need thereof.
All documents cited to or relied upon below are expressly incorporated herein by reference. Unless otherwise indicated, the following specific terms and phrases used in the description and claims are defined as follows: As used herein, the term "alkyl", alone or in combination with other groups, refers to a branched or straight-chain monovalent saturated aliphatic hydrocarbon radical of one to twenty carbon atoms, preferably one to sixteen carbon atoms, more preferably one to ten carbon atoms. The term "lower alkyl", alone or in combination with other groups, refers to a branched or straight-chain alkyl radical of one to nine carbon atoms, preferably one to six carbon atoms, more preferably one to four carbon atoms. This term is further exemplified by radicals such as methyl, ethyl, n-propyl, isopropyl, w-butyl, s-butyl, isobutyl, f-butyl, H-pentyl, 3-methylbutyl, H-hexyl, 2-ethylbutyl and the like.
The term "cycloalkyl" refers to a monovalent mono- or polycarbocyclic radical of three to ten, preferably three to six carbon atoms. This term is further exemplified by radicals such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, norbornyl, adamantyl and the like. In a preferred embodiment, the "cycloalkyl" moieties can optionally be substituted with one, two, three or four substituents, with the understanding that said substituents are not, in turn, substituted further. Each substituent can independently be, alkyl, alkoxy, halogen, amino, hydroxyl or oxygen (0=) unless otherwise specifically indicated. Examples of cycloalkyl moieties include, but are not limited to, optionally substituted cyclopropyl, optionally substituted cyclobutyl, optionally substituted cyclopentyl, optionally substituted cyclopentenyl, optionally substituted cyclohexyl, optionally substituted cyclohexylene, optionally substituted cycloheptyl, and the like or those which are specifically exemplified herein.
The term "heterocycloalkyl" denotes a mono- or polycyclic alkyl ring, wherein one, two or three of the carbon ring atoms is replaced by a heteroatom such as N, O or S. Examples of heterocycloalkyl groups include, but are not limited to, morpholinyl, thiomorpholinyl, piperazinyl, piperidinyl, pyrrolidinyl, tetrahydropyranyl,
tetrahydrofuranyl, 1,3-dioxanyl and the like. The heterocycloalkyl groups may be unsubstituted or substituted and attachment may be through their carbon frame or through their heteroatom(s) where appropriate, with the understanding that said substituents are not, in turn, substituted further.
The term "aryl" refers to an aromatic mono- or polycarbocyclic radical of 6 to 12 carbon atoms having at least one aromatic ring. Examples of such groups include, but are not limited to, phenyl, naphthyl, 1,2,3,4-tetrahydronaphthalene, 1,2- dihydronaphthalene, indanyl, lH-indenyl and the like.
The term "heteroaryl," refers to an aromatic mono- or polycyclic radical of 5 to 12 atoms having at least one aromatic ring containing one, two, or three ring heteroatoms selected from N, O, and S, with the remaining ring atoms being C. Examples of such groups include, but are not limited to, pyridine, thiazole and pyranyl.
The alkyl, lower alkyl, aryl and heteroaryl groups described above may be substituted independently with one, two, or three substituents, with the understanding that said substituents are not, in turn, substituted further. Substituents may include, for example, halogen, lower alkyl, -CF3, -S02CH3, alkoxy, -C(0)CH3, -OH, -SCH3 and - CH2CH2OH.
As used herein, the term "alkoxy" means alkyl-O-; and "alkoyl" means alkyl-CO-. Alkoxy substituent groups or alkoxy-containing substituent groups may be substituted by, for example, one or more alkyl groups, with the understanding that said substituents are not, in turn, substituted further.
As used herein, the term "halogen" means a fluorine, chlorine, bromine or iodine radical, preferably a fluorine, chlorine or bromine radical, and more preferably a fluorine or chlorine radical.
Compounds of formula I can have one or more asymmetric carbon atoms and can exist in the form of optically pure enantiomers, mixtures of enantiomers such as, for example, racemates, optically pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates or mixtures of diastereoisomeric racemates. The optically active forms can be obtained for example by resolution of the racemates, by asymmetric synthesis or asymmetric chromatography (chromatography with a chiral adsorbents or eluant). The invention embraces all of these forms. As used herein, the term "pharmaceutically acceptable salt" means any
pharmaceutically acceptable salt of the compound of formula (I). Salts may be prepared from pharmaceutically acceptable non-toxic acids and bases including inorganic and organic acids and bases. Such acids include, for example, acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethenesulfonic, dichloro acetic, formic, fumaric, gluconic, glutamic, hippuric, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, oxalic, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, oxalic, p-toluenesulfonic and the like. Particularly preferred are fumaric, hydrochloric, hydrobromic, phosphoric, succinic, sulfuric and methanesulfonic acids. Acceptable base salts include alkali metal (e.g. sodium, potassium), alkaline earth metal (e.g. calcium, magnesium) and aluminum salts.
In the practice of the method of the present invention, an effective amount of any one of the compounds of this invention or a combination of any of the compounds of this invention or a pharmaceutically acceptable salt thereof, is administered via any of the usual and acceptable methods known in the art, either singly or in combination. The compounds or compositions can thus be administered orally (e.g., buccal cavity), sublingually, parenterally (e.g., intramuscularly, intravenously, or subcutaneously), rectally (e.g., by suppositories or washings), transdermally (e.g., skin electroporation) or by inhalation (e.g., by aerosol), and in the form or solid, liquid or gaseous dosages, including tablets and suspensions. The administration can be conducted in a single unit dosage form with continuous therapy or in a single dose therapy ad libitum. The therapeutic composition can also be in the form of an oil emulsion or dispersion in conjunction with a lipophilic salt such as pamoic acid, or in the form of a
biodegradable sustained-release composition for subcutaneous or intramuscular administration.
Useful pharmaceutical carriers for the preparation of the compositions hereof, can be solids, liquids or gases. Thus, the compositions can take the form of tablets, pills, capsules, suppositories, powders, enterically coated or other protected formulations (e.g. binding on ion-exchange resins or packaging in lipid-protein vesicles), sustained release formulations, solutions, suspensions, elixirs, aerosols, and the like. The carrier can be selected from the various oils including those of petroleum, animal, vegetable or synthetic origin, e.g., peanut oil, soybean oil, mineral oil, sesame oil, and the like. Water, saline, aqueous dextrose, and glycols are preferred liquid carriers, particularly (when isotonic with the blood) for injectable solutions. For example, formulations for intravenous administration comprise sterile aqueous solutions of the active ingredient(s) which are prepared by dissolving solid active ingredient(s) in water to produce an aqueous solution, and rendering the solution sterile. Suitable
pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, talc, gelatin, malt, rice, flour, chalk, silica, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk, glycerol, propylene glycol, water, ethanol, and the like. The compositions may be subjected to conventional
pharmaceutical additives such as preservatives, stabilizing agents, wetting or emulsifying agents, salts for adjusting osmotic pressure, buffers and the like. Suitable pharmaceutical carriers and their formulation are described in Remington's
Pharmaceutical Sciences by E. W. Martin. Such compositions will, in any event, contain an effective amount of the active compound together with a suitable carrier so as to prepare the proper dosage form for proper administration to the recipient.
The dose of a compound of the present invention depends on a number of factors, such as, for example, the manner of administration, the age and the body weight of the subject, and the condition of the subject to be treated, and ultimately will be decided by the attending physician or veterinarian. Such an amount of the active compound as determined by the attending physician or veterinarian is referred to herein, and in the claims, as a "therapeutically effective amount". For example, the dose of a compound of the present invention is typically in the range of about 1 to about 1000 mg per day. Preferably, the therapeutically effective amount is in an amount of from about 1 mg to about 500 mg per day.
The present invention provides compounds having the general formula (I):
Figure imgf000009_0001
wherein:
Ar is: -phenyl, unsubstituted or mono- or bi-substituted independently with halogen, lower alkyl, -CF3, -SO2CH3, alkoxy, -C(0)CH3, unsubstituted heteroaryl or heteroaryl substituted with lower alkyl;
-biphenyl, unsubstituted or mono- or bi-substituted independently with -OH, lower alkyl, -SCH3 or -S02CH3; or -pyridine, unsubstituted or substituted independently with unsubstituted phenyl or phenyl mono- or bi-substituted independently with lower alkyl, -CF3 or - CH2CH2OH; and
R1 is hydrogen or lower alkyl,
or a pharmaceutically acceptable salt thereof.
In another embodiment of the present invention, provided is a compound of formula (I) wherein Ar is phenyl, unsubstituted or mono- or bi-substituted independently with fluorine, chlorine, bromine, -CH(CH3)2, -CF3, -S02CH3, -OCH3, -C(0)CH3 or - pyridine-methyl.
In another embodiment of the present invention, provided is a compound of formula (I) wherein Ar is biphenyl, unsubstituted or mono- or bi-substituted independently with - CH3,
-CH(CH3)2, -C(CH3)3, -OH, -SCH3 or -S02CH3. In another embodiment of the present invention, provided is a compound of formula (I) wherein Ar is pyridine substituted independently with unsubstituted phenyl or phenyl mono- or bi-substituted independently with -CH3, -CH(CH3)2, -C(CH )3, -CF3 or - CH2CH2OH.
In another embodiment of the present invention, provided is a compound of formula (I) wherein R1 is hydrogen.
In another embodiment of the present invention, provided is a compound of formula (I) wherein R1 is methyl.
Particular compounds of formula (I) include the following:
[5-(3,5-Bis-trifluoromethyl-benzenesulfonylamino)-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy] -acetic acid;
[5-(3,5-Dichloro-benzenesulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l- yloxy]-acetic acid;
[5-(Biphenyl-3-sulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy]- acetic acid;
[5-(Biphenyl-4-sulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy]- acetic acid;
[5-(3-Methanesulfonyl-benzenesulfonylamino)-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy] -acetic acid;
[5-(3-Fluoro-5-trifluoromethyl-benzenesulfonylamino)-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy] -acetic acid;
{5-[(3-Fluoro-5-trifluoromethyl-benzenesulfonyl)-methyl-amino]-6,7,8,9-tetrahydro 5H-benzocyclohepten- 1 -yloxy} -acetic acid;
[5-(3-Bromo-5-trifluoromethyl-benzenesulfonylamino)-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy] -acetic acid;
{5-[(3-Bromo-5-trifluoromethyl-benzenesulfonyl)-methyl-amino]-6,7,8,9-tetrahydro- 5H-benzocyclohepten- 1 -yloxy} -acetic acid;
[5-(3,5-Bis-methanesulfonyl-benzenesulfonylamino)-6,7,8,9-tetrahydro-5H
benzocyclohepten- 1 -yloxy] -acetic acid;
{5-[(3,5-Bis-methanesulfonyl-benzenesulfonyl)-methyl-amino]-6,7,8,9-tetrahydro- 5H-benzocyclohepten- 1 -yloxy} -acetic acid; {5-[(Biphenyl-4-sulfonyl)-methyl-amino]-6,7,8,9-tetrahydro-5H-benzocyclohepten-l- yloxy} -acetic acid;
[5-(3-Methoxy-5-trifluoromethyl-benzenesulfonylamino)-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy] -acetic acid;
{5-[(3-Methoxy-5-trifluoromethyl-benzenesulfonyl)-methyl-amino]-6,7,8,9- tetrahydro-5H-benzocyclohepten-l-yloxy}-acetic acid;
[5-(3-Acetyl-5-trifluoromethyl-benzenesulfonylamino)-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy] -acetic acid;
{5-[(3-Acetyl-5-trifluoromethyl-benzenesulfonyl)-methyl-amino]-6,7,8,9-tetrahydro- 5H-benzocyclohepten- 1 -yloxy} -acetic acid;
[5-(3-Methanesulfonyl-5-trifluoromethyl-benzenesulfonylamino)-6,7,8,9-tetrahydro- 5H-benzocyclohepten- 1 -yloxy] -acetic acid;
{5-[(3-Methanesulfonyl-5-trifluoromethyl-benzenesulfonyl)-methyl-amino]-6,7,8,9- tetrahydro-5H-benzocyclohepten-l-yloxy}-acetic acid;
[5-(3'-Isopropyl-biphenyl-4-sulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten- 1 -yloxy] -acetic acid;
{5-[(3'-Isopropyl-biphenyl-4-sulfonyl)-methyl-amino]-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy } -acetic acid;
[5-(3'-tert-Butyl-5'-methyl-biphenyl-4-sulfonylamino)-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy] -acetic acid;
{5-[(3'-tert-Butyl-5'-methyl-biphenyl-4-sulfonyl)-methyl-amino]-6,7,8,9-tetrahydro- 5H-benzocyclohepten- 1 -yloxy} -acetic acid;
[5-(4'-Hydroxy-biphenyl-4-sulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten- 1 -yloxy] -acetic acid;
{5-[(4'-Hydroxy-biphenyl-4-sulfonyl)-methyl-amino]-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy } -acetic acid;
{5-[4-(5-Methyl-pyridin-3-yl)-benzenesulfonylamino]-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy } -acetic acid;
(5-{Methyl-[4-(5-methyl-pyridin-3-yl)-benzenesulfonyl]-amino}-6,7,8,9-tetrahydro- 5H-benzocyclohepten-l-yloxy)-acetic acid;
[5-(3'-Methylsulfanyl-biphenyl-4-sulfonylamino)-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy] -acetic acid;
{5-[Methyl-(3'-methylsulfanyl-biphenyl-4-sulfonyl)-amino]-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy } -acetic acid; [5-(3'-Methanesulfonyl-biphenyl-4-sulfonylamino)-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy] -acetic acid;
{5-[(3'-Methanesulfonyl-biphenyl-4-sulfonyl)-methyl-amino]-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy } -acetic acid;
{5-[5-(3-Isopropyl-phenyl)-pyridine-2-sulfonylamino]-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy } -acetic acid;
(5-{ [5-(3-Isopropyl-phenyl)-pyridine-2-sulfonyl]-methyl-amino}-6,7,8,9-tetrahydro- 5H-benzocyclohepten-l-yloxy)-acetic acid;
{5-[5-(3-Trifluoromethyl-phenyl)-pyridine-2-sulfonylamino]-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy } -acetic acid;
(5-{Methyl-[5-(3-trifluoromethyl-phenyl)-pyridine-2-sulfonyl]-amino}-6,7,8,9- tetrahydro-5H-benzocyclohepten-l-yloxy)-acetic acid;
{5-[5-(3-tert-Butyl-5-methyl-phenyl)-pyridine-2-sulfonylamino]-6,7,8,9-tetrahydro- 5H-benzocyclohepten- 1 -yloxy} -acetic acid;
(5-{ [5-(3-tert-Butyl-5-methyl-phenyl)-pyridine-2-sulfonyl]-methyl-amino}-6,7,8,9- tetrahydro-5H-benzocyclohepten-l-yloxy)-acetic acid;
(5-{5-[3-(2-Hydroxy-ethyl)-phenyl]-pyridine-2-sulfonylamino}-6,7,8,9-tetrahydro- 5H-benzocyclohepten-l-yloxy)-acetic acid;
[5-({5-[3-(2-Hydroxy-ethyl)-phenyl]-pyridine-2-sulfonyl}-methyl-amino)-6,7,8,9- tetrahydro-5H-benzocyclohepten- 1 -yloxy] -acetic acid;
[5-(4'-Methyl-biphenyl-3-sulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l- yloxy]-acetic acid;
{5-[Methyl-(4'-methyl-biphenyl-3-sulfonyl)-amino]-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy } -acetic acid;
[5-(3'-Isopropyl-biphenyl-3-sulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten- 1 -yloxy] -acetic acid;
{5-[(3'-Isopropyl-biphenyl-3-sulfonyl)-methyl-amino]-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy } -acetic acid;
[5-(3-Isopropyl-5-trifluoromethyl-benzenesulfonylamino)-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy] -acetic acid;
{5-[(3-Isopropyl-5-trifluoromethyl-benzenesulfonyl)-methyl-amino]-6,7,8,9- tetrahydro-5H-benzocyclohepten-l-yloxy}-acetic acid; and
[5-(3,5-Bis-trifluoromethyl-benzenesulfonylamino)-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy] -acetic acid. In another embodiment of the invention, provided is a compound of formula (I) for use as a therapeutically active substance.
In another embodiment of the invention, provided is pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) and a therapeutically inert carrier.
In another embodiment of the invention, provided is a use of a compound according to formula (I) for the treatment or prophylaxis of asthma or COPD.
In another embodiment of the invention, provided is a use of a compound according to formula (I) for the preparation of a medicament for the treatment or prophylaxis of asthma or COPD. In another embodiment of the invention, provided is a compound according to formula (I) for the treatment or prophylaxis of asthma or COPD.
In another embodiment of the invention, provided is compound according formula (I), when manufactured according to a process below.
In another embodiment of the invention, provided is a method for the treatment or prophylaxis of asthma or COPD, which method comprises the step of administering a therapeutically effective amount of a compound of formula (I) to a patient in need thereof.
In another embodiment of the invention, provided is an invention as hereinbefore described.
It will be appreciated, that the compounds of general formula I in this invention may be derivatized at functional groups to provide derivatives which are capable of conversion back to the parent compound in vivo. Physiologically acceptable and metabolically labile derivatives, which are capable of producing the parent compounds of general formula I in vivo are also within the scope of this invention.
Compounds of the present invention can be prepared beginning with commercially available starting materials, or utilizing general synthetic techniques and procedures known to those skilled in the art. Chemicals may be purchased from companies such as for example Aldrich, Argonaut Technologies, VWR, Lancaster, Princeton, Alfa, Oakwood, TCI, Fluorochem, Apollo, Matrix, Maybridge or Meinoah.
Chromatography supplies and equipment may be purchased from such companies as for example AnaLogix, Inc, Burlington, WI; Biotage AB, Charlottesville, VA;
Analytical Sales and Services, Inc., Pompton Plains, NJ; Teledyne Isco, Lincoln, NE; VWR International, Bridgeport, NJ; Varian Inc., Palo Alto, CA, and Multigram II Mettler Toledo Instrument Newark, DE. Biotage, ISCO and Analogix columns are pre-packed silica gel columns used in standard chromatography. Final compounds and intermediates were named using the AutoNom2000 feature in the MDL ISIS Draw application.
The present invention is also directed to the administration of a therapeutically effective amount of a compound of formula I in combination or association with other drugs or active agents for the treatment of inflammatory or allergic diseases and disorders. In one embodiment, the present invention relates to a method for the treatment and/or prevention of such diseases or disorders comprising administering to a human or animal simultaneously, sequentially, or separately, a therapeutically effective amount of a compound of formula I and another drug or active agent (such as another anti-inflammatory or anti-allergic drug or agent). These other drugs or active agents may have the same, similar, or a completely different mode of action. Suitable other drugs or active agents may include, but are not limited to: Beta2- adrenergic agonists such as albuterol or salmeterol; corticosteroids such as dexamethasone or fluticasone; antihistamines such as loratidine; leukotriene antagonists such as montelukast or zafirlukast; anti-IgE antibody therapies such as omalizumab; anti-infectives such as fusidic acid (particularly for the treatment of atopic dermatitis); anti-fungals such as clotrimazole (particularly for the treatment of atopic dermatitis); immunosuppressants such as tacrolimus and pimecrolimus; other antagonists of PGD2 acting at other receptors such as DP antagonists; inhibitors of phosphodiesterase type 4 such as cilomilast; drugs that modulate cytokine production such as inhibitors of TNF-alpha converting enzyme (TACE); drugs that modulate the activity of Th2 cytokines IL-4 and IL-5 such as blocking monoclonal antibodies and soluble receptors; PPAR-gamma agonists such as rosiglitazone; and 5-lipoxygenase inhibitors such as zileuton. Preferably, the compounds of formula I, can be prepared by the following general reaction scheme.
General Synthesis
The compounds of the present invention can be prepared by any conventional means. Suitable processes for synthesizing these compounds are provided in the examples. Generally, compounds of formula I can be prepared according to the schemes illustrated below. For example, certain compounds of the invention may be made using the approach outlined in Scheme 1.
Figure imgf000015_0001
Scheme 1
According to Scheme 1, benzosuberone, the compound of formula 2 (which may be purchased from suppliers such as Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA and TCI America, 9211 N. Harborgate Street, Portland, OR 97203, USA) is brominated to give the bromo-derivative of formula 3. The compound of formula 3 is then subjected to a palladium-catalyzed hydroxylation reaction to give the compound of formula 4 which is alkylated to give the compound of formula 5. Reductive animation of the ketone then gives the amine of formula 6, which is reacted with an aryl-sulfonyl chloride of formula 34 to give the compound of formula 7. Removal of the tert-butyl protective group then gives the compound of the invention of formula 8. Alternatively, the compound of formula 7 may be methylated to give the compound of formula 9, followed by removal of the tert-butyl protective group to give the compound of the invention of formula 10.
The bromination of the compound of benzosuberone (the compound of formula 2) is a known reaction and the reaction may be carried out using the conditions reported in the literature, or using such modifications of these conditions as are obvious to one skilled in the art of organic synthesis. For example, the reaction may be carried out by heating the compound of formula 2 with bromine in the presence of aluminum chloride at a temperature of about 75-80 °C to give a mixture of the desired compound, l-bromo-6,7,8,9-tetrahydro-benzocyclohepten-5-one; the isomeric compound, 3- bromo-6,7,8,9-tetrahydro-benzocyclohepten-5-one; and the disubstituted compound, l,3-dibromo-6,7,8,9-tetrahydro-benzocyclohepten-5-one. Examples of conditions suitable for carrying out this reaction may be found in the literature, for example in McCormick, K. D. et al. WO 2010042475; in Cornelius, L. A. M. and Combs, D. W. Synth. Commun. 1994, 24, 2777-2788; or else in the Examples below. The mixture of products may be separated by distillation, or preferably by supercritical fluid chromatography, as described in the experimental section below.
Alternatively, the compound of formula 3 may be prepared by the cyclization of 5- (2- bromo-phenyl)-pentanoic acid using polyphosphoric acid at a temperature of about 150 °C as described by Gruber, R. et al. Bull. Chem. Soc. France 1983, 96-104. The conversion of the compound of formula 3 to the phenol of formula 4 may conveniently be carried out using a palladium-catalyzed hydroxylation reaction. The reaction may be carried out by heating the compound of formula 3 with potassium hydroxide in the presence of tris(dibenzylideneacetone)dipalladium(0) (which may be purchased from suppliers such as Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA; Alfa Aesar, 26 Parkridge Road, Ward Hill, MA 01835, USA; and TCI America, 9211 N. Harborgate Street, Portland, OR 97203, USA) and 2-di-tert-butyl-phosphino-2',4',6'-triisopropylbiphenyl (which may be purchased from suppliers such as Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA; and Strem Chemicals, Inc., 7 Mulliken Way, Dexter Industrial Park, Newburyport, MA, USA) in a mixture of water and dioxane at a temperature between about 80 °C and about 100 °C. An example of conditions useful for this reaction may be found in the literature, in Anderson, K. et al. /. Am. Chem. Soc. 2006, 128, 10694-10695. Alternatively, the compound of formula 3 may be made using the procedure described in Ito, F. et al. JP 2006063064 where l-methoxy-6,7,8,9-tetrahydrobenzocyclohepten- 5-one may be hydrolyzed by heating in a mixture of acetic acid and 48% aqueous hydrobromic acid at reflux. The multi-step preparation of l-methoxy-6,7,8,9- tetrahydrobenzocyclohepten-5-one is described in da Conceicao, C. M. M. et al. J. Chem. Res. 1995, 347.
The alkylation of the phenol of formula 4 may be carried out using any conventional means. For example, the reaction may conveniently be effected by treating the phenol with tert-butyl bromoacetate in the presence of an inorganic base such as CS2CO3 or K2CO3 in an inert solvent such as DMF or CH3CN or acetone or 2-butanone at a temperature between about 20 °C and about 80 °C. Examples of appropriate conditions may be found in the literature, for example in Blanc, J.-B. et al. US 20100041714; in Firooznia, F. et al. US 20100041713; in Isaad, J. et al. Eur. J. Org. Chem. 2009, 2748-2764; in Matsumoto, T. et al. Chem. Lett. 1988, 1399-1402; in Akahane, A. et al. US 6,355,640; or in Ohkawa, S. et al. US 6,248,766.
The reductive amination of the ketone of formula 5 may be carried out using any of a number of reactions that are familiar to one of average skill in the art of organic synthesis. For example, the reaction may be conveniently carried out by treating the ketone of formula 5 with an acid addition salt of ammonia such as ammonium acetate in the presence of a reducing agent such as sodium triacetoxyborohydride or sodium cyanoborohydride in an inert solvent such as methanol or ethanol at about room temperature. Examples of specific conditions useful for this reaction may be found in the literature, for example in Blanc, J.-B. et al. US 20100041760; in Chow, K. et al. WO 2009023757; and in Gross, M. F. et al. Bioorg. Med. Chem. Lett. 2009, 19, 3063- 3066. Alternatively, the ketone of formula 5 may be converted to the corresponding oxime by heating with hydroxylamine hydrochloride in MeOH or EtOH at reflux in the presence of an organic base such as triethylamine or diisopropylethylamine or sodium acetate followed by treatment of the oxime under dissolving metal conditions such as by treatment with sodium metal in propanol at reflux to give the amine of formula 6. Examples of specific conditions useful for this reaction may be found in the literature, for example in Bhandari, K. et al. Bioorg. Med. Chem. 2004, 12, 4189- 4196. Alternatively, the ketone of formula 5 may be treated with O- methylhydroxylamine hydrochloride in MeOH at room temperature, followed by treatment of the resulting oxime ether with borane-THF complex in THF at about
60 °C to give the amine of formula 6. Examples of specific conditions useful for this reaction may be found in the literature, for example in S0rensen, U. S. et al. US 7,737,167. The sulfonylation of a compound of formula 6 can be effected using procedures that are well known in the field of organic synthesis. For example, the compound of formula 6 may be treated with an arylsulfonyl chloride in the presence of an appropriate base for example pyridine, which may also be used as solvent. The reaction may also be performed by using a tertiary amine as the base, in the presence of an inert solvent such as tetrahydrofuran or dichloromethane; or in aqueous solution using an alkali metal hydroxide such as sodium hydroxide as the base. The reaction is conveniently carried out at a temperature of between about room temperature and about 80 °C, preferably at about room temperature. Examples of conditions suitable for carrying out this reaction may be found in the literature, for example in Gillespie, J. et al. WO 2009147167; in Allerton, C. M. M. WO 2007057775; in Firooznia, F. et al. US 20100041713; and in Guianvarc'h, D. et al. J. Med. Chem. 2004, 47, 2365-2374.
Removal of the tert-butyl group from a compound of formula 7 to give a compound of the invention of formula 8 may be accomplished using a variety of conditions that are well known to one of average skill in the art of organic synthesis. For example, many conditions for effecting such a transformation are outlined in "Protective Groups in Organic Synthesis" [T. W. Greene and P. G. M. Wuts, 2nd Edition, John Wiley & Sons, N.Y. 1991]. For example, the compound of formula 7 may be treated with a strong organic acid (preferably trifluoroacetic acid) in an inert solvent such as a halogenated hydrocarbon (preferably dichloromethane or chloroform) at a temperature about room temperature. Exact conditions for such a reaction may be found in the literature, for example in Bartel, S. et al. US 20100029772; in Thompson, T. and Willis, P. US 20080146612; in Ford, R. et al. US 20080153850; and in Hirashima, S. et al. J. Med. Chem. 2006, 49, 4721-4736. Alternatively, the reaction may be effected by heating the compound of formula 7 in 2,2,2-trifluoroethanol or hexafluoroisopropanol at a temperature between about 100 °C and about 150 °C with or without microwave irradiation (for an example of conditions, see Choi, J. C.-C. et al. US 20090203910). Most preferably, the reaction can be accomplished by treating the compound of formula 7 with an excess of an alkali metal hydroxide such as lithium hydroxide or preferably sodium hydroxide in an inert solvent such as a mixture of tetrahydrofuran and water at about room temperature.
Methylation of a compound of formula 7 to give a compound of formula 9 may be accomplished using any conventional means. For example, the reaction may be conveniently carried out by treating the compound of formula 7 with a methylating agent such as methyl iodide or dimethyl sulfate in the presence of a base such as potassium carbonate or cesium carbonate or sodium hydride in an inert solvent such as DMF or tetrahydrofuran at a temperature between about 0 °C and about room temperature, preferably at about room temperature. Examples of conditions for such a reaction may be found in the literature, for example in Yates, C. M. et al. J. Med.
Chem. 2010, 53, 4531-4544; in Blanc, J.-B. et al. US 20100041760; in Kremoser, C. et al. US 20100184809; and in Mailyan, A. K. et al. J. Org. Chem. 2009, 74, 8444- 8447. Removal of the tert-butyl group from a compound of formula 9 to give a compound of the invention of formula 10 may be accomplished using any of the conditions described above for the removal of the tert-butyl group from a compound of formula 7 to give a compound of the invention of formula 8.
Additionally, certain compounds of the invention may be made as shown in Scheme 2
Figure imgf000020_0001
Scheme 2
According to Scheme 2, the compound of formula 6, which may be prepared as outlined in Scheme 1, is reacted with an aryl-sulfonyl chloride to give the compound of formula 11, in which Y represents a group such as bromo or iodo that can act as a leaving group in a noble metal-catalyzed coupling reaction such as a Suzuki reaction, a Stille reaction, or a Negishi reaction. The compound of formula 11 then undergoes a noble metal-catalyzed reaction to give a biaryl of formula 12, which may be hydrolyzed to give the compound of the invention of formula 13, or methylated and then hydrolyzed to give the compound of the invention of formula 15.
The sulfonylation of a compound of formula 6 to give a compound of formula 11 where X is N or CH and Y is a group which is commonly used in a Suzuki, Stille, or Negishi reaction, such as bromine, iodine, or trifluoromethanesulfonyl, may be effected using the conditions described above for the sulfonylation of a compound of formula 6 to give a compound of formula 7. The reaction of a compound of formula 11 to give a biaryl derivative of formula 12 may be accomplished using reactions that are well known to one of average skill in the art of organic synthesis. For example, the reaction may be accomplished using one of a set of reactions which use noble metal catalysis, and which include the Suzuki reaction, the Stille reaction, and the Negishi reaction. For example, the reaction can be conveniently carried out by reacting a compound of formula 11 with a compound of formula 44 where V represents B(OH)2 or the pinacol ester thereof, in a convenient inert solvent such as a polar aprotic solvent (e.g., Ν,Ν-dimethylformamide) or an ether (e.g., dioxane) or water, or indeed in a mixture of such solvents, in the presence of a catalytic amount of a compound that can be reduced in situ to give palladium(O) (for example, palladium(II) acetate or bis(triphenylphosphine)palladium(II) chloride), in the optional additional presence of a catalytic amount of a phosphine ligand, for example tri-o-tolylphosphine or tri-tert-butylphosphine, or alternatively in the presence of a preformed complex of palladium(O) with a phosphine ligand such as bis(tri-cyclohexylphosphine)palladium, tetrakis(triphenylphosphine)-palladium(0) or [l,l-bis(diphenylphosphino)ferrocene]dichloropalladium(II)), and also in the presence of an inorganic base, for example, an alkali metal carbonate, bicarbonate or phosphate (e.g., potassium phosphate or sodium carbonate) at a temperature between about room temperature and about 100 degrees, and preferably between about room temperature and about 50 degrees. The Suzuki reaction is familiar to one of ordinary skill in the art of organic synthesis, and has been reviewed several times, notably in Miyaura, N.; Suzuki, A. Chem. Rev. 1995, 95, 2457-2483 and, more recently, in Alonso, F.;
Beletskaya, I. P.; Yus, M. Tetrahedron 2008, 64, 3047-3101. Examples of specific conditions useful for Suzuki coupling may be found in many references in the literature including: Tiede, S. et al. Angew. Chem, Intl. Edn. 2010, 49, 3972-3975; Schmidt, A. and Rahimi, A. Chem. Commun. 2010, 46, 2995-2997; Lee, S. H. et al. US 20100063281; and Tobisu, M. et al. J. Org. Chem. 2010, 75, 4835-4840
(Supporting Information). Stille coupling is well known to one of average skill in the field of organic synthesis, and may be used as an alternative to the Suzuki coupling, examples of conditions for which have been provided above. Stille coupling has been reviewed, including in Farina, V. et al. Org. Reactions 1997, 50, 1-652. Examples of specific conditions that have been used for Stille coupling may be found in the literature, for example in Littke, A. F. et al. /. Am. Chem. Soc. 2002, 124, 5343-6348; in Alberati-Giani, D. et al. US 7,462,617; and in Robl, J. A. US 5,072,023. Removal of the tert-butyl group from a compound of formula 12 to give a compound of the invention of formula 13 may be accomplished using any of the conditions described above for the removal of the tert-butyl group from a compound of formula 7 to give a compound of the invention of formula 8. Methylation of a compound of formula 12 to give a compound of formula 14 may be accomplished using the conditions outlined above for the conversion of a compound of formula 7 to a compound of formula 9. Removal of the tert-butyl group from a compound of formula 14 to give a compound of the invention of formula 15 may be accomplished using any of the conditions described above for the removal of the tert-butyl group from a compound of formula 7 to give a compound of the invention of formula 8.
Additionally, certain compounds of the invention may be made as shown in Scheme 3.
Figure imgf000022_0001
Scheme 3
According to Scheme 3, the compound of formula 6, which may be prepared as outlined in Scheme 1, is reacted with 3-fluoro-5-(trifluoromethyl)benzenesulfonyl chloride (which may be purchased from Alfa Aesar, 26 Parkridge Road, Ward Hill, MA 01835, USA) to give the sulfonamide of formula 16. This compound may be reacted with the sodium salt of a lower alcohol to effect simultaneous substitution of the fluorine and hydrolysis of the tert-butyl protective group to give the compound of the invention of formula 17. Alternatively, the sulfonamide of formula 16 may be methylated to give the compound of formula 18, and then reacted with the sodium salt of a lower alcohol to effect simultaneous substitution of the fluorine and hydrolysis of the tert-butyl protective group to give the compound of the invention of formula 19.
The sulfonylation of a compound of formula 6 to give a compound of formula 16 may be effected using the conditions described above for the sulfonylation of a compound of formula 6 to give a compound of formula 7.
The conversion of a compound of formula 16 to give a compound of formula 17 may be effected by treating the compound of formula 16 with the sodium salt of a lower alcohol in an inert solvent such as the same lower alcohol or a mixture of the lower alcohol and DMF at a temperature between about the reflux temperature of the solvent and about 150 °C, with or without microwave irradiation. Depending on the conditions used, the tert-butyl protective group may be deprotected during the course of the reaction giving directly the compound of the invention of formula 17. However, if the tert-butyl group is not cleaved during the nucleophilic substitution reaction, the it can be removed using any of the conditions described above for the removal of the tert-butyl group from a compound of formula 7 to give a compound of the invention of formula 8. Methylation of a compound of formula 16 to give a compound of formula 18 may be accomplished using the conditions outlined above for the conversion of a compound of formula 7 to a compound of formula 9.
The conversion of a compound of formula 18 to give a compound of the invention of formula 19 may be effected using the conditions outlined above for the conversion of a compound of formula 16 to a compound of formula 17.
Additionally, certain compounds of the invention may be made as shown in Scheme 4.
Figure imgf000024_0001
Scheme 4
According to Scheme 4, the compound of formula 6, which may be prepared as outlined in Scheme 1, is reacted with a 3-bromo- substituted benzenesulfonyl chloride to give the sulfonamide of formula 20. This compound may be reacted with a tributyl(l-ethoxyvinyl)tin derivative under Stille coupling conditions to give the ketone of formula 21, which may be hydrolyzed to give the compound of the invention of formula 22, or methylated and then hydrolyzed to give the compound of the invention of formula 24.
The sulfonylation of a compound of formula 6 to give a compound of formula 20 may be effected using the conditions described above for the sulfonylation of a compound of formula 6 to give a compound of formula 7.
The conversion of a compound of formula 20 to give a compound of formula 21 can be conveniently carried out by subjecting the compound of formula 20 to a Stille coupling reaction to give a vinyl ether which is then hydrolyzed to give the ketone. Accordingly, the compound of formula 20 is treated with a tributyl(l-ethoxyvinyl)tin derivative in the presence of a catalytic amount of a compound that can be reduced in situ to give palladium(O) (for example, palladium(II) acetate or
bis(triphenylphosphine)palladium(II) chloride), in the optional additional presence of a catalytic amount of a phosphine ligand, for example tri-o-tolylphosphine or tri-tert- butylphosphine or triphenylarsine, or alternatively in the presence of a preformed complex of palladium(O) with a phosphine ligand such as bis(tri- cyclohexylphosphine)palladium, tetrakis(triphenylphosphine)-palladium(0) or [1,1- bis(diphenylphosphino)ferrocene]dichloropalladium(II)), in an inert solvent such as DMF or dioxane at a temperature between about room temperature and about 100 °C, and preferably at about 100 °C. Examples of specific conditions that may be used for this reaction can be found in the literature, for example in Qian, X. et al. ACS Med. Chem. Lett. 2010, 1, 30-34; in Clawson, R. W., Jr. et al. Tetrahedron 2009, 65, 8786- 8793; and in Fotouhi, N. et al. US 7,579,368. The intermediate vinyl ether may then be hydrolyzed, without or without isolation and purification, to give the desired ketone of formula 21. The hydrolysis is conveniently carried out by treating the vinyl ether with aqueous hydrochloric acid in an inert solvent such as the solvent used for the Stille coupling reaction, or DMF or dioxane at about room temperature.
Removal of the tert-butyl group from a compound of formula 21 to give a compound of the invention of formula 22 may be accomplished using any of the conditions described above for the removal of the tert-butyl group from a compound of formula 7 to give a compound of the invention of formula 8.
Methylation of a compound of formula 21 to give a compound of formula 23 may be accomplished using the conditions outlined above for the conversion of a compound of formula 7 to a compound of formula 9.
Removal of the tert-butyl group from a compound of formula 23 to give a compound of the invention of formula 24 may be accomplished using any of the conditions described above for the removal of the tert-butyl group from a compound of formula 7 to give a compound of the invention of formula 8.
Additionally, certain compounds of the invention may be made as shown in Scheme 5.
Figure imgf000026_0001
Scheme 5
According to Scheme 5, the compound of formula 20, which may be prepared as outlined in Scheme 4, is reacted with a lower alkylsulfinic acid to give the sulfone of formula 25. This compound may be hydrolyzed to give the compound of the invention of formula 26, or methylated and then hydrolyzed to give the compound of the invention of formula 28. The conversion of the compound of formula 20 to the compound of formula 25 may be conveniently carried out by treating the compound of formula 20 with a lower alkanesulfinate of formula R7S(=0)OH in the presence of a copper catalyst such as copper(I) iodide in an inert solvent such as DMF or N-methylpyrrolidone at a temperature between about 100 °C and about 150 °C. Examples of specific conditions that may be used for this reaction can be found in the literature, for example in Chesworth, R. et al. WO 2009158467; in Ivachtchenko, A. V. et al. Eur. J. Med. Chem. 2010, 45, 782-789; in Qin, Z. et al. J. Med. Chem. 2007, 50, 2682-2692; and in Sturino, C. F. et al. J. Med. Chem. 2007, 50, 794-806. Removal of the tert-butyl group from a compound of formula 25 to give a compound of the invention of formula 26 may be accomplished using any of the conditions described above for the removal of the tert-butyl group from a compound of formula 7 to give a compound of the invention of formula 8. Methylation of a compound of formula 25 to give a compound of formula 27 may be accomplished using the conditions outlined above for the conversion of a compound of formula 7 to a compound of formula 9. Removal of the tert-butyl group from a compound of formula 27 to give a compound of the invention of formula 28 may be accomplished using any of the conditions described above for the removal of the tert-butyl group from a compound of formula 7 to give a compound of the invention of formula 8.
Additionally, certain compounds of the invention may be made as shown in Scheme 6.
Figure imgf000027_0001
Scheme 6
According to Scheme 6, the compound of formula 20, which may be prepared as outlined in Scheme 4, is reacted with a vinylboronic acid to give the olefin of formula 29. This compound may be hydrogenated to give the compound of formula 30.
Removal of the tert-butyl group then gives the compound of the invention of formula 31. Alternatively, the compound of formula 30 may be methylated and then hydrolyzed to give the compound of the invention of formula 33.
The conversion of the compound of formula 20 to the compound of formula 29 may be conveniently carried out by subjecting the compound of formula 20 to a Suzuki coupling reaction with a vinylboronic acid or the ester of a vinylboronic acid in a convenient inert solvent such as a polar aprotic solvent (e.g., N,N-dimethylformamide) or an ether (e.g., dioxane) or water, or indeed in a mixture of such solvents, in the presence of a catalytic amount of a compound that can be reduced in situ to give palladium(O) (for example, palladium(II) acetate or
bis(triphenylphosphine)palladium(II) chloride), in the optional additional presence of a catalytic amount of a phosphine ligand, for example tri-o-tolylphosphine or tri-tert- butylphosphine, or alternatively in the presence of a preformed complex of
palladium(O) with a phosphine ligand such as bis(tri-cyclohexylphosphine)palladium, tetrakis(triphenylphosphine)-palladium(0) or [1,1- bis(diphenylphosphino)ferrocene]dichloropalladium(II)), and also in the presence of an inorganic base, for example, an alkali metal carbonate, bicarbonate or phosphate (e.g., potassium phosphate or sodium carbonate) at a temperature between about room temperature and about 100 degrees, and preferably between about room temperature and about 50 degrees. The Suzuki reaction is familiar to one of ordinary skill in the art of organic synthesis, and has been reviewed several times, notably in Miyaura, N.; Suzuki, A. Chem. Rev. 1995, 95, 2457-2483 and, more recently, in Alonso, F.;
Beletskaya, I. P.; Yus, M. Tetrahedron 2008, 64, 3047-3101. Examples of specific conditions useful for Suzuki coupling may be found in many references in the literature including: Chessari, G. et al. US 7,700,625; Beck, H. et al. WO 2008030520; Grove, S. J. A. et al. US 20100210680; Wang, X. et al. Org. Lett. 2009, 11, 5490- 5493; and Beckett, R. P. et al. WO 2008157751.
The conversion of the compound of formula 29 to the compound of formula 30 may be carried out by treating the compound of formula 29 with hydrogen gas at ambient pressure or at a pressure of up to approximately 50 pounds per square inch in an inert solvent such as ethanol or ethyl acetate at about room temperature.
Removal of the tert-butyl group from a compound of formula 30 to give a compound of the invention of formula 31 may be accomplished using any of the conditions described above for the removal of the tert-butyl group from a compound of formula 7 to give a compound of the invention of formula 8.
Methylation of a compound of formula 30 to give a compound of formula 32 may be accomplished using the conditions outlined above for the conversion of a compound of formula 7 to a compound of formula 9. Removal of the tert-butyl group from a compound of formula 32 to give a compound of the invention of formula 33 may be accomplished using any of the conditions described above for the removal of the tert-butyl group from a compound of formula 7 to give a compound of the invention of formula 8.
Many arylsulfonyl chlorides of formula 34 useful for the conversion of a compound of formula 6 to a compound of formula 7 are commercially available; many others are known in the scientific literature and may be synthesized using procedures that are known in the art; and yet others, although not yet reported, may be made using procedures that are obvious to one of average skill in the art of organic synthesis.
For example, the following compounds are available from the suppliers indicated below.
From Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA: 2,3,4-trichlorobenzenesulfonyl chloride; 2,3,4- trifluorobenzenesulfonyl chloride; 2,3-dichlorobenzenesulfonyl chloride; 2,4,5- trichlorobenzenesulfonyl chloride; 2,5-bis(trifluoromethyl)benzenesulfonyl chloride; 2,5-dichlorobenzenesulfonyl chloride; 2,5-dimethoxybenzenesulfonyl chloride; 2- bromo-5-(trifluoromethyl)benzenesulfonyl chloride; 2-methyl-5-nitrobenzenesulfonyl chloride; 3-(trifluoromethoxy)benzenesulfonyl chloride; 3-
(trifluoromethyl)benzenesulfonyl chloride; 3,4,5-trifluorobenzenesulfonyl chloride;
3.4- dichlorobenzenesulfonyl chloride; 3,4-dimethoxybenzenesulfonyl chloride; 3,5- bis(trifluoromethyl)benzenesulfonyl chloride; 3,5-dichlorobenzenesulfonyl chloride;
3.5- difluorobenzenesulfonyl chloride; 3,5-dimethylbenzenesulfonyl chloride; 3- bromo-5-(trifluoromethyl)benzenesulfonyl chloride; 3-chloro-4- fluorobenzenesulfonyl chloride; 3-chlorobenzenesulfonyl chloride; 3-cyano-4- fluorobenzenesulfonyl chloride; 3-cyanobenzenesulfonyl chloride; 3-fluoro-4- methylbenzenesulfonyl chloride; 3-fluorobenzenesulfonyl chloride; 3- nitrobenzenesulfonyl chloride; 4-biphenylsulfonyl chloride; 4-bromo-2,5- difluorobenzenesulfonyl chloride; 4-bromo-3-(trifluoromethyl)benzenesulfonyl chloride; 4-bromo-3-fluorobenzenesulfonyl chloride; 4-methyl-3-nitrobenzenesulfonyl chloride; 4-nitro-3-(trifluoromethyl)benzenesulfonyl chloride; 5-bromo-2- methoxybenzenesulfonyl chloride; m-toluenesulfonyl chloride; and
pentamethylbenzenesulfonyl chloride.
From Alfa Aesar, 26 Parkridge Road, Ward Hill, MA 01835, USA: 2,3,5,6- tetramethylbenzenesulfonyl chloride; 2,4-dichloro-5-methylbenzenesulfonyl chloride; 2,5-dibromo-3,6-difluorobenzenesulfonyl chloride; 2,5-dimethylbenzenesulfonyl chloride; 2-chloro-5-(trifluoromethyl)benzenesulfonyl chloride; 2-fluoro-5- (trifluoromethyl)benzene sulphonyl chloride; 3-fluoro-5-
(trifluoromethyl)benzenesulfonyl chloride; 4-chloro-2,5-dimethylbenzenesulfonyl chloride; 4-fluoro-3-(trifluoromethyl)benzenesulfonyl chloride; 4-methoxy-3-
(trifluoromethyl)benzenesulfonyl chloride; and 4'-methylbiphenyl-4-sulfonyl chloride.
From Apollo Scientific Ltd., Whitefield Road, Bredbury, Stockport, Cheshire SK6 2QR, United Kingdom: 2,4-dichloro-5-fluorobenzenesulphonyl chloride; 2-bromo-3- (trifluoromethyl)benzenesulphonyl chloride; and 4,5-dichloro-2- fluorobenzenesulphonyl chloride.
From Butt Park Ltd., Braysdown Works, Peasedown St. John, Bath, BA2 8LL, United Kingdom: 3,5-dichloro-4-methoxybenzene-l-sulfonyl chloride; 3-bromo-2-fluoro-5- (methylsulfonyl)benzenesulfonyl chloride; 3-iodobenzene-l-sulfonyl chloride; 5- (trifluoromethyl)-2-methoxybenzene-l-sulfonyl chloride; 2-methyl-5-(propane-2- sulfonyl)-benzenesulfonyl chloride; 5-ethanesulfonyl-2-methyl-benzenesulfonyl chloride; and 2-methyl-5-(propane-l-sulfonyl)-benzenesulfonyl chloride From Chem-Impex International, Inc., 935 Dillon Drive, Wood Dale, IL 60191, USA: (3 - [3 , 5 -bis (trifluoromethyl)phenyl] phenyl) sulf onylchloride; (3 - [4- (trifluoromethyl)phenyl]phenyl)sulfonylchloride; (4-[4- (trifluoromethyl)phenyl]phenyl)sulfonylchloride; [3-(3,5- dichlorophenyl)phenyl] sulphonyl chloride; 3-(3,4-dichlorophenyl)benzenesulfonyl chloride; 3',4'-dichloro[l,r-biphenyl]-4-sulfonyl chloride; 3',5'-dichloro[l,l'- biphenyl]-4-sulfonyl chloride; 4-[3,5-bis(trifluoromethyl)phenyl]benzenesulphonyl chloride; and 4'-chloro[l,l'-biphenyl]-4-sulfonyl chloride. From Enamine, 23A Motrosova Street, Kiev 01103, Ukraine: 4-fluoro-3- methanesulfonylbenzene-l-sulfonyl chloride; and 4-methyl-3- (trifluoromethyl)benzene-l-sulfonyl chloride. From Maybridge, Trevillet, PL34 OHW Tintagel, Cornwall, United Kingdom: 3-(l- methyl- lH-pyrazol-3-yl)benzenesulfonyl chloride; 3-(l-methyl- lH-pyrazol-5- yl)benzenesulfonyl chloride; 3-pyrimidin-2-ylbenzenesulfonyl chloride; 4-(l-methyl- lH-pyrazol-3-yl)benzenesulfonyl chloride; and 4-pyrimidin-2-ylbenzenesulfonyl chloride.
From Oakwood Products, Inc., 1741 Old Dunbar Road, West Columbia, SC 29172, USA: 2',4'-difluoro-biphenyl-4-sulfonyl chloride; 2',4'-dimethoxy-biphenyl-3-sulfonyl chloride; 2'-4'-dimethoxy-biphenyl-4-sulfonyl chloride; 2-chloro-4,5- difluorobenzenesulfonyl chloride; 2'-chloro-biphenyl-4-sulfonyl chloride; 2'-fluoro- biphenyl-3-sulfonyl chloride; 2'-fluoro-biphenyl-4-sulfonyl chloride; 2'-methoxy- biphenyl-3-sulfonyl chloride; 2'-methoxy-biphenyl-4-sulfonyl chloride; 2'-methyl- biphenyl-3-sulfonyl chloride; 2'-methyl-biphenyl-4-sulfonyl chloride; 3-(4- fluorophenyl)benzenesulfonyl chloride; 3-(methylsulfonyl)benzenesulfonyl chloride; 3,5-bis(methylsulfonyl)benzenesulfonyl chloride; 3,5-dichloro-4- fluorobenzenesulfonyl chloride; 3'-4'-dimethoxy-biphenyl-4-sulfonyl chloride; 3'- fluoro-biphenyl-3-sulfonyl chloride; 3'-fluoro-biphenyl-4-sulfonyl chloride; 3'- methoxy-biphenyl-3-sulfonyl chloride; 3'-methoxy-biphenyl-4-sulfonyl chloride; 3'- methyl-biphenyl-3-sulfonyl chloride; 3'-methyl-biphenyl-4-sulfonyl chloride; 3- phenylbenzenesulfonyl chloride; 3-tert-butyl benzenesulfonyl chloride; 3-tert-butyl-4- methoxy-benzenesulfonyl chloride; 4'-bromo-2'-fluorobiphenyl-4-sulfonyl chloride; 4- bromo-3,5-dichlorobenzenesulfonyl chloride; 4'-bromobiphenyl-4-sulfonyl chloride;
4- chloro-2,5-difluorobenzenesulfonyl chloride; 4-chloro-3-
(trifluoromethyl)benzenesulfonyl chloride; 4'-chloro-biphenyl-3-sulfonyl chloride; 4'- fluoro[l,l'-biphenyl]-4-sulfonyl chloride; 4'-methoxy-biphenyl-3-sulfonyl chloride; 4'-methoxy-biphenyl-4-sulfonyl chloride; 4'-methyl-biphenyl-3-sulfonyl chloride; 4'- nitrobiphenyl-4-sulfonyl chloride; 5-isopropyl-2-methoxy-benzenesulfonyl chloride;
5- methanesulfonyl-2-methylbenzene-l-sulfonyl chloride; and 5-tert-butyl-2-methyl- benzenesulfonyl chloride. Sulfonyl chlorides of formula 34 can also be made by reactions that are well known in the field of organic synthesis, such as those outlined below.
V0H ► Vci
Scheme 7
For example, a sulfonyl chloride of formula 34 can be made from a sulfonic acid of formula 35 as shown in Scheme 7. The chlorination of an arylsulfonic acid, or a salt thereof, of formula 35 can be accomplished conveniently by treating it with a chlorinating agent such as thionyl chloride or phosphorus oxychloride or phosphorus pentachloride, in the optional additional presence of a catalytic amount of N,N- dimethylformamide, at a temperature between about 0 °C and about 120 °C depending on the reactivity of the chlorinating agent. Examples of specific conditions useful for this reaction may be found in the literature, for example in Morikawa, A. et al. /. Med. Chem. 1989, 32, 42-46; in Baucherel, X. and Sheldon, R. A. US 7,019,175; in Sandanayaka, V. P. et al. US 20020099035; in Kunda, S. A. et al. US 6,140,505; and in Wu, C. J. Org. Chem. 1998, 63, 2348-2350.
Figure imgf000032_0001
Scheme 8
Sulfonyl chlorides of formula 34 can be made by electrophilic aromatic substitution of an aromatic compound of formula 36 as shown in Scheme 8. As is known to one of average skill in the art, this process is suitable for the preparation of arylsulfonyl chlorides with particular substitution patterns, such as for example where there is an ortho/para directing substituent in a benzene ring ortho or para to the site of introduction of the sulfonyl group. The reaction is conveniently carried out by treating the aromatic compound of formula 36 with chloro sulfonic acid in the absence of solvent and then heating the mixture at a temperature between about 70 °C and about 100 °C. Examples of specific conditions useful for this reaction may be found in the literature, for example in Arduini, A. et al. Tetrahedron Lett. 2003, 44, 5755-5757; in Derdau, V. et al. . Org. Chem. 2003, 68, 5168-5173; in Wischnat, R. and Rudolf, J.
WO 2003002546; in Lima, L. M. et al. Bioorg. Med. Chem. 2002, 10, 3067-3073; in Aboud-Gharbia, M. A. US 4,857,644; in Christidis, Y. US 4,948,827; in Pal, M. et al. . Med. Chem. 2003, 46, 3975-3984; in Dollings, P. J. et al. US 6,103,708; and in Clark, B. P. US 6,482,824.
Figure imgf000033_0001
Scheme 9
Sulfonyl chlorides of formula 34 can also be made from anilines of formula 37 by a diazotization/sulfonylation reaction sequence as shown in Scheme 9. The
diazotization reaction is conveniently carried out by treating the aniline of formula 37 or an acid addition salt thereof (such as the hydrochloride salt) in aqueous solution in the presence of a mineral acid such as hydrochloric acid or sulfuric acid with an alkali metal nitrite salt such as sodium nitrite at a temperature less than 10 °C, preferably around 0 °C. The diazonium salt obtained in this way can be converted directly to the sulfonyl chloride using a variety of reagents and conditions which are known in the field of organic synthesis. Examples of suitable reagents include sulfur dioxide and copper(I) chloride or copper(II) chloride in acetic acid/water, or thionyl chloride and copper(I) chloride or copper(II) chloride in water, according to the procedure of P. J. Hogan (US 6,531,605). For example, the sulfonylation reaction can be carried out by adding the solution of the diazonium salt, prepared as described above, to a mixture of sulfur dioxide and copper(II) chloride in a suitable inert solvent, such as glacial acetic acid, at a temperature around 0 °C. Examples of specific conditions useful for this reaction may be found in the literature, for example in N. Ikemoto, N. et al.
Tetrahedron 2003, 59, 1317-1325; in C. Binisti, C. et al. Eur. J. Med. Chem. 2001, 36, 809-828; in Gonzalez, M. A. and Otterbacher, E. W. US 6,433,169; in Gwaltney, S. L. et al. Bioorg. Med. Chem. Lett. 2001, 11, 871-874; in Meier, M. and Wagner, R. US 5,436,370; in Cherney, R. J. et al. J. Med. Chem. 2003, 46, 1811-1823; in Wagman, A. S. et al. . Org. Chem. 2000 -9113.
Figure imgf000033_0002
Scheme 10
A sulfonyl chloride of formula 34 can also be made from an aryl benzyl sulfide of formula 38 by an oxidative chlorination reaction as shown in Scheme 10. The reaction is conveniently carried out by bubbling chlorine gas into a solution or suspension of the aryl benzyl sulfide of formula 38 in a suitable inert solvent such as a mixture of acetic acid and water at a temperature around room temperature. Examples of specific conditions useful for this reaction may be found in the literature, for example in Andrews, S. P. and Ladlow, M. /. Org. Chem. 2003, 68, 5525-5533; in Baker, R. H. et al. /. Am. Chem. Soc. 1946, 68, 2636-2639; in Hay, J. V. et al. US 4,521,241; in Howbert, J. J. and Crowell, T. A. Synthetic Commun. 1990, 20, 3193-3195; in Barry, W. J. and Finar, I. L. J. Chem. Soc. 1954, 138-140; in Baum, J. C. et al. Can. J. Chem. 1990, 68, 1450-1455.
Figure imgf000034_0001
Sulfonyl chlorides of formula 34 can also be made as shown in Scheme 11 from an aryl bromide of formula 39 by metal-halogen exchange, followed by reaction of the organometallic intermediate with sulfur dioxide to give an arylsulfonate salt, followed by reaction with sulfuryl chloride to give the arylsulfonyl chloride. The reaction can be carried out by treating the aryl bromide with an organometallic reagent such as n- butyl lithium or preferably sec-butyl lithium, in the optional additional presence of tetramethylethylenediamine (TMEDA) in a suitable inert solvent such as
tetrahydrofuran (THF) or diethyl ether at low temperature (for example, around - 78 °C) to give the aryllithium intermediate. This can then be reacted, without isolation, with a mixture of sulfur dioxide and a solvent such as diethyl ether, again at low temperature, such as for example between about -78 °C and about -60 °C. The resulting arylsulfonate salt can then be converted to the arylsulfonyl chloride, again without isolation of the intermediate, by treatment with sulfuryl chloride at a temperature around 0 °C. Examples of specific conditions useful for this reaction may be found in the literature, for example in Chan, M. F. et al. Bioorg. Med. Chem. 1998, 6, 2301-2316; in Ewing, W. R. et al. . Med. Chem. 1999, 42, 3557-3571; in Tamura, Y. et al. J. Med. Chem. 1998, 41, 640-649; in Raju, B. et al. Bioorg. Med. Chem. Lett. 1997, 7, 939-944; and in Hamada, T. and Yonemitsu, O. Synthesis 1986, 852-854.
A
Figure imgf000034_0002
Scheme 12
Sulfonyl chlorides of formula 34 can be made from an aryl thiol of formula 40 by oxidation using chlorine as shown in Scheme 12. For example, the reaction can be carried out by treating the aryl thiol of formula 40 with a solution of chlorine in an inert solvent such as glacial acetic acid at a temperature around 0 °C; or by treating the aryl thiol of formula 40 with N-chlorosuccinimide in a mixture of aqueous hydrochloric acid and acetonitrile at a temperature below about 20 °C. Examples of specific conditions useful for this reaction may be found in the literature, for example in Curran, W. V. et al. US 3,932,440; in Crich, D. and Sharma, I. Angew. Chem. Intl. Edn. 2009, 121, 7727-7730; in Malecha, J. W. et al. US 20070027184; in Vedejs, E. et al. . Org. Chem. 2000, 65, 2309-2318; in Shankar, R. B. US 4,937,350; and in Lepone, G. E. US 4,454,135. One example of an aryl thiol of formula 40 that is particularly useful for the preparation of certain compounds of the invention is 5- bromo-pyridine-2-thiol. This compound is commercially available from a number of different vendors including Combi-Blocks Inc., 7949 Silverton Avenue, Suite 915,
San Diego, CA 92126, USA; Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA; and Enamine, 23 A. Motrosova Street, Kiev 01103, Ukraine. 5-Bromo-pyridine-2-thiol may also be synthesized according to the procedure disclosed in Fuchss, T. et al. WO 2007039578 or according to the procedure disclosed in Raeth, C. Liebigs Ann. Chem. 1931, 487, 105-119.
Figure imgf000035_0001
Scheme 13
Sulfonyl chlorides of formula 34 can be made from phenols of formula 41 through a sequence of reactions outlined in Scheme 13. The phenol of formula 41 can be converted to the 0-aryl-N,N'-dialkylthiocarbamate of formula 42 by reaction with an Ν,Ν'-dialkylthiocarbamoyl chloride in an inert solvent in the presence of a base. The resulting 0-aryl-N,N'-dialkylthiocarbamate of formula 42 can be rearranged to the S- aryl-N,N'-dialkylthiocarbamate of formula 43 by heating neat at high temperature such as at around 250 °C. The S-aryl-N,N'-dialkylthiocarbamate of formula 43 can then be converted to the sulfonyl chloride of formula 34 by oxidation using chlorine in a suitable inert solvent such as a mixture of formic acid and water at a temperature around 0 °C. Examples of specific conditions useful for this reaction may be found in the literature, for example in Percec, V. et al. J. Org. Chem. 2001, 66, 2104-2117; in Allison, B. D. et al. WO 2008124524; and in Deng, X. et al. US 7,288,651.
The following sulfonyl chlorides of formula 34 which are particularly useful for the preparation of sulfonamides of formula 11 in Scheme 2 are commercially available: 4- iodobenzenesulfonyl chloride (available from Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA; Alfa Aesar, 26 Parkridge Road, Ward Hill, MA 01835, USA; and TCI America, 9211 N. Harborgate Street, Portland, OR 97203, USA); and 3-bromobenzenesulfonyl chloride (available from Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA; Alfa Aesar, 26 Parkridge Road, Ward Hill, MA 01835, USA; and Combi-Blocks Inc., 7949 Silverton Avenue, Suite 915, San Diego, CA 92126, USA).
Many boronic acids of formula 44 where V represents -B(OH)2 useful for the conversion of a compound of formula 11 to a compound of formula 12 (see Scheme 2) are commercially available; many others are known in the scientific literature and may be synthesized using procedures that are known in the art; and yet others, although not yet reported, may be made using procedures that are obvious to one of average skill in the art of organic synthesis.
For example, the following compounds are available from the suppliers indicated below. These examples of commercially available compounds are provided for the purposes of illustration and are not intended to limit the invention. The suppliers indicated are not necessarily the only suppliers of these reagents, and these and other suppliers also provide other building blocks useful for the preparation of compounds of the invention. From Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA: 2,3,4,5-tetrafluorophenylboronic acid; 2,3,4,6- tetrafiuorophenylboronic acid; 2,3,5, 6-tetramethylphenylboronic acid; 2,4,5- trimethylphenylboronic acid; 2,5-difluorophenylboronic acid; 2,5- dimethoxyphenylboronic acid; 2-chloro-6-fluoro-3-methylphenylboronic acid; 2- chloro-6-fluoro-5-methylphenylboronic acid; 2-methoxy-5-methylphenylboronic acid; 3-(methylthio)phenylboronic acid; 3,4-dimethoxyphenylboronic acid; 3,5- difluorophenylboronic acid; 3-acetyl-2-fluorophenylboronic acid; 3- acetylphenylboronic acid; 3-chloro-4-fluorophenylboronic acid; 3-chloro-4- methylphenylboronic acid; 3-chlorophenylboronic acid; 3-efhoxy-2- fluorophenylboronic acid; 3-fluoro-4-methoxyphenylboronic acid; 3- propoxyphenylboronic acid; 3-(trifluoromethyl)phenyiboronic acid; 3- trimethylsilylphenylboronic acid; 4-ethoxy-3 -fluorophenylboronic acid; 4- hydroxyphenylboronic acid; 4-methoxy-3-methylphenylboronic acid; 4-methyl-3- nitrophenylboronic acid; 4-methylphenylboronic acid; 5-chloro-2-fluoro-3- methylphenylboronic acid; 5-ethoxy-2- fluorophenylboronic acid; and 5-fluoro-2- methylphenylboronic acid.
From Alfa Aesar, 26 Parkridge Road, Ward Hill, MA 01835, USA: 2,3,5,6- tetrafluorophenylboronic acid; 2,5-dichlorophenylboronic acid; 2,5-dichloropyridine- 3-boronic acid; 2-fluoro-5-hydroxymethylphenylboronic acid; 3,4- difluorophenylboronic acid; 3,5-dichlorophenylboronic acid; 3- acetamidophenylboronic acid; 3-chloro-5-fluorophenylboronic acid; 3- isopropylphenylboronic acid; 3-methylphenylboronic acid; 5-chloro-2,4- difluorophenylboronic acid; and 5-chloropyridine-3-boronic acid.
From ChemBridge Corporation, 16981 Via Tazon, Suite G, San Diego, CA 92127, USA: [3-(l-methoxyethyl)phenyl]boronic acid; [4-fluoro-3- (hydroxymethyl)phenyl]boronic acid; and 4-chloro-3-fluorophenylboronic acid. From Combi-Blocks, Inc., 7949 Silverton Avenue, Suite 915, San Diego, CA 92126, USA: 5-chloro-2-methoxypyridine-3-boronic acid; (2-aminomethyl-5- fluoro)phenyiboronic acid hydrochloride; (2-chloro-3-methylphenyl)boronic acid; (2- methyl-5-nitrophenyl)boronic acid; (3-aminomethylphenyl)boronic acid
hydrochloride; (3-carbamothioyl)benzeneboronic acid; (3-chloro-2- cyanophenyl)boronic acid; (3-chloro-2-methylphenyl)boronic acid; (3-fluoro-5- methylphenyl)boronic acid; (4-aminocarbonyl-3-chloro)benzeneboronic acid; (4- chloro-3-ethoxyphenyl)boronic acid; [3-(3-hydroxypropyl)phenyl]boronic acid; 2,3,4- trichlorophenylboronic acid; 2,3,5-trichlorophenylboronic acid; 2,3,5- trifluorophenylboronic acid; 2,3,6-trifluorophenylboronic acid; 2,3- dichlorophenylboronic acid; 2,3-dichloropyridine-5-boronic acid; 2,3-difluoro-4- methoxyphenylboronic acid; 2,3-difluoro-6-methoxyphenylboronic acid; 2,3- dimethylphenylboronic acid; 2,4,5-trifluorophenylboronic acid; 2,4-dichloro-3- cyanophenylboronic acid; 2,4-dichloro-3-methoxyphenylboronic acid; 2,4-dichloro-5- methoxyphenylboronic acid; 2,5-difluoro-4-methoxyphenylboronic acid; 2,5- dimethyl-4-methoxybenzeneboronic acid; 2,6-dichloro-3-methylphenylboronic acid; 2,6-difluoro-3-methoxyphenylboronic acid; 2-chloro-3-ethoxyphenylboronic acid; 2- chloro-3-fluorophenylboronic acid; 2-chloro-3-fluoropyridine-5-boronic acid; 2- chloro-3-methoxyphenylboronic acid; 2-chloro-3-methylpyridine-5-boronic acid; 2- chloro-4-fluoro-5-methoxy-benzeneboronic acid; 2-chloro-5-boronobenzamide; 2- chloro-5-cyanophenylboronic acid; 2-chloro-5-cyanopyridine-3-boronic acid; 2- chloro-5-ethoxybenzeneboronic acid; 2-chloro-5-fhiorophenylboronic acid; 2-chloro- 5-fluoropyridine-3-boronic acid; 2-chloro-5-hydroxymethylphenylboronic acid; 2- chloro-5-methoxyphenylboronic acid; 2-chloro-5-methoxypyridine-3-boronic acid; 2- chloro-5-methylphenylboronic acid; 2-chloro-5-methylpyridine-3-boronic acid; 2- chloro-5-nitrophenylboronic acid; 2-chloro-6-fluoro-3-methoxyphenylboronic acid; 2- ethoxy-5-fluorophenylboronic acid; 2-ethoxy-5-methylphenylboronic acid; 2-fluoro- 3-methylphenylboronic acid; 2-fluoro-3-methylpyridine-5-boronic acid; 2-fluoro-3- nitrophenylboronic acid; 2-fluoro-5-isopropylphenylboronic acid; 2-fluoro-5- methoxyphenylboronic acid; 2-fluoro-5-methylphenylboronic acid; 2-fluoro-5- methylpyridine-3-boronic acid; 2-fluoro-5-nitrophenylboronic acid; 2-methoxy-3- methylphenyl boronic acid; 2-methyl-3-nitrophenylboronic acid; 3-(l- hydroxyethyl)phenylboronic acid; 3-(2-cyanoethyl)phenylboronic acid; 3-(2- hydroxyethyl)phenylboronic acid; 3-(3-boronophenyl)acrylonitrile; 3- (aminocarbonyl)-4-fluorobenzeneboronic acid; 3-(aminocarbonyl)-5- fluorobenzeneboronic acid; 3-(aminomethyl)-2-fluorophenylboronic acid,
hydrochloride salt; 3-(chloromethyl)benzeneboronic acid; 3-(difluoromethoxy)- benzeneboronic acid; 3-(hydrazinecarbonyl)benzeneboronic acid; 3- (methoxymethoxy)phenylboronic acid; 3-(methylsulfonyl)phenylboronic acid; 3- (N,N-dimethylamino)phenylboronic acid; 3-(N-methylaminocarbonyl)phenylboronic acid; 3,4,5-trichlorophenylboronic acid; 3,4-dichloro-2-methylbenzeneboronic acid;
3.4- difluoro-2-methoxyphenylboronic acid; 3,4-difluoro-5-methoxybenzeneboronic acid; 3,4-dimethylphenylboronic acid; 3,5-dichloro-2-methylphenylboronic acid; 3,5- dichloro-4- methoxyphenylboronic acid; 3,5-difluoro-2-methoxyphenylboronic acid;
3.5- difluoro-4-(hydroxymethyl)phenylboronic acid; 3,5-dimethoxyphenylboronic acid; 3,5-dimethyl-4-chlorophenylboronic acid; 3,5-dimethyl-4-methoxyphenylboronic acid; 3,5-dimethylphenylboronic acid; 3-allyloxyphenylboronic acid; 3-borono-5- chlorobenzamide; 3-boronobenzenesulfonamide; 3-chloro-2,6-difluorophenylboronic acid; 3-chloro-2-methoxyphenylboronic acid; 3-chloro-2-methoxypyridine-5-boronic acid; 3-chloro-4-cyanophenylboronic acid; 3-chloro-4-ethoxyphenylboronic acid; 3- chloro-4-methoxyphenylboronic acid; 3-chloro-5-ethoxyphenylboronic acid; 3-chloro- 5-methoxyphenylboronic acid; 3-chloro-5-methylphenylboronic acid; 3-cyano-2- fluorophenylboronic acid; 3-cyano-4-fluorophenylboronic acid; 3-cyano-4- methylphenylboronic acid; 3-cyanomethoxyphenylboronic acid; 3- cyanomethylphenylboronic acid; 3-dimethylaminophenylboronic acid hydrochloride salt; 3-ethoxy-4-fluorophenylboronic acid; 3-ethoxy-5-fluorophenylboronic acid; 3- ethoxy-5-methylphenylboronic acid; 3-ethylphenylboronic acid; 3- ethylsulfinylphenylboronic acid; 3-ethylthiophenylboronic acid; 3-fluoro-2- methoxyphenylboronic acid; 3-fluoro-2-methoxypyridine-5-boronic acid; 3-fluoro-2- methylphenylboronic acid; 3-fluoro-4-(methylthio)phenylboronic acid; 3-fluoro-4- methylphenylboronic acid; 3-fluoro-5-methoxyphenylboronic acid; 3- isopropoxyphenylboronic acid; 3-isopropylphenylboronic acid; 3- mercaptophenylboronic acid; 3-methoxy-4-methylphenylboronic acid; 3-methoxy-5- methylphenyl boronic acid; 3-methoxycarbonylphenylboronic acid; 3- methoxymethylphenylboronic acid; 3-methylsulfinylphenylboronic acid; 3- nitrophenylboronic acid; (3-t-butyl-5-methylphenyl)boronic acid; 3- vinylphenylboronic acid; 4-(aminomethyl)-3-fluorophenylboronic acid, hydrochloride salt; 4,5-difluoro-2-methoxyphenylboronic acid; 4-acetyl-3-fluorophenylboronic acid; 4-carbamoyl-3-fluorophenylboronic acid; 4-chloro-2-fluoro-3-methoxyphenylboronic acid; 4-chloro-3-cyanophenylboronic acid; 4-chloro-3-ethylphenylboronic acid; 4- chloro-3-methoxyphenylboronic acid; 4-chloro-3-methylphenylboronic acid; 4- chloro-3-nitrophenylboronic acid; 4-cyano-3-fluorophenylboronic acid; 4-cyano-3- methoxyphenylboronic acid; 4-ethoxy-3-methylphenylboronic acid; 4-fluoro-2,3- dimethylphenylboronic acid; 4-fluoro-2,5-dimethylphenylboronic acid; 4-fluoro-3- methylphenylboronic acid; 4-fluoro-3-nitrophenylboronic acid; 4-hydroxymethyl-3- methylphenylboronic acid; 5-(aminomethyl)-2-fluorophenylboronic acid,
hydrochloride salt; 5-(methylsulphonyl)pyridine-3-boronic acid; 5- (methylthio)pyridine-3-boronic acid; 5-acetyl-2-chlorophenylboronic acid; 5-acetyl-2- fluorophenylboronic acid; 5-carbamoyl-2-chlorophenylboronic acid; 5-carbamoyl-2- fluorobenzeneboronic acid; 5-chloro-2-cyanophenylboronic acid; 5-chloro-2- ethoxyphenylboromc acid; 5-chloro-2-ethoxypyridine-3-boronic acid; 5-chloro-2- fluoro-4-methoxyphenylboronic acid; 5-chloro-2-fluoro-4-methylphenylboronic acid; 5-chloro-2-fluoropyridine-3-boronic acid; 5-chloro-2-methoxyphenylboronic acid; 5- chloro-2-nitrophenylboronic acid; 5-chloro-4-methoxy-2-methylphenylboronic acid; 5-chloro-6-ethoxypyridine-3-boronic acid; 5-cyano-2-fluorobenzeneboronic acid; 5- cyano-2-methoxyphenylboronic acid; 5-cyano-2-methylphenylboronic acid; 5-cyano- 3-pyridinyl boronic acid; 5-fluoro-2-(methylthio)phenylboronic acid; 5-fluoro-2- methoxypyridine-3-boronic acid; 5-fluoropyridine-3-boronic acid; 5- methoxypyridine-3-boronic acid; 5-methylpyridine-3-boronic acid; 5-trifluoromethyl- pyridine-3-boronic acid; methyl 5-borononicotinate; and N,N,2-trimethylaniline-4- boronic acid.
From Matrix Scientific, P.O. Box 25067, Columbia, SC 29224-5067, USA: 2-fluoro- 3-methoxyphenylboronic acid; 3-(hydroxymethyl)phenylboronic acid; 3,4,5- trifluorophenylboronic acid; 3,4-dichlorophenylboronic acid; 3- aminocarbonylphenylboronic acid; 4-fluoro-3-methoxyphenylboronic acid; 5-chloro-
2- methylphenylboronic acid; 5-fluoro-2-methoxyphenylboronic acid; and 5-fluoro-2- nitrobenzeneboronic acid.
From Oakwood Products, Inc., 1741 Old Dunbar Road, West Columbia, SC 29172, USA: 3-(trifluoromethyl)phenylboronic acid; 3,6-difluoro-2-methoxybenzeneboronic acid; 3-chloro-2,4-difluorobenzeneboronic acid; 3-chloro-2-fluorophenylboronic acid;
3- fluorophenylboronic acid; 3-methoxyphenylboronic acid; 5-chloro-2- fluorophenylboronic acid; 6-chloro-2,3-difluorophenylboronic acid; 6-chloro-2- fluoro-3-methoxyphenylboronic acid; and m-t-butylphenylboronic acid.
From TCI America, 9211 N. Harborgate Street, Portland, OR 97203, USA: 2,3,4- trifluorophenylboronic acid; 2,3-difluorophenylboronic acid; 2,3- dimethoxyphenylboronic acid; 2,4-dimethylphenylboronic acid; 2,5- dimethylphenylboronic acid; 2-fiuoro-4-methylphenylboronic acid; 3- cyanophenylboronic acid; 3-ethoxyphenylboronic acid; 4-acetylphenylboronic acid; 4- chlorophenylboronic acid; 4-cyanophenylboronic acid; 4-ethoxyphenylboronic acid;
4- ethylphenylboronic acid; 4-(hydroxymethyl)phenylboronic acid; 4- isopropylphenylboronic acid; 4-methoxyphenylboronic acid; 4- (methylthio)phenylboronic acid; 4-(methylsulfonyl)phenylboronic acid; 4-tert- butylphenylboronic acid; 4-(trifluoromethyl)phenylboronic acid; 4- (trifluoromethoxy)phenylboronic acid.
Compounds of formula 44 where V represents -B(OH)2, that is compounds of formula 46, may be synthesized by procedures that are well known to one skilled in the art of organic synthesis.
Ar— X 3
45 46
Scheme 14
For example, a compound of this type can conveniently be synthesized according to Scheme 14 from a compound of formula 45, in which X represents bromine or iodine, by treatment with an alkyllithium (e.g., n-butyllithium) or magnesium (to form the Grignard reagent) in a suitable inert solvent such as an ether (such as tetrahydrofuran or diethyl ether) at a temperature appropriate for the reaction (for example, at approximately -78 degrees for reaction with an alkyllithium, or at approximately room temperature for reaction with magnesium), followed by treatment with a trialkyl borate and then with dilute acid to form the compound of formula 46. Examples of specific conditions that may be used for this reaction can be found in the literature, for example in Gimeno, N. et al. Angew. Chem. Int. Edn. 2004, 43, 5235-5238
Supporting Information; in Erickson-Miller, C. J. et al. US 20040019190; in
Sundermann, B. et al. US 20020198251; in Hirano, M. et al. US 7,001,917; and in Zbruyev, A. I. et al. Tetrahedron 2007, 63, 4297-4303.
Compounds of formula 44 where V represents 4,4,5, 5-tetramethyl- [l,3,2]dioxaborolane, that is compounds of formula 47, may be synthesized by procedures that are well kno f organic synthesis.
Figure imgf000041_0001
Scheme 15
For example, a compound of this type can conveniently be synthesized according to Scheme 15 from a compound of formula 45, in which X represents bromine or iodine or trifluoromethanesulfonate. A compound of formula 47 may be conveniently prepared according to this procedure by treating the compound of formula 45 with bis(pinacolato)diboron (which is commercially available from many vendors including Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue,
Milwaukee, WI 53233, USA) in the presence of a palladium catalyst such as dichloro[l,l'- bis(diphenylphosphino)ferrocene]-palladium(II) or the dichloromethane adduct thereof in the presence of a base such as potassium acetate in an inert solvent such as 1 ,4-dioxane or dimethylsulfoxide or N,N-dimethylformamide at a temperature between about 80 °C and about 100 °C. The reaction may be advantageously carried out under an inert atmosphere. Examples of specific conditions that may be used for this reaction can be found in the literature, for example in Goodacre, S. C. et al. J. Med. Chem. 2006, 49, 35-38 Supporting Information; in Bouillot, A. M. I. et al. WO 2009071504; and in Ahmad, S. WO 2010104818. A compound of formula 47 may also be conveniently prepared according to Scheme 15 by treating the compound of formula 45 with pinacolborane (which is
commercially available from several vendors including Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA) in the presence of a base such as triethylamine, a palladium catalyst such as dichloro[l,l'- bis(diphenylphosphino)ferrocene]-palladium(II) or the dichloromethane adduct thereof or dichlorobis(triphenylphosphine)palladium(II), or else a mixture of a palladium catalyst such as palladium(II) acetate in the presence of a ligand such as 2- dicyclohexylphosphino-l,l'-biphenyl, in an inert solvent such as 1,4-dioxane at a temperature between about 80 °C and about 100 °C. Examples of specific conditions that may be used for this reaction can be found in the literature, for example in Baudoin, O. et al. J. Org. Chem. 2000, 65, 9268-9271 ; Mizojiri, R. et al. US
7,659,263; in Dodic, N. and Gellibert, F. US 20050234029; and in Wager, T. T. et al T. US 20050043354. Many arylstannanes of formula 44 where V represents -SnMe3 or -SnBu3 useful for the conversion of a compound of formula 11 to a compound of formula 12 (see Scheme 2) are commercially available; many others are known in the scientific literature and may be synthesized using procedures that are known in the art; and yet others, although not yet reported, may be made using procedures that are analogous to reported procedures or obvious to one of average skill in the art of organic synthesis. For example, the following compounds are available from the suppliers indicated below. From Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA: (4-benzyloxyphenyl)tributylstannane; 2-bromo-5- (tributylstannyl)pyridine; 2-fluoro-3-(tributylstannyl)pyridine; tributyl(4- chloro)phenylstannane; tributylphenyltin; and trimethyl(phenyl)tin. From Alfa Aesar, 26 Parkridge Road, Ward Hill, MA 01835, USA: 2-methoxy-3-
(tributylstannyl)pyridine; 2-methylthio-5-(tributylstannyl)pyridine; 2-morpholino-5- (tributylstannyl)pyridine; and 3-(tributylstannyl)pyridine.
From Maybridge, Trevillet, PL34 OHW Tintagel, Cornwall, United Kingdom:
tributyl(4-fluorophenyl)stannane and tributyl[3-(trifluoromethyl)phenyl]stannane.
Compounds of formula 44 where V represents -SnMe3 or -SnBu3, that is compounds of formula 48, may be synthesized by procedures that are well known to one skilled in the art of organic synthesis.
R I
Ar— X Ar— Sn-R
45 48 R
Scheme 16
For example, a compound of this type can conveniently be synthesized according to Scheme 16 from a compound of formula 45, in which X represents bromine or iodine. A compound of formula 47 may be conveniently prepared according to this procedure by treating the compound of formula 45 with tert-butyllithium or n-butyllithium in an inert solvent such as tetrahydrofuran or diethyl ether at -78 °C, adding trimethyltin chloride or tributyltin chloride, and allowing the reaction to proceed at room temperature. Examples of specific conditions that may be used for this reaction can be found in the literature, for example in John, V. et al. US 20090270367; in Halbert, S. M. et al. WO 2010059943; and in Pellicciari, R. et al. WO 2006013085. A compound of formula 48 may also be conveniently prepared according to Scheme 16 by treating the compound of formula 45 with hexamethyldistannane (which is commercially available from several vendors including Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA) or
hexabutyldistannane (which is commercially available from several vendors including Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA) (to give the compounds of formula 48 where R represents methyl or butyl, respectively) in the optional presence of lithium chloride, a palladium catalyst such as tetrakis(triphenylphosphine)palladfum(0) (which is commercially available from several vendors including Aldrich Chemical Company, Inc., 1001 West Saint
Paul Avenue, Milwaukee, WI 53233, USA) in an inert solvent such as 1,4-dioxane or toluene at a temperature about 100 °C or alternatively at a higher temperature such as at about 150 °C under microwave irradiation. Examples of specific conditions that may be used for this reaction can be found in the literature, for example in Ritter, T. et al. WO 2010059943; in Ronen, Sabrina M. et al. US 20100062465; and in Dimagno, S. WO 2010048170.
EXAMPLES
Although certain exemplary embodiments are depicted and described herein, the compounds of the present invention can be prepared using appropriate starting materials according to the methods described generally herein and/or by methods available to one of ordinary skill in the art.
Materials and Instrumentation In General
Intermediates and final compounds were purified by either flash chromatography and/or preparative HPLC (high performance liquid chromatography). Flash chromatography was performed using (1) the Biotage SP1™ system and the Quad 12/25 Cartridge module from Biotage AB) or (2) the ISCO CombiFlash®
chromatography instrument (from Teledyne Isco, Inc.); unless otherwise noted. The silica gel brand and pore size utilized were: (1) KP-SIL™ 60 A, particle size: 40-60 micron (from Biotage AB); (2) Silica Gel CAS registry No: 63231-67-4, particle size: 47-60 micron; or (3) ZCX from Qingdao Haiyang Chemical Co., Ltd, pore size: 200- 300 mesh or 300-400 mesh. Preparative HPLC was performed on a reversed phase column using an Xbridge™ Prep C18 (5 m, OBD™ 30 x 100 mm) column (from Waters Corporation), a SunFire™ Prep Ci8 (5 m, OBD™ 30 x 100 mm) column (from Waters Corporation), or a Varian Pursuit® C-18 column 20 X 150 mm (from Varian, Inc.).
Mass spectrometry (MS) or high resolution mass spectrometry (HRMS) was performed using a Waters® ZQ™ 4000 (from Waters Corporation), a Waters®
Alliance® 2795-ZQ™2000 (from Waters Corporation), a Waters® Quattro micro™ API (from Waters Corporation), or an MDS Sciex™ API-2000™n API (from MDS Inc.). Mass spectra data generally only indicates the parent ions unless otherwise stated. MS or HRMS data is provided for a particular intermediate or compound where indicated.
Nuclear magnetic resonance spectroscopy (NMR) was performed using a Varian® Mercury300 NMR spectrometer (for the HNMR spectrum acquired at 300 MHz) and a Varian® Inova400 NMR spectrometer (for the HNMR spectrum acquired at 400 MHz) both from Varian Inc. NMR data is provided for a particular intermediate or compound where indicated.
Microwave assisted reactions were carried out in a Biotage Initiator™ Sixty (or earlier models) (from Biotage AB) or by a CEM Discover® model (with gas addition accessory) (from CEM Corporation).
Chiral separation was performed by supercritical fluid chromatography (SFC) using a Multigram® ΠΙ instrument (from Thar Technologies, Inc.). All reactions involving air- sensitive reagents were performed under an inert atmosphere. Reagents were used as received from commercial suppliers unless otherwise noted.
PART I: GENERAL PROCEDURES
General Procedure 1
Sulfonylation of (5-Amino-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy)-acetic acid tert-butyl ester
Figure imgf000046_0001
Diisopropylethylamine (1.2 equivalents) was added to a solution of (5-amino-6,7,8,9- tetrahydro-5H-benzocyclohepten-l-yloxy)-acetic acid tert-butyl ester (which may be prepared as described for Intermediate 1.04; 1 equivalent) and the sulfonyl chloride (1.2 equivalents) in anhydrous CH2CI2 at 0 °C. The mixture was stirred at room temperature for 12 h, and then concentrated under reduced pressure. Water (5 mL) was added and the mixture was extracted with ethyl acetate (3 x 10 mL). The organic extracts were combined, washed with water (2 x 3 mL), dried over anhydrous Na2S04, filtered, and evaporated. The residue was purified by silica gel chromatography, using 10-30% EtOAc hexanes as eluent, to give the product.
General Procedure 2
Sulfonylation of (5-Amino-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy)-acetic
-butyl ester
Figure imgf000046_0002
Diisopropylethylamine (2 equivalents) and the sulfonyl chloride (1 equivalent) were added to a solution of (5-amino-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy)- acetic acid tert-butyl ester (which may be prepared as described for Intermediate 1.04; 1 equivalent) in THF (10 mL/mmol) at room temperature under nitrogen. The mixture was stirred at room temperature for 3 h, and then concentrated under reduced pressure. The residue was purified by silica gel chromatography, using 15-25% EtOAc/hexanes as eluent, to give the product.
General Procedure 3 Methylation of 5-Arylsulfonylamino-6,7,8,9-tetrahydro-5H-benzocyclohepten- 1- -acetic Acid tert-Butyl Ester
Figure imgf000047_0001
Methyl iodide (2 equivalents) was added to a mixture of the 5-arylsulfonylamino- 6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy]-acetic acid tert-butyl ester (1 equivalent) and K2CO3 (2 equivalents) in DMF (20 mL/mmol) at room temperature under nitrogen. The mixture was stirred overnight at room temperature, then diluted with water and extracted with ethyl acetate (3 x 50 mL/mmol). The organic extracts were combined, dried over anhydrous Na2S04, filtered, and evaporated to give the [5- (arylsulfonyl-methyl-amino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy]-acetic acid tert-butyl ester which was used directly in the next step without further purification.
General Procedure 4
Suzuki Reaction
Figure imgf000047_0002
The arylboronic acid (1.2 equivalents), Pd(PPh3)4 (0.05 equivalents), and an aqueous solution of K2CO3 (1 M; 3 equivalents) were added to a degassed solution of the iodobenzenesulfonamide (1 equivalent) in dioxane (30 mL/mmol) at room
temperature under argon. The mixture was heated at reflux for 4 h, then cooled and concentrated under reduced pressure. Ethyl acetate (150 mL/mmol) was added and the mixture was washed with water (2 x 30 mL/mmol), dried over anhydrous Na2S04, filtered, and evaporated. The residue was purified by silica gel column
chromatography, using 10-25% ethyl acetate/hexanes as eluent, to give the product.
General Procedure 5
Suzuki Reaction
Figure imgf000048_0001
The arylboronic acid (1.2 equivalents), Pd(PPh3)4 (0.05 equivalents), and an aqueous solution of K2CO3 (1 M; 3 equivalents) were added to a degassed solution of the bromopyridinesulfonamide (1 equivalent) in dioxane (30 mL/mmol) at room temperature under argon. The mixture was heated at reflux for 4 h, then cooled and concentrated under reduced pressure. Ethyl acetate (150 mL/mmol) was added and the mixture was washed with water (2 x 30 mL/mmol), dried over anhydrous Na2S04, filtered, and evaporated. The residue was purified by silica gel column
chromatography, using 10-25% ethyl acetate/hexanes as eluent, to give the product.
General Procedure 6
Suzuki Reaction
Figure imgf000048_0002
The arylboronic acid (1.2 equivalents), Pd(PPli3)4 (0.05 equivalents), and an aqueous solution of K2CO3 (1 M; 3 equivalents) were added to a degassed solution of the bromobenzenesulfonamide (1 equivalent) in dioxane (30 mL/mmol) at room temperature under argon. The mixture was heated at reflux for 4 h, then cooled and concentrated under reduced pressure. Ethyl acetate (50 mL/mmol) was added and the mixture was washed with water (2 x 30 mL/mmol), dried over anhydrous Na2S04, filtered, and evaporated. The residue was purified by silica gel column
chromatography, using 10-25% ethyl acetate/hexanes as eluent, to give the product.
General Procedure 7
Hydrolysis of 5-Arylsulfonylamino-6,7,8,9-tetrahydro-5H-benzocyclohepten- 1- -acetic Acid tert- Butyl Esters
Figure imgf000049_0001
2 N Aqueous sodium hydroxide (20 equivalents) was added to a solution of the 5- arylsulfonylamino-6,7,8,9-tetrahydro-5H-benzocyclohepten- l-yloxy]-acetic acid tert- butyl ester (1 equivalent) in THF/H2O (5:1; 18 mL/mmol). The reaction mixture was stirred at room temperature overnight. THF was removed from the mixture under reduced pressure, and the pH was adjusted to approximately 7 by the drop wise addition of 1 N HC1. The mixture was extracted with ethyl acetate (100 mL/mmol), and the organic extract was washed with water (3 x 20 mL/mmol), dried over anhydrous Na2S04, filtered, and evaporated. The residue was purified by acid-base purification, by washing with organic solvent, or by preparative HPLC.
PART II: PREPARATION OF PREFERRED INTERMEDIATES
Intermediate 1.01
-6,7,8,9-tetrahydro-benzocyclohepten-5-one
Figure imgf000049_0002
The titled compound was prepared using conditions similar to those described in Cornelius, L. A. M. and Combs, D. W. Synth. Commun. 1994, 24, 2777-2788. Aluminum chloride (17.18 g, 0.129 mol) was placed in a 250 mL, three-necked round- bottomed flask under argon. The flask was fitted with a condenser, overhead stirrer, and rubber septum; and 1-benzosuberone (available from Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA; approx. 7.6 mL; approx. 0.05 mol) was added slowly over 3 min. The mixture was stirred for 5 min, and then bromine (approx. 3.1 mL, approx. 0.06 mol) was added slowly over 9 min. The reaction vessel was placed in an oil bath at 80 °C and stirred for 5 min. The reaction mixture was then poured over a mixture of ice (100 g) and HC1 (20 mL). Vigorous gas evolution occurred. The flask was rinsed with water and the combined rinsings and diluted reaction mixture were stirred for about 7 min. The mixture was extracted twice with ether. The combined extracts were washed with water and brine, dried (MgS04), filtered, and evaporated to give 12.71 g of crude material.
Unsuccessful attempts were made to purify this material by chromatography (using a mixture of THF and hexanes as eluent) and also by distillation. The material was finally purified in two batches (of 6 g and 4.9 g) by supercritical fluid chromatography using a Daicel AD 5 x 25 cm column, and eluting with 20% MeOH/CC>2. The cycle time was 8.2 min, and the material was purified using 500 mg injections. 12 runs were made to purify the 6 g batch, and 10 runs were used to purify the 4.9 g batch. Purification of the 6 g batch gave 2.77 g of l-bromo-6,7,8,9-tetrahydro- benzocyclohepten-5-one as an orange oil [1H NMR (300 MHz, DMSO-d6) δ: 7.79 (dd, J=8.0, 1.1 Hz, 1 H), 7.46 (dd, J=7.5, 0.9 Hz, 1 H), 7.17-7.32 (m, 1 H), 3.03 (t, J=6.3 Hz, 2 H), 2.60-2.72 (m, 2 H), 1.54-1.83 (m, 4 H)]; 2.17 g of 3-bromo-6,7,8,9- tetrahydro-benzocyclohepten-5-one [lR NMR (300 MHz, DMSO-d6) δ: 7 '.62-7.69 (m, 2 H), 7.27 (d, J=8.2 Hz, 1 H), 2.88 (t, J=6.2 Hz, 2 H), 2.64-2.72 (m, 2 H), 1.61-1.82 (m, 4 H)]; and 0.44 g of l,3-dibromo-6,7,8,9-tetrahydro-benzocyclohepten-5-one [1H NMR (300 MHz, DMSO-d6) δ: 8.05 (d, J=2.1 Hz, 1 H), 7.55 (d, J=1.8 Hz, 1 H), 2.99 (t, J=6.2 Hz, 2 H), 2.60-2.72 (m, 2 H), 1.57-1.80 (m, 4 H)]. Purification of the 4.9 g batch gave 1.19 g of l-bromo-6,7,8,9-tetrahydro- benzocyclohepten-5-one [1H NMR (300 MHz, DMSO-d6) δ: 7.79 (dd, J=7.8, 0.9 Hz, 1 H), 7.46 (dd, J=7.7, 1.1 Hz, 1 H), 7.20-7.30 (m, 1 H), 2.94-3.15 (m, 2 H), 2.56-2.79 (m, 2 H), 1.50-1.86 (m, 4 H)]; 2.10 g of 3-bromo-6,7,8,9-tetrahydro- benzocyclohepten-5-one [1H NMR (300 MHz, DMSO-d6) δ: 7.62-7.68 (m, 2 H), 7.27 (d, J=7.8 Hz, 1 H), 2.88 (t, J=6.0 Hz, 2 H), 2.65-2.71 (m, 2 H), 1.62-1.81 (m, 4 H)]; and 1.38 g of l,3-dibromo-6,7,8,9-tetrahydro-benzocyclohepten-5-one [1H NMR (300 MHz, DMSO-de) δ: 8.05 (d, J=2.1 Hz, 1 H), 7.55 (d, J=1.8 Hz, 1 H), 2.99 (t, J=6.2 Hz, 2 H), 2.63-2.69 (m, 2 H), 1.56-1.80 (m, 4 H)]. The total yield of l-bromo-6,7,8,9-tetrahydro-benzocyclohepten-5-one was 3.96 g (approx. 33%).
Intermediate 1.02
Hydroxy-6,7,8,9-tetrahydro-benzocyclohept(
Figure imgf000051_0001
KOH pellets (632 mg, 11.3 mmol) were placed in a 25 mL round-bottomed flask and tris(dibenzylideneacetone)dipalladium(0) (available from Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA; 101 mg, 0.11 mmol) and 2-di-tert-butyl-phosphino-2',4',6'-triisopropylbiphenyl (available from Strem
Chemicals, Inc., 7 Mulliken Way, Dexter Industrial Park, Newburyport, MA, USA; 383 mg, 0.9 mmol) were added. The flask was evacuated and filled with argon.
Degassed water (2.5 mL) and a mixture of l-bromo-6,7,8,9-tetrahydro- benzocyclohepten-5-one (from the second SFC purification described in the description of the preparation of Intermediate 1.01; 1.19 g, 5.0 mmol) in dioxane (2.5 mL) were added. The round-bottomed flask was placed in a preheated oil bath at 80 °C and heated overnight. The mixture was cooled to room temperature and 1 M HC1 (5 mL) was added. The mixture was extracted three times with ethyl acetate, and the combined organic solutions were washed with brine, dried over MgS04, filtered and evaporated. The resulting crude material was purified using an Analogix
Intelliflash 280 system, with a 24 g column. The mixture was eluted at 40 mL/min for 3 min with hexanes, then with a gradient of 0-25% ethyl acetate/hexanes for 10 min, and finally with 25% ethyl acetate/hexanes for 5 min. Fractions containing the product were evaporated to give l-hydroxy-6,7,8,9-tetrahydro-benzocyclohepten-5-one (0.69 g, 79%) as a yellow solid. lH NMR (300 MHz, DMSO-d6) δ: 9.64 (s, 1 H), 7.04-7.12 (m, 1 H), 6.93-7.00 (m, 2 H), 2.86 (t, J=5.7 Hz, 2 H), 2.61 (t, J=5.9 Hz, 2 H), 1.62- 1.73 (m, 4 H). Intermediate 1.03
(5-Oxo-6,7, 8,9-tetrahydro-5H-benzocyclohepten-l-yloxy)-acetic acid tert-butyl ester
Figure imgf000052_0001
tert-Butyl bromoacetate (available from Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA; 2.76 g, 14.2 mmol) was added to a stirred mixture of l-hydroxy-6,7,8,9-tetrahydro-benzocyclohepten-5-one (which may be prepared as described for Intermediate 1.02; 1.0 g, 5.67 mmol) and CS2CO3 (5.52 g, 17.0 mmol) in CH3CN (30 mL) at room temperature under nitrogen. The mixture was stirred at room temperature overnight and then filtered through celite. The celite was washed with EtOAc (10 mL) and the combined filtrates were concentrated under reduced pressure to give a gum. EtOAc (50 mL) was added and the mixture was washed with water (3 x 20 mL). The organic solution was dried over Na2S04, filtered, and evaporated. The residue was purified by silica gel chromatography, using 5-10% EtOAc/hexanes as eluent, to give (5-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-l- yloxy)-acetic acid tert-butyl ester (1.5 g, 91%) as a light yellow sticky material. !H NMR (300 MHz, DMSO-d6) δ: 7.25 (t, J = 6.0 Hz, 1 H), 7.13 (d, J = 5.6 Hz, 1 H), 7.06 (d, J = 6.1 Hz, 1 H), 4.73 (s, 2 H), 2.96-2.98 (m, 2 H), 2.64-2.67 (m, 2 H), 1.66- 1.74 (m, 4 H), 1.42 (s, 9 H).
Intermediate 1.04
(5-Amino-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy)-acetic acid tert-butyl ester
Figure imgf000052_0002
Ammonium acetate (13.27 g, 172.4 mmol) was added to a solution of (5-oxo-6,7,8,9- tetrahydro-5H-benzocyclohepten-l-yloxy)-acetic acid tert-butyl ester (which may be prepared as described for Intermediate 1.03; 2.5 g, 8.62 mmol) in MeOH (30 mL) at room temperature under nitrogen. The reaction mixture was stirred for 4 h at room temperature, and then cooled to ~0 °C. Sodium cyanoborohydride (1.35 g, 21.6 mmol) was added, and the reaction mixture was allowed to stir at room temperature for 24 h. The reaction mixture was concentrated, and the pH was adjusted to ~7 by the addition of aqueous saturated Na2C03. The mixture was extracted with EtOAc (3 x 100 mL). The combined organic extracts were dried over anhydrous Na2S04, filtered, and evaporated. The residue was purified by silica gel chromatography, using 2-5%
Με0Η/Ο¾θ2 as eluent, to give (5-amino-6,7,8,9-tetrahydro-5H-benzocyclohepten- l-yloxy)-acetic acid tert-butyl ester (1.45 g, 58%) as a colorless semi- solid. 1H NMR (300 MHz, DMSO-dg) δ: 7.18-7.22 (t, J = 6.0 Hz, 1 H), 6.77-6.84 (m, 2 H), 4.68 (s, 2 H), 4.51-4.54 (m, 1 H), 2.42-2.45 (m, 1 H), 1.75-1.99 (m, 5 H), 1.49-1.51 (m, 1 H), 1.42 (s, 9 H), 1.12-1.23 (m, 3 H). Intermediate 1.05
-Bromo-pyridine-2-thiol
Figure imgf000053_0001
Lawesson's reagent (available from Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA; 2.32 g, 5.74 mmol) was added in portions to a suspension of 5-bromo-2(l H)-pyridone (available from Aldrich
Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA; 2 g, 11.5 mmol) in dry toluene (50 mL) under nitrogen. The reaction mixture was heated at reflux for 1 h and then cooled to room temperature. The product that precipitated on cooling was collected by filtration and dried under high vacuum to give 5-bromo-pyridine-2-thiol (2.1 g, 96%), which was used directly in the next step without further purification.
Intermediate 1.06
5-Bromo-pyridine-2-sulfonyl chloride
Figure imgf000053_0002
A suspension of 5-bromo-pyridine-2-thiol (which may be prepared as described for Intermediate 1.05; 2 g, 10.5 mmol) in carbon tetrachloride (40 mL) and water (8 mL) was cooled to ~0 °C using an ice-bath. Chlorine gas was bubbled through the reaction mixture for 20 min and then CH2CI2 (100 mL) was added. The mixture was washed with brine. The organic layer was dried over anhydrous Na2S04, filtered, and evaporated under reduced pressure to give 5-bromo-pyridine-2-sulfonyl chloride (1.92 g, 71%) as a light yellow solid which was used directly in the next step without further purification. !H NMR (400 MHz, DMSO-ifc) δ: 8.63 (d, 7=1.5 Hz, 3 H), 8.07 (dd, 7=8.3, 2.2 Hz, 3 H), 7.68 (d, 7=8.3 Hz, 3 H).
Intermediate 1.07
[5-(3-Isopropenyl-5-trifluoromethyl-benzenesulfonylamino)-6,7,8,9-tetrahydro- benzocyclohepten-l-yloxy] -acetic acid tert-butyl ester
Figure imgf000054_0001
1 M K2CO3 (0.5 mL, 0.5 mmol), Pd(PPh3)4 (available from Aldrich Chemical
Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA; 60 mg, 0.05 mmol), and isopropenylboronic acid pinacol ester (available from Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA; 171 mg, 1.02 mmol) were added to a solution of [5-(3-bromo-5-trifluoromethyl- benzenesulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten- 1-yloxy] -acetic acid tert-butyl ester (which may be prepared as described for Intermediate 2.07; 200 mg, 0.34 mmol) in dioxane (8 mL) with continuous purging with argon. The tube was sealed and the mixture was heated at 100 °C for 16 h. The mixture was cooled to room temperature and partitioned between water and ethyl acetate. The organic layer was dried over anhydrous Na2S04, filtered, and evaporated to give [5-(3-isopropenyl-5- trifluoromethyl-benzenesulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l- yloxy]-acetic acid tert-butyl ester (200 mg, crude yield: 107%) as a white solid. lH NMR (400 MHz, DMSC 6) δ: 8.38 (br. s., 1 H), 8.02 (s, 1 H), 7.95 (s, 1 H), 7.87 (s, 1 H), 6.90 (t, 7=7.9 Hz, 1 H), 6.72 (d, .7=7.3 Hz, 1 H), 6.60 (d, .7=7.9 Hz, 1 H), 5.59 (s, 1 H), 5.32 (s, 1 H), 4.45-4.59 (m, 3 H), 2.97-3.07 (m, 1 H), 2.62-2.70 (m, 1 H), 2.13 (s, 3 H), 1.47-1.86 (m, 4 H), 1.41 (s, 9 H). Intermediate 1.08
[5-(4-Iodo-benzenesulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy]- -butyl ester
Figure imgf000055_0001
A mixture of (5-amino-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy)-acetic acid tert-butyl ester (which may be prepared as described for Intermediate 1.04; 400 mg, 1.4 mmol), diisopropylethylamine (0.46 mL, 2.6 mmol), and 4-iodobenzenesulfonyl chloride (available from Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA; 414.4 mg, 1.4 mmol) in THF (10 mL) was stirred at room temperature for 14 h. The reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography, using 9% EtOAc/hexane as eluent, to give [5-(4-iodo-benzenesulfonylamino)-6,7,8,9- tetrahydro-5H-benzocyclohepten-l-yloxy] -acetic acid tert-butyl ester (500 mg, 65%). 1H NMR (400 MHz, DMSO- ) δ: 8.26 (d, 7=7.6 Hz, 1 H), 7.91 (d, .7=8.1 Hz, 2 H), 7.52 (d, 7=8.1 Hz, 2 H), 6.94-7.05 (m, 1 H), 6.81 (d, 7=7.6 Hz, 1 H), 6.67 (d, 7=8.3 Hz, 1 H), 4.59 (s, 2 H), 4.43 (br. s., 1 H), 3.11-3.18 (m, 1 H), 1.67-1.76 (m, 1 H), 1.46- 1.57 (m, 5 H), 1.41 (s, 9 H), 1.17-1.29 (m, 1 H), 0.74-1.09 (m, 1 H).
Intermediate 1.09
[5-(5-Bromo-pyridine-2-sulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l- yloxy] -acetic acid tert-butyl ester
Figure imgf000056_0001
Using the conditions described for the preparation of Intermediate 1.08, (5-amino- 6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy)-acetic acid tert-butyl ester (which may be prepared as described for Intermediate 1.04; 168.8 mg, 0.58 mmol) was reacted with diisopropylethylamine (0.2 mL, 1.2 mmol) and 5-bromo-pyridine-2- sulfonyl chloride (which may be prepared as described for Intermediate 1.06; 150 mg, 0.58 mmol) to give [5-(5-bromo-pyridine-2-sulfonylamino)-6,7,8,9-tetrahydro-5H- benzocyclohepten-l-yloxy] -acetic acid tert-butyl ester (100 mg, 34%). lH NMR (400 MHz, DMSO- ) δ: 8.84 (s, 1 H), 8.54 (d, .7=7.8 Hz, 1 H), 8.24 (d, 7=8.3 Hz, 1 H), 7.77 (d, 7=8.3 Hz, 1 H), 6.94-7.03 (m, 1 H), 6.86 (d, 7=7.3 Hz, 1 H), 6.66 (d, 7=7.8 Hz, 1 H), 4.64 (t, 7=7.8 Hz, 1 H), 4.59 (s, 2 H), 3.16-3.25 (m, 1 H), 1.50-1.82 (m, 5 H), 1.41 (s, 9 H), 1.13-1.35 (m, 2 H).
Intermediate 1.10
[5-(3-Bromo-benzenesulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l- loxy] -acetic acid tert-butyl ester
Figure imgf000056_0002
A mixture of (5-amino-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy)-acetic acid tert-butyl ester (which may be prepared as described for Intermediate 1.04; 200 mg, 0.7 mmol), diisopropylethylamine (0.3 mL, 1.7 mmol), and 3-bromobenzenesulfonyl chloride (available from Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA; 150 mg, 0.59 mmol) in THF (6 mL) was stirred at room temperature under nitrogen for 3 h. The mixture was concentrated under reduced pressure and the residue was purified by silica gel column chromatography to give [5-(3-bromo-benzenesulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l- yloxy]-acetic acid tert-butyl ester (200 mg, 57%). 1H NMR (400 MHz, DMSO-d6) δ: 8.31 (br. s., 1 H), 7.87 (s, 1 H), 7.79 (t, 7=8.7 Hz, 2 H), 7.50 (t, 7=7.8 Hz, 1 H), 6.95- 7.07 (m, 1 H), 6.79 (d, 7=7.6 Hz, 1 H), 6.67 (d, 7=8.1 Hz, 1 H), 4.58 (s, 2 H), 4.47 (br. s., 1 H), 3.07-3.12 (m, 1 H), 2.54-2.64 (m, 1 H), 1.71-1.79 (m, 1 H), 1.47-1.57 (m, 4 H), 1.41 (s, 9 H), 1.21-1.31 (m, 1 H).
Intermediate 2.01
[5-(3,5-Bis-trifluoromethyl-benzenesulfonylamino)-6,7,8,9-tetrahydro-5H- benzocyclohepten-l-yloxy] -acetic acid tert-butyl ester
Figure imgf000057_0001
Diisopropylethylamine (0.15 mL, 0.86 mmol) was added at 0 °C to a stirred solution of (5-amino-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy)-acetic acid tert-butyl ester (which may be prepared as described for Intermediate 1.04; 0.10 g, 0.34 mmol) in anhydrous CH2CI2 (3 mL). The reaction mixture was stirred at this temperature for 15 min and then a solution of bis-(3,5-trifluoromethyl)benzenesulfonyl chloride (available from Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA; 0.129 g, 0.41 mmol) was added. The reaction mixture was stirred at room temperature overnight and then concentrated. EtOAc was added and the mixture was washed with water. The organic layer was dried over anhydrous Na2S04, filtered, evaporated, and purified by silica gel column chromatography (eluting with 10% EtOAc/hexane) to give [5-(3,5-bis-trifluoromethyl- benzenesulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy]-acetic acid tert-butyl ester (85 mg, 49%) as a solid. XH NMR (400 MHz, DMSO-ifc) δ: 8.52 (d, 7=7.8 Hz, 1 H), 8.31 (s, 1 H), 8.19 (s, 2 H), 6.81-6.91 (m, 1 H), 6.66 (d, 7=7.3 Hz, 1 H), 6.55 (d, 7=8.3 Hz, 1 H), 4.60 (t, 7=6.8 Hz, 1 H), 4.35-4.52 (m, 2 H), 2.81 (br. s., 2 H), 1.70-1.92 (m, 2 H), 1.52-1.66 (m, 2 H), 1.41 (s, 9 H), 1.17-1.28 (m, 2 H).
Intermediate 2.02
[5-(3,5-Dichloro-benzenesulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l- yloxy] -acetic acid tert-butyl ester
Figure imgf000058_0001
Using the conditions described for the preparation of Intermediate 2.04, (5-amino- 6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy)-acetic acid tert-butyl ester (which may be prepared as described for Intermediate 1.04; 0.25 g, 0.86 mmol) was reacted with 3,5-dichlorobenzenesulfonyl chloride (available from Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA; 252 mg, 1.03 mmol) in the presence of diisopropylethylamine (0.35 mL, 2.0 mmol) in CH2CI2 (5 mL) to give [[5-(3,5-dichloro-benzenesulfonylamino)-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy] -acetic acid tert-butyl ester (180 mg, 42%) as a solid. lH NMR (400 MHz, DMSO-i6) δ: 8.40 (s, 1 H), 7.86 (s, 1 H), 7.67 (d, 7=1.5 Hz, 2 H), 6.92-7.04 (m, 1 H), 6.76 (d, 7=7.3 Hz, 1 H), 6.67 (d, 7=8.3 Hz, 1 H), 4.50-4.57 (m, 3 H), 2.94-3.06 (m, 1 H), 2.64-2.78 (m, 1 H), 1.75-1.85 (m, 1 H), 1.51-1.67 (m, 3 H), 1.42 (s, 9 H), 1.28-1.36 (m, 1 H).
Intermediate 2.03
[5-(Biphenyl-3-sulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy]- acetic acid tert-butyl ester
Figure imgf000059_0001
Using the conditions described for the preparation of Intermediate 2.04, (5-amino- 6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy)-acetic acid tert-butyl ester (which may be prepared as described for Intermediate 1.04; 0.25 g, 0.86 mmol) was reacted with 3-phenylbenzenesulfonyl chloride (available from Chem-Impex International, Inc., 935 Dillon Drive, Wood Dale, IL 60191, USA; 0.26 g, 1.03 mmol) in the presence of diisopropylethylamine (0.35 mL, 2.14 mmol) in CH2CI2 (5 mL) to give [5-(biphenyl-3-sulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten- l-yloxy]- acetic acid tert-butyl ester (160 mg, 37%) as a solid. !H NMR (400 MHz, OMSO-d6) δ: 8.23 (d, 7=7.8 Hz, 1 H), 8.00 (s, 1 H), 7.89 (d, 7=7.8 Hz, 1 H), 7.78 (d, 7=7.8 Hz, 1 H), 7.60-7.67 (m, 3 H), 7.51 (t, 7=7.6 Hz, 2 H), 7.40-7.46 (m, 1 H), 6.93-7.01 (m, 1 H), 6.84 (d, 7=7.3 Hz, 1 H), 6.65 (d, 7=7.8 Hz, 1 H), 4.55 (s, 2 H), 4.45-4.53 (m, 1 H), 3.18 (dd, 7=13.2, 7.3 Hz, 1 H), 2.54-2.61 (m, 1 H), 1.68-1.76 (m, 1 H), 1.46-1.59 (m, 4 H), 1.41 (s, 9 H), 1.21- 1.27 (m, 1 H).
Intermediate 2.04
[5-(Biphenyl-4-sulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy]- acetic acid tert-but l ester
Figure imgf000059_0002
Biphenyl-4-sulfonyl chloride (available from Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA; 0.26 g, 1.03 mmol), and diisopropylethylamine (0.35 mL, 2.0 mmol) were added to a ~0°C solution of (5- amino-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy)-acetic acid tert-butyl ester (which may be prepared as described for Intermediate 1.04; 0.25 g, 0.86 mmol) in CH2CI2 (5 mL) under nitrogen. The mixture was stirred at room temperature for 5 h and then water (5 mL) was added. The mixture was extracted with CH2CI2 (2 x 20 mL) and the combined extracts were washed with water (10 mL) and brine (10 mL), dried over anhydrous Na2S04, filtered and concentrated. The residue was purified by silica gel column chromatography (eluting with 5% EtOAc hexane) to give [5-(biphenyl-4- sulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy] -acetic acid tert- butyl ester (170 mg, 39%) as a solid. XH NMR (400 MHz, DMSO-d6) δ: 8.22 (d, /=7.8 Hz, 1 H), 7.84 (s, 4 H), 7.73 (d, 7=7.3 Hz, 2 H), 7.48-7.54 (m, 2 H), 7.41-7.46 (m, 1
H), 6.95-7.04 (m, 1 H), 6.86 (d, 7=7.3 Hz, 1 H), 6.67 (d, 7=8.3 Hz, 1 H), 4.57 (s, 2 H), 4.48 (t, 7=6.4 Hz, 1 H), 3.14-3.23 (m, 1 H), 1.69-1.75 (m, 1 H), 1.46-1.60 (m, 4 H), 1.40 (s, 9 H), 1.20-1.31 (m, 2 H).
Intermediate 2.05
[5-(3-Methanesulfonyl-benzenesulfonylamino)-6,7,8,9-tetrahydro- benzoc clohepten-l-yloxy] -acetic acid tert-butyl ester
Figure imgf000060_0001
Using the conditions described for the preparation of Intermediate 2.04, (5-amino- 6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy)-acetic acid tert-butyl ester (which may be prepared as described for Intermediate 1.04; 0.25 g, 0.86 mmol) was reacted with 3-(methylsulfonyl)benzenesulfonyl chloride (available from Oakwood Products, Inc., 1741 Old Dunbar Road, West Columbia, SC 29172, USA; 262 mg, 1.03 mmol) in the presence of diisopropylethylamine (0.35 mL, 2.0 mmol) in CH2CI2 (5 mL) to give [5-(3-methanesulfonyl-benzenesulfonylamino)-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy] -acetic acid tert-butyl ester (185 mg, 42%) as a solid. 1H NMR (400 MHz, DMSO-d6) δ: 8.44 (d, 7=7.3 Hz, 1 H), 8.26 (s, 1 H), 8.12 (d, 7=7.8 Hz, 1 H), 8.05 (d, 7=8.1 Hz, 1 H), 7.77-7.81 (m, 1 H), 6.94 (t, 7=7.9 Hz, 1 H), 6.74 (d, 7=7.8 Hz, 1 H), 6.63 (d, 7=8.1 Hz, 1 H), 4.56 (s, 2 H), 4.49-4.54 (m, 1 H), 3.24 (s, 3 H), 3.05-3.13 (m, 1 H), 2.59-2.69 (m, 1 H), 1.69-1.81 (m, 1 H), 1.49-1.61 (m, 4 H), 1.41 (s, 9 H), 1.22-1.31 (m, 1 H).
Intermediate 2.06
[5-(3-Fluoro-5-trifluoromethyl-benzenesulfonylamino)-6,7,8,9-tetrahydro- benzocyclohepten-l-yloxy] -acetic acid tert-butyl ester
Figure imgf000061_0001
Using the conditions of General Procedure 2, (5-amino-6,7,8,9-tetrahydro-5H- benzocyclohepten-l-yloxy)-acetic acid tert-butyl ester (which may be prepared as described for Intermediate 1.04; 1.0 g, 3.4 mmol) was reacted with 3-fluoro-5- (trifluoromethyl)benzenesulfonyl chloride (available from Alfa Aesar, 26 Parkridge Road, Ward Hill, MA 01835, USA; 0.9 g, 3.4 mmol) in the presence of
diisopropylethylamine (0.89 g, 6.9 mmol) in THF (20 mL) to give [5-(3-fluoro-5- trifluoromethyl-benzenesulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l- yloxy]-acetic acid tert-butyl ester (0.7 g, 39%). 1H NMR (400 MHz, DMSO-rf6) δ: 8.48 (br s, 1 H), 7.96 (d, .7=8.3 Hz, 1 H), 7.84 (s, 1 H), 7.80 (d, .7=7.6 Hz, 1 H), 6.93 (t, 7=8.1 Hz, 1 H), 6.72 (d, .7=7.6 Hz, 1 H), 6.63 (d, .7=8.1 Hz, 1 H), 4.49-4.58 (m, 3 H), 2.93-3.02 (m, 1 H), 2.66-2.76 (m, 1 H), 1.51-1.85 (m, 5 H), 1.41 (s, 9 H), 1.16-1.27 (m, 1 H).
Intermediate 2.07
[5-(3-Bromo-5-trifluoromethyl-benzenesulfonylamino)-6,7,8,9-tetrahydro-5H- benzocyclohepten-l-yloxy] -acetic acid tert-butyl ester
Figure imgf000062_0001
Using the conditions described for the preparation of Intermediate 1.08, (5-amino- 6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy)-acetic acid tert-butyl ester (which may be prepared as described for Intermediate 1.04; 400 mg, 1.4 mmol) was reacted with 3-bromo-5-(trifluoromethyl)benzenesulfonyl chloride (available from Alfa Aesar, 26 Parkridge Road, Ward Hill, MA 01835, USA; 444 mg, 1.4 mmol) in the presence of diisopropylethylamine (0.46 g, 2.6 mmol) to give [5-(3-bromo-5-trifluoromethyl- benzenesulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy]-acetic acid tert-butyl ester (300 mg, 38%). 1H NMR (400 MHz, DMSO- ) δ: 8.45 (br. s., 1 H), 8.19 (br. s., 1 H), 8.04 (br. s., 1 H), 7.95 (s, 1 H), 6.89-6.97 (m, 1 H), 6.71 (d, .7=7.6 Hz, 1 H), 6.62 (d, 7=8.1 Hz, 1 H), 4.48-4.62 (m, 3 H), 1.50-1.62 (m, 1 H), 1.42 (s, 9 H), 1.13-1.31 (s, 1 H).
Intermediate 2.08
[5-(3,5-Bis-methanesulfonyl-benzenesulfonylamino)-6,7,8,9-tetrahydro- benzocyclohepten-l-yloxy] -acetic acid tert-butyl ester
Figure imgf000062_0002
Using the conditions of General Procedure 2, (5-amino-6,7,8,9-tetrahydro-5H- benzocyclohepten-l-yloxy)-acetic acid tert-butyl ester (which may be prepared as described for Intermediate 1.04; 0.2 g, 0.69 mmol) was reacted with 3,5- bis(methylsulfonyl)benzenesulfonyl chloride (available from Oakwood Products, Inc., 1741 Old Dunbar Road, West Columbia, SC 29172, USA; 0.229 g, 0.69 mmol) in the presence of diisopropylethylamine (2.4 mL, 1.4 mmol), in THF (5 mL), to give [5- (3,5-bis-methanesulfonyl-benzenesulfonylamino)-6,7,8,9-tetrahydro-5H- benzocyclohepten-l-yloxy] -acetic acid tert-butyl ester (0.22 g, 54%). !H NMR (400 MHz, DMSO- ) δ: 8.62 (d, .7=7.3 Hz, 1 H), 8.52 (s, 1 H), 8.45 (s, 2 H), 6.84-6.94 (m, 1 H), 6.67 (d, 7=7.8 Hz, 1 H), 6.55 (d, .7=8.3 Hz, 1 H), 4.56-4.66 (m, 1 H), 4.51 (s, 2 H), 2.69-2.96 (m, 2 H), 1.52-1.89 (m, 4 H), 1.42 (s, 9 H), 1.22-1.28 (m, 1 H).
Intermediate 2.09
[5-(Biphenyl-4-sulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy]- acetic acid tert-but l ester
Figure imgf000063_0001
Using the conditions of General Procedure 2, (5-amino-6,7,8,9-tetrahydro-5H- benzocyclohepten-l-yloxy)-acetic acid tert-butyl ester (which may be prepared as described for Intermediate 1.04; 0.2 g, 0.69 mmol) was reacted with 4- biphenylsulfonyl chloride (available from Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA; 0.174 g, 0.69 mmol) in the presence of diisopropylethylamine (0.178 g, 1.37 mmol) in THF (5 mL) to give [5- (biphenyl-4-sulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy]-acetic acid tert-butyl ester (0.21 g, 60%). 1H NMR (400 MHz, DMSO-d6) δ: 8.24 (d, =7.8 Hz, 1 H), 7.85 (s, 4 H), 7.73 (d, 7=7.3 Hz, 2 H), 7.39-7.56 (m, 2 H), 6.94-7.04 (m, 1 H), 6.86 (d, 7=7.3 Hz, 1 H), 6.66 (d, 7=8.3 Hz, 1 H), 4.57 (s, 2 H), 4.47 (br. s., 1 H), 1.46-1.80 (m, 5 H), 1.40 (s, 9 H), 1.20-1.30 (m, 1 H).
Intermediate 2.10 [5-(3-Acetyl-5-trifluoromethyl-benzenesulfonylamino)-6,7,8,9-tetrahydro benzocyclohepten-l-yloxy] -acetic acid tert-butyl ester
Figure imgf000064_0001
A mixture of [5-(3-bromo-5-trifluoromethyl-benzenesulfonylamino)-6,7,8,9- tetrahydro-5H-benzocyclohepten-l-yloxy] -acetic acid tert-butyl ester (which may be prepared as described for Intermediate 2.07; 200 mg, 0.35 mmol),
tris(dibenzylideneacetone)dipalladium(0) (available from Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA; 35 mg, 0.04 mmol), triphenylarsine (available from Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA; 35 mg, 0.11 mmol), and tributyl(l- ethoxyvinyl)tin (available from Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA; 0.2 mL, 0.6 mmol) in DMF (2 mL) was heated at 80 °C for 2 h. The reaction mixture was cooled to room temperature and 4 N HC1 (0.1 mL) was added. The mixture was stirred for 10 min at room temperature and then poured into water (4 mL). The mixture was extracted with EtOAc (3 10 mL).
The organic layers were combined, washed with brine (10 mL), dried over anhydrous Na2SC>4, filtered, and evaporated. The residue was purified by silica gel
chromatography to give [5-(3-acetyl-5-trifluoromethyl-benzenesulfonylamino)- 6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy]-acetic acid tert-butyl ester (165 mg, 88%). 1H NMR (400 MHz, DMSO-dg) δ: 8.49 (d, 7=7.8 Hz, 1 H), 8.36 (s, 1 H), 8.32 (s, 1 H), 8.16 (s, 1 H), 6.84-6.91 (m, 1 H), 6.69 (d, 7=7.8 Hz, 1 H), 6.55 (d, 7=8.3 Hz, 1 H), 4.56 (d, 7=6.8 Hz, 1 H), 4.41-4.53 (m, 2 H), 2.69-2.95 (m, 2 H), 2.65 (s, 3 H), 1.52-1.89 (m, 5 H), 1.42 (s, 9 H).
Intermediate 2.11
[5-(3-Methanesulfonyl-5-trifluoromethyl-benzenesulfonylamino)-6,7,8,9
5H-benzocyclohepten-l-yloxy] -acetic acid tert-butyl ester
Figure imgf000065_0001
Sodium methanesulfinate (available from Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA; 80 mg, 0.78 mmol) and copper(I) iodide (149 mg, 0.78 mmol) were added to a degassed solution of [5-(3- bromo-5-trifluoromethyl-benzenesulfonylamino)-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy] -acetic acid tert-butyl ester (which may be prepared as described for Intermediate 2.07; 100 mg, 0.17 mmol) in NMP (5 mL). The reaction mixture was heated at 150 °C for 3 h. The reaction mixture was cooled to room temperature. Ethyl acetate (20 mL) was added and the mixture was washed with brine (10 mL). The organic layer was dried over anhydrous Na2S04, filtered, and evaporated. The residue was purified by silica gel chromatography, using 15% EtOAc/hexanes as eluent, to give [5-(3-methanesulfonyl-5-trifluoromethyl- benzenesulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy]-acetic acid tert-butyl ester (80 mg, 80%).
Intermediate 2.12
[5-(3'-Isopropyl-biphenyl-4-sulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten- l-yloxy]-acetic acid tert-butyl ester
Figure imgf000065_0002
Using the conditions of General Procedure 4, [5-(4-iodo-benzenesulfonylamino)- 6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy]-acetic acid tert-butyl ester (which may be prepared as described for Intermediate 1.08; 300 mg, 0.54 mmol) was reacted with 3-isopropylphenylboronic acid (available from Alfa Aesar, 26 Parkridge Road, Ward Hill, MA 01835, USA; 106 mg, 0.65 mmol) in the presence of Pd(PPh3)4 (available from Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA; 60 mg, 0.05 mmol), and 1 M aqueous K2C03 (0.8 mL, 0.8 mmol) in dioxane (7 mL) to give [5-(3'-isopropyl-biphenyl-4-sulfonylamino)- 6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy]-acetic acid tert-butyl ester (280 mg 97%). 1H NMR (400 MHz, DMSO-d6) δ: 8.22 (d, 7-7.6 Hz, 1 H), 7.84 (s, 4 H), 7.58 (s, 1 H), 7.53 (d, 7=7.6 Hz, 1 H), 7.42 (t, 7=7.7 Hz, 1 H), 7.32 (d, 7=7.6 Hz, 1 H), 6.94-7.04 (m, 1 H), 6.87 (d, 7=7.6 Hz, 1 H), 6.67 (d, 7=8.3 Hz, 1 H), 4.57 (s, 2 H), 4.47 (br. s., 1 H), 3.16-3.23 (m, 1 H), 2.99 (dt, 7=13.7, 6.8 Hz, 1 H), 1.45-1.78 (m, 5 H), 1.40 (s, 9 H), 1.22-1.31 (m, 10 H).
Intermediate 2.13
[5-(3'-tert-Butyl-5'-methyl-biphenyl-4-sulfonylamino)-6,7,8,9-tetrahydro- benzoc clohepten-l-yloxy] -acetic acid tert-butyl ester
Figure imgf000066_0001
Using the conditions of General Procedure 4, [5-(4-iodo-benzenesulfonylamino)-
6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy]-acetic acid tert-butyl ester (which may be prepared as described for Intermediate 1.08; 300 mg, 0.54 mmol) was reacted with (3-t-butyl-5-methylphenyl)boronic acid (available from Combi-Blocks Inc., 7949 Silverton Avenue, Suite 915, San Diego, CA 92126, USA; 124 mg, 0.65 mmol) in the presence of Pd(PPh3)4 (available from Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA; 60 mg, 0.05 mmol), and 1 M aqueous K2C03 (0.8 mL, 0.8 mmol) in dioxane (7 mL) to give [5-(3'-tert-butyl-5'- methyl-biphenyl-4-sulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy]- acetic acid tert-butyl ester (230 mg, 74%). 1H NMR (400 MHz, DMSO-d6) δ: 8.22 (d, .7=7.8 Hz, 1 H), 7.76-7.88 (m, 4 H), 7.47 (s, 1 H), 7.34 (s, 1 H), 7.28 (s, 1 H), 6.95- 7.05 (m, 1 H), 6.87 (d, /=7.6 Hz, 1 H), 6.66 (d, .7=8.1 Hz, 1 H), 4.57 (s, 2 H), 4.44- 4.48 (m, 1 H), 3.12-3.25 (m, 1 H), 2.38 (s, 3 H), 1.45-1.79 (m, 6 H), 1.40 (s, 9 H), 1.33 (s, 9 H), 1.21-1.28 (m, 3 H).
Intermediate 2.14
[5-(4'-Hydroxy-biphenyl-4-sulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten- -yloxy] -acetic acid tert-butyl ester
Figure imgf000067_0001
Using the conditions of General Procedure 4, [5-(4-iodo-benzenesulfonylamino)- 6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy]-acetic acid tert-butyl ester (which may be prepared as described for Intermediate 1.08; 200 mg, 0.36 mmol) was reacted with 4-hydroxyphenylboronic acid (available from Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA; 58 mg, 0.42 mmol) in the presence of Pd(PPh3)4 (available from Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA; 40 mg, 0.035 mmol), and 1 M aqueous K2CO3 (0.6 mL, 0.6 mmol) in dioxane (5 mL) to give [5-(4'-hydroxy- biphenyl-4-sulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy]-acetic acid tert-butyl ester (120 mg, 64%).
Intermediate 2.15
{5-[4-(5-Methyl-pyridin-3-yl)-benzenesulfonylamino]-6,7,8,9-tetrahydro- benzocyclohepten-l-yloxy}-acetic acid tert-butyl ester
Figure imgf000068_0001
Using the conditions of General Procedure 4, [5-(4-iodo-benzenesulfonylamino)- 6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy]-acetic acid tert-butyl ester (which may be prepared as described for Intermediate 1.08; 300 mg, 0.54 mmol) was reacted with 5-methylpyridine-3-boronic acid (available from Combi-Blocks Inc., 7949
Silverton Avenue, Suite 915, San Diego, CA 92126, USA; 89 mg, 0.65 mmol) in the presence of Pd(PPh3)4 (available from Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA; 60 mg, 0.05 mmol), and 1 M aqueous K2CO3 (0.8 mL, 0.8 mmol) in dioxane (20 mL) to give {5-[4-(5-methyl- pyridin-3-yl)-benzenesulfonylamino]-6,7,8,9-tetrahydro-5H-benzocyclohepten-l- yloxyj-acetic acid tert-butyl ester (195 mg, 69%).
Intermediate 2.16
[5-(3'-Methylsulfanyl-biphenyl-4-sulfonylamino)-6,7,8,9-tetrahydro- benzoc clohepten-l-yloxy] -acetic acid tert-butyl ester
Figure imgf000068_0002
Using the conditions of General Procedure 4, [5-(4-iodo-benzenesulfonylamino)- 6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy]-acetic acid tert-butyl ester (which may be prepared as described for Intermediate 1.08; 300 mg, 0.54 mmol) was reacted with 3-(methylthio)phenylboronic acid (available from Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA; 109 mg, 0.65 mmol) in the presence of Pd(PPh3)4 (available from Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA; 60 mg, 0.05 mmol), and 1 M aqueous K2CO3 (0.8 mL, 0.8 mmol) in dioxane (7 mL) to give [5-(3'-methylsulfanyl- biphenyl-4-sulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy]-acetic acid tert-butyl ester (195 mg, 65%). 1H NMR (400 MHz, DMSCM6) δ: 8.24 (d, /=7.8 Hz, 1 H), 7.85 (s, 4 H), 7.55 (s, 1 H), 7.41-7.51 (m, 2 H), 7.33 (d, 7=7.6 Hz, 1 H), 6.96-7.02 (m, 1 H), 6.86 (d, 7=7.6 Hz, 1 H), 6.67 (d, 7=8.1 Hz, 1 H), 4.57 (s, 2 H), 4.45-4.49 (m, 1 H), 3.16-3.22 (m, 1 H), 2.56 (s, 3 H), 1.45-1.78 (m, 6 H), 1.40 (s, 9 H), 1.21-1.29 (m, 4 H).
Intermediate 2.17
[5-(3'-Methanesulfonyl-biphenyl-4-sulfonylamino)-6,7,8,9-tetrahydro-5H- benzoc clohepten-l-yloxy] -acetic acid tert-butyl ester
Figure imgf000069_0001
Using the conditions of General Procedure 4, [5-(4-iodo-benzenesulfonylamino)- 6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy]-acetic acid tert-butyl ester (which may be prepared as described for Intermediate 1.08; 300 mg, 0.54 mmol) was reacted with 3-(methylsulfonyl)phenylboronic acid (available from Combi-Blocks Inc., 7949 Silverton Avenue, Suite 915, San Diego, CA 92126, USA; 129 mg, 0.65 mmol) in the presence of Pd(PPh3)4 (available from Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA; 60 mg, 0.05 mmol), and 1 M aqueous K2CO3 (0.8 mL, 0.8 mmol) in dioxane (7 mL) to give [5-(3'- methanesulfonyl-biphenyl-4-sulfonylamino)-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy] -acetic acid tert-butyl ester (200 mg, 63%). lH NMR (400 MHz, DMSO-de) δ: 8.28 (d, .7=7.8 Hz, 1 H), 8.22 (s, 1 H), 8.10 (d, 7=7.8 Hz, 1 H), 7.88-8.01 (m, 5 H), 7.77-7.82 (m, 1 H), 6.97-7.03 (m, 1 H), 6.86 (d, 7=7.8 Hz, 1 H), 6.67 (d, 7=7.8 Hz, 1 H), 4.57 (s, 2 H), 4.46-4.52 (m, 1 H), 1.46-1.77 (m, 5 H), 1.40 (s, 9 H), 1.21-1.29 (m, 2 H).
Intermediate 2.18
{5-[5-(3-Isopropyl-phenyl)-pyridine-2-sulfonylamino]-6,7,8,9-tetrahydro- benzoc clohepten-l-yloxy}-acetic acid tert-butyl ester
Figure imgf000070_0001
Using the conditions of General Procedure 5, [5-(5-bromo-pyridine-2-sulfonylamino)- 6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy]-acetic acid tert-butyl ester (which may be prepared as described for Intermediate 1.09; 500 mg, 0.98 mmol) was reacted with 3-isopropylphenylboronic acid (available from Alfa Aesar, 26 Parkridge Road, Ward Hill, MA 01835, USA; 0.192 g, 1.17 mmol), in the presence of Pd(PPh3)4 (available from Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA; 80 mg, 0.07 mmol), and 1 M aqueous K2C03 (1.5 mL, 1.5 mmol) in dioxane to give {5-[5-(3-isopropyl-phenyl)-pyridine-2-sulfonylamino]-
6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy}-acetic acid tert-butyl ester (450 mg, 84%).
Intermediate 2.19
{5-[5-(3-Trifluoromethyl-phenyl)-pyridine-2-sulfonylamino]-6,7,8,9-tetrahyd]
benzocyclohepten-l-yloxy}-acetic acid tert-butyl ester
Figure imgf000071_0001
Using the conditions of General Procedure 5, [5-(5-bromo-pyridine-2-sulfonylamino)- 6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy]-acetic acid tert-butyl ester (which may be prepared as described for Intermediate 1.09; 150 mg, 0.29 mmol) was reacted with 3-(trifluoromethyl)phenylboronic acid (available from Aldrich Chemical
Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA; 65 mg, 0.34 mmol), in the presence of Pd(PPh3)4 (available from Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA; 30 mg, 0.03 mmol), and 1 M aqueous K2CO3 (0.6 mL, 0.6 mmol) in dioxane (5 mL) to give {5-[5-(3- trifluoromethyl-phenyl)-pyridine-2-sulfonylamino]-6,7,8,9-tetrahydro-5H- benzocyclohepten-l-yloxy} -acetic acid tert-butyl ester (185 mg, crude yield: 109%). This material was used directly in the next step without further purification.
Intermediate 2.20
{5-[5-(3-tert-Butyl-5-methyl-phenyl)-pyridine-2-sulfonylamino]-6,7,8,9-tetrahydro- 5H-benzoc clohepten-l-yloxy}-acetic acid tert-butyl ester
Figure imgf000071_0002
Using the conditions of General Procedure 5, [5-(5-bromo-pyridine-2-sulfonylamino)- 6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy]-acetic acid tert-butyl ester (which may be prepared as described for Intermediate 1.09; 500 mg, 0.98 mmol) was reacted with (3-t-butyl-5-methylphenyl)boronic acid (available from Combi-Blocks Inc., 7949 Silverton Avenue, Suite 915, San Diego, CA 92126, USA; 220 mg, 1.15 mmol), in the presence of Pd(PPh3)4 (available from Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA; 80 mg, 0.07 mmol), and 1 M aqueous K2CO3 (1.5 mL, 1.5 mmol) to give {5-[5-(3-tert-butyl-5-methyl-phenyl)- pyridine-2-sulfonylamino]-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy}-acetic acid tert-butyl ester (470 mg, 83%).
Intermediate 2.21
(5-{5-[3-(2-Hydroxy-ethyl)-phenyl]-pyridine-2-sulfonylamino}-6,7,8,9-tetrahydro- 5H-benzoc clohepten-l-yloxy)-acetic acid tert-butyl ester
Figure imgf000072_0001
Using the conditions of General Procedure 5, [5-(5-bromo-pyridine-2-sulfonylamino)- 6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy]-acetic acid tert-butyl ester (which may be prepared as described for Intermediate 1.09; 500 mg, 0.98 mmol) was reacted with 3-(2-hydroxyethyl)benzeneboronic acid (available from Combi-Blocks Inc., 7949 Silverton Avenue, Suite 915, San Diego, CA 92126, USA; 195 mg, 1.17 mmol), in the presence of Pd(PPh3)4 (available from Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA; 80 mg, 0.07 mmol), and 1 M aqueous K2CO3 (1.5 mL, 1.5 mmol) to give (5-{5-[3-(2-hydroxy-ethyl)-phenyl]- pyridine-2-sulfonylamino}-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy)-acetic acid tert-butyl ester (480 mg, 89%).
Intermediate 2.22
[5-(4'-Methyl-biphenyl-3-sulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l- yloxy] -acetic acid tert-butyl ester
Figure imgf000073_0001
Using the conditions of General Procedure 6, [5-(3-bromo-benzenesulfonylamino)- 6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy]-acetic acid tert-butyl ester (which may be prepared as described for Intermediate 1.10; 450 mg, 0.88 mmol) was reacted with 4-methylphenylboronic acid (available from Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA; 0.213 g, 1.57 mmol), in the presence of Pd(PPli3)4 (available from Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA; 40 mg, 0.03 mmol), and 1 M aqueous K2CO3 (1.35 mL, 1.35 mmol) in dioxane (7 mL) to give [5-(4'-methyl- biphenyl-3-sulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy]-acetic acid tert-butyl ester (350 mg, 76%).
Intermediate 2.23
[5-(3'-Isopropyl-biphenyl-3-sulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-
1- loxy] -acetic acid tert-butyl ester
Figure imgf000073_0002
Using the conditions of General Procedure 6, [5-(3-bromo-benzenesulfonylamino)- 6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy]-acetic acid tert-butyl ester (which may be prepared as described for Intermediate 1.10; 200 mg, 0.4 mmol) was reacted with 3-isopropylphenylboronic acid (available from Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA; 80 mg, 0.5 mmol), in the presence of Pd(PPIi3)4 (available from Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA; 20 mg, 0.02 mmol), and 1 M aqueous K2CO3 (1.5 mL, 1.5 mmol) in dioxane (5 mL) to give [5-(3'-isopropyl- biphenyl-3-sulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy]-acetic acid tert-butyl ester ( 125 mg, 58 % ) .
Intermediate 2.24
[5-(3-Isopropyl-5-trifluoromethyl-benzenesulfonylamino)-6,7,8,9-tetrahydro- benzocyclohepten-l-yloxy] -acetic acid tert-butyl ester
Figure imgf000074_0001
A mixture of [5-(3-isopropenyl-5-trifluoromethyl-benzenesulfonylamino)-6,7,8,9- tetrahydro-5H-benzocyclohepten-l-yloxy] -acetic acid tert-butyl ester (which may be prepared as described for Intermediate 1.07; 200 mg, 0.38 mmol) and 10% palladium- on-carbon (40 mg) in methanol was stirred for 16 h at room temperature under an atmosphere of hydrogen. The mixture was filtered through celite and the celite was washed with methanol. The filtrates were concentrated to give [5-(3-isopropyl-5- trifluoromethyl-benzenesulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l- yloxy]-acetic acid tert-butyl ester (150 mg, 75%) as a white solid. 1H NMR (400 MHz, DMSO- e) δ: 8.35 (br. s., 1 H), 7.89 (s, 1 H), 7.77 (s, 2 H), 6.90 (t, 7=7.8 Hz, 1 H), 6.72 (d, 7=7.3 Hz, 1 H), 6.61 (d, 7=8.3 Hz, 1 H), 4.47-4.56 (m, 3 H), 3.01-3.12 (m, 2 H), 2.59-2.68 (m, 1 H), 1.46-1.83 (m, 5 H), 1.41 (s, 9 H), 1.27-1.35 (m, 1 H), 1.16- 1.24 (m, 6 H).
Intermediate 3.01
{5-[(3-Fluoro-5-trifluoromethyl-benzenesulfonyl)-methyl-amino]-6,7,8,9
5H-benzocyclohepten-l-yloxy}-acetic acid tert-butyl ester
Figure imgf000075_0001
A mixture of [5-(3-fluoro-5-trifluoromethyl-benzenesulfonylamino)-6,7,8,9- tetrahydro-5H-benzocyclohepten-l-yloxy] -acetic acid tert-butyl ester (which may be prepared as described for Intermediate 2.06; 0.30 g, 0.6 mmol), methyl iodide (0.091 g, 0.64 mmol) and K2C03 (88 mg, 0.64 mmol) in DMF (2 mL) was stirred for 20 h at room temperature. Ice-water (6 mL) was added and the mixture was extracted with EtOAc (2 x 15 mL). The organic layers were dried over anhydrous Na2S04, filtered, evaporated, and purified by silica gel chromatography, using 5-8% EtOAc/hexanes as eluent, to give {5-[(3-fluoro-5-trifluoromethyl-benzenesulfonyl)-methyl-amino]- 6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy}-acetic acid tert-butyl ester (0.26 g, 84%). 1H NMR (400 MHz, DMSO-i6) δ: 8.13-88.17 (m, 2 H), 8.00 (s, 1 H), 7.08 (t, 7=7.9 Hz, 1 H), 6.75 (dd, J=l.l, 2.8 Hz, 2 H), 5.21 (d, .7=8.6 Hz, 1 H), 4.64 (s, 2 H), 4.59 (s, 1 H), 3.45 (dd, 7=14.1, 6.7 Hz, 1 H), 2.88 (s, 3 H), 2.39-2.45 (m, 1 H), 1.51- 1.90 (m, 4 H), 1.42 (s, 9 H), 1.23 (s, 4 H), 1.05 (br. s., 1 H).
Intermediate 3.02
{5-[(3-Bromo-5-trifluoromethyl-benzenesulfonyl)-methyl-amino]-6,7,8,9
5H-benzocyclohepten-l-yloxy}-acetic acid tert-butyl ester
Figure imgf000075_0002
Using the conditions described for the preparation of Intermediate 3.20, [5-(3-bromo- 5-trifluoromethyl-benzenesulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l- yloxy]-acetic acid tert-butyl ester (which may be prepared as described for
Intermediate 2.07; 0.15 g, 0.26 mmol) was reacted with methyl iodide (0.034 mL, 0.55 mmol) in the presence of K2CO3 (79 mg, 0.57 mmol) to give {5-[(3-bromo-5- trifluoromethyl-benzenesulfonyl)-methyl-amino]-6,7,8,9-tetrahydro-5H- benzocyclohepten-l-yloxy} -acetic acid tert-butyl ester (150 mg, 98%). 1H NMR (400 MHz, CDC13) 6: 8.11 (s, 1 H), 8.00 (s, 2 H), 7.95 (s, 1 H), 7.92 (s, 1 H), 7.00 (t, 7=7.8 Hz, 1 H), 6.65 (d, 7=7.8 Hz, 1 H), 6.62 (d, 7=8.3 Hz, 1 H), 5.29 (d, 7=9.8 Hz, 1 H), 4.48 (s, 2 H), 3.56 (dd, 7=14.4, 7.1 Hz, 1 H), 2.94 (s, 8 H), 2.87 (s, 8 H), 2.42 (t,
7=13.0 Hz, 1 H), 1.89-1.96 (m, 2 H), 1.52-1.69 (m, 8 H), 1.47 (s, 9 H), 1.21-1.31 (m, 4 H).
Intermediate 3.03
{5-[(3,5-Bis-methanesulfonyl-benzenesulfonyl)-methyl-amino]-6,7,8,9-tetrahydro- 5H-benzocyclohepten-l-yloxy}-acetic acid tert-butyl ester
Figure imgf000076_0001
Using the conditions of General Procedure 3, [5-(3,5-bis-methanesulfonyl- benzenesulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten- 1-yloxy] -acetic acid tert-butyl ester (which may be prepared as described for Intermediate 2.08; 0.15 g, 0.26 mmol) was reacted with methyl iodide (72.5 mg, 0.51 mmol) in the presence of K2CO3 (72.5 mg, 0.51 mmol) in DMF (2 mL) to give {5-[(3,5-bis-methanesulfonyl- benzenesulfonyl)-methyl-amino]-6,7,8,9-tetrahydro-5H-benzocyclohepten- 1-yloxy }- acetic acid tert-butyl ester (110 mg, 72%). 1H NMR (400 MHz, DMSO- ) δ: 8.66 (s, 1 H), 8.63 (s, 2 H), 7.05-7.11 (m, 1 H), 6.72-6.76 (m, 2 H), 5.30 (d, 7=8.8 Hz, 1 H), 4.64 (s, 2 H), 3.46 (s, 6 H), 2.91 (s, 3 H), 1.42 (s, 9 H), 1.20-1.30 (m, 8 H). Intermediate 3.04
{5-[(Biphenyl-4-sulfonyl)-methyl-amino]-6,7,8,9-tetrahydro-5H-benzocyclohepten-l- loxyj-acetic acid tert-butyl ester
Figure imgf000077_0001
Using the conditions of General Procedure 3, [5-(biphenyl-4-sulfonylamino)-6,7,8,9- tetrahydro-5H-benzocyclohepten-l-yloxy] -acetic acid tert-butyl ester (which may be prepared as described for Intermediate 2.09; 0.15 g, 0.30 mmol) was reacted with methyl iodide (84 mg, 0.59 mmol) in the presence of K2CO3 (81.5 mg, 0.59 mmol) in DMF (2 mL) to give {5-[(biphenyl-4-sulfonyl)-methyl-amino]-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxyj-acetic acid tert-butyl ester (100 mg, 65%). This material was used directly in the next step without characterization.
Intermediate 3.05
{5-[(3-Acetyl-5-trifluoromethyl-benzenesulfonyl)-methyl-amino]-6,7,8,9
-benzocyclohepten-l-yloxy}-acetic acid tert-butyl ester
Figure imgf000077_0002
Using the conditions of General Procedure 3, [5-(3-acetyl-5-trifluoromethyl- benzenesulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy]-acetic acid tert-butyl ester (which may be prepared as described for Intermediate 2.10; 0.15 g, 0.28 mmol) was reacted with methyl iodide (79 mg, 0.56 mmol) in the presence of K2C03 (76.6 mg, 0.55 mmol) in DMF (2 mL) to give {5-[(3-acetyl-5-trifluoromethyl- benzenesulfonyl)-methyl-amino]-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy}- acetic acid tert-butyl ester (150 mg, 97%). This material was used directly in the next step without characterization.
Intermediate 3.06
{5-[(3-Methanesulfonyl-5-trifluoromethyl-benzenesulfonyl)-methyl-amino]-6,7,8,9- tetrahydro-5H-benzocyclohepten-l-yloxy}-acetic acid tert-butyl ester
Figure imgf000078_0001
Using the conditions of General Procedure 3, [5-(3-methanesulfonyl-5- trifluoromethyl-benzenesulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l- yloxy]-acetic acid tert-butyl ester (which may be prepared as described for
Intermediate 2.11; 80 mg, 0.14 mmol) was reacted with methyl iodide (40 mg, 0.28 mmol) in the presence of K2CO3 (39 mg, 0.28 mmol) in DMF (2 mL) to give {5-[(3- methanesulfonyl-5-trifluoromethyl-benzenesulfonyl)-methyl-amino]-6,7,8,9- tetrahydro-5H-benzocyclohepten-l-yloxy}-acetic acid tert-butyl ester (80 mg, 98%). This material was used directly in the next step without characterization.
Intermediate 3.07
{5-[(3'-Isopropyl-biphenyl-4-sulfonyl)-methyl-amino]-6,7,8,9-tetrahydro-5H- benzocyclohepten-l-yloxy}-acetic acid tert-butyl ester
Figure imgf000079_0001
Using the conditions of General Procedure 3, [5-(3'-isopropyl-biphenyl-4- sulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy] -acetic acid tert- butyl ester (which may be prepared as described for Intermediate 2.12; 100 mg, 0.18 mmol) was reacted with methyl iodide (29 mg, 0.2 mmol) in the presence of K2CO3 (28 mg, 0.2 mmol) in DMF to give {5-[(3'-isopropyl-biphenyl-4-sulfonyl)-methyl- amino]-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy}-acetic acid tert-butyl ester (70 mg, 68%). 1H NMR (400 MHz, DMSO-d6) δ: 7.98-8.05 (m, 2 H), 7.89 (d, =7.8 Hz, 1 H), 7.71-7.77 (m, 1 H), 7.50-7.59 (m, 2 H), 7.41-7.47 (m, 1 H), 7.33 (d, 7=7.8 Hz, 1 H), 7.10 (t, 7=7.8 Hz, 1 H), 6.83 (d, 7=7.8 Hz, 1 H), 6.74 (d, 7=8.3 Hz, 1 H), 5.21 (br. s., 1 H), 4.63 (s, 2 H), 3.44-3.52 (m, 1 H), 2.96-3.04 (m, 1 H), 2.87 (s, 3 H), 1.70-1.80 (m, 1 H), 1.42 (s, 9 H), 1.15-1.28 (m, 8 H).
Intermediate 3.08
{5-[(3'-tert-Butyl-5'-methyl-biphenyl-4-sulfonyl)-methyl-amino]-6,7,8,9-tetrahydro- 5H-benzoc clohepten-l-yloxy}-acetic acid tert-butyl ester
Figure imgf000079_0002
Using the conditions of General Procedure 3, [5-(3'-tert-butyl-5'-methyl-biphenyl-4- sulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy] -acetic acid tert- butyl ester (which may be prepared as described for Intermediate 2.13; 100 mg, 0.19 mmol) was reacted with methyl iodide (27 mg, 0.19 mmol) in the presence of 2CO3 (26 mg, 0.19 mmol) in DMF (2 mL) to give {5-[(3'-tert-butyl-5'-methyl-biphenyl-4- sulfonyl)-methyl-amino]-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy} -acetic acid tert-butyl ester (45 mg, 44%).
Intermediate 3.09
{5-[(4'-Hydroxy-biphenyl-4-sulfonyl)-methyl-amino]-6,7,8,9-tetrahydro
benzocyclohepten-l-yloxy}-acetic acid tert-butyl ester
Figure imgf000080_0001
Using the conditions of General Procedure 4, {5-[(4-Iodo-benzenesulfonyl)-mefhyl- amino]-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy}-acetic acid tert-butyl ester (which may be prepared as described for Intermediate 3.20; 200 mg, 0.35 mmol) was reacted with 4-hydroxyphenylboronic acid (available from Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA; 58 mg, 0.42 mmol) in the presence of Pd(PPh3)4 (available from Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA; 40 mg, 0.035 mmol), and 1 M aqueous K2CO3 (0.6 mL, 0.6 mmol) to give {5-[(4'-hydroxy- biphenyl-4-sulfonyl)-methyl-amino]-6,7,8,9-tetrahydro-5H-benzocyclohepten-l- yloxy} -acetic acid tert-butyl ester (100 mg, 52%).
Intermediate 3.10
(5-{Methyl-[4-(5-methyl-pyridin-3-yl)-benzenesulfonyl]-amino}-6,7,8,9-tetrahydro- 5H-benzocyclohepten-l-yloxy)-acetic acid tert-butyl ester
Figure imgf000081_0001
Using the conditions of General Procedure 4, {5-[(4-iodo-benzenesulfonyl)-methyl- amino]-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy}-acetic acid tert-butyl ester (which may be prepared as described for Intermediate 3.20; 100 mg, 0.17 mmol) was reacted with 5-methylpyridine-3-boronic acid (available from Combi-Blocks Inc., 7949 Silverton Avenue, Suite 915, San Diego, CA 92126, USA; 29 mg, 0.21 mmol) in the presence of Pd(PPli3)4 (available from Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA; 10 mg, 0.01 mmol), and 1 M aqueous K2CO3 (1.5 mL, 1.5 mmol) in dioxane (5 mL) to give (5-{methyl-[4-(5- methyl-pyridin-3-yl)-benzenesulfonyl]-amino}-6,7,8,9-tetrahydro-5H- benzocyclohepten-l-yloxy)-acetic acid tert-butyl ester (50 mg, 53%). iH NMR (400 MHz, DMSO-de) δ: 8.79 (s, 1 H), 8.50 (s, 1 H), 7.96-8.07 (m, 5 H), 7.11 (t, /=8.1 Hz, 1 H), 6.84 (d, 7=8.3 Hz, 1 H), 6.75 (d, .7=7.8 Hz, 1 H), 5.14-5.19 (m, 1 H), 4.64 (s, 2 H), 3.44-3.52 (m, 1 H), 2.87 (s, 3 H), 2.64-2.70 (m, 1 H), 2.33-2.42 (m, 5 H), 1.42 (s, 9 H), 1.22-1.39 (m, 3 H).
Intermediate 3.11
{5-[Methyl-(3'-methylsulfanyl-biphenyl-4-sulfonyl)-amino]-6,7,8,9-tetrahydro-5H- benzocyclohepten-l-yloxy}-acetic acid tert-butyl ester
Figure imgf000082_0001
Using the conditions of General Procedure 3, [5-(3'-methylsulfanyl-biphenyl-4- sulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy] -acetic acid tert- butyl ester (which may be prepared as described for Intermediate 2.16; 100 mg, 0.18 mmol) was reacted with methyl iodide (29 mg, 0.20 mmol) in the presence of 2CO3 (28 mg, 0.20 mmol) in DMF (2 mL) to give {5-[methyl-(3'-methylsulfanyl-biphenyl- 4-sulfonyl)-amino]-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy}-acetic acid tert- butyl ester (45 mg, 42%).
Intermediate 3.12
{5-[(3'-Methanesulfonyl-biphenyl-4-sulfonyl)-methyl-amino]-6,7,8,9-tetrahydro-5H- benzoc clohepten-l-yloxy}-acetic acid tert-butyl ester
Figure imgf000082_0002
Using the conditions of General Procedure 3, [5-(3'-methanesulfonyl-biphenyl-4- sulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy] -acetic acid tert- butyl ester (which may be prepared as described for Intermediate 2.17; 100 mg, 0.17 mmol) was reacted with methyl iodide (46 mg, 0.33 mmol) in the presence of K2CO3 (45 mg, 0.33 mmol) in DMF (2 mL) to give {5-[(3'-methanesulfonyl-biphenyl-4- sulfonyl)-methyl-amino]-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy} -acetic acid tert-butyl ester (98 mg, 96%).
Intermediate 3.13
(5-{ [5-(3-Isopropyl-phenyl)-pyridine-2-sulfonyl]-methyl-amino}-6,7,8,9-tetrahydro- 5H-benzoc clohepten-l-yloxy)-acetic acid tert-butyl ester
Figure imgf000083_0001
Using the conditions described for the preparation of Intermediate 3.14, {5-[5-(3- isopropyl-phenyl)-pyridine-2-sulfonylamino]-6,7,8,9-tetrahydro-5H- benzocyclohepten-l-yloxy} -acetic acid tert-butyl ester (which may be prepared as described for Intermediate 2.18; 120 mg, 0.22 mmol) was reacted with methyl iodide (34 mg, 0.24 mmol) in the presence of K2CO3 (33 mg, 0.24 mmol) in DMF to give (5- { [5-(3-isopropyl-phenyl)-pyridine-2-sulfonyl]-methyl-amino}-6,7,8,9-tetrahydro-5H- benzocyclohepten-l-yloxy)-acetic acid tert-butyl ester (90 mg, 73%). !H NMR (400 MHz, DMSO-de) δ: 9.13 (d, 7=1.5 Hz, 1 H), 8.39 (dd, .7=8.2, 2.1 Hz, 1 H), 8.03 (d, 7=8.3 Hz, 1 H), 7.71 (s, 1 H), 7.65 (d, 7=7.6 Hz, 1 H), 7.48 (t, 7=7.7 Hz, 1 H), 7.36- 7.41 (m, 1 H), 7.12 (t, 7=8.1 Hz, 1 H), 6.87 (d, 7=7.8 Hz, 1 H), 6.74 (d, 7=8.3 Hz, 1 H), 5.27 (d, 7=10.3 Hz, 1 H), 4.64 (s, 2 H), 3.92 (quin, 7=7.3 Hz, 1 H), 2.99-3.05 (m, 1 H), 2.97 (s, 3 H), 2.24-2.34 (m, 1 H), 1.56-1.89 (m, 4 H), 1.42 (s, 9 H), 1.28 (d, 7=6.8 Hz, 6 H), 1.04-1.12 (m, 1 H).
Intermediate 3.14
(5-{Methyl-[5-(3-trifluoromethyl-phenyl)-pyridine-2-sulfonyl]-amino}-6,7,8,9- tetrahydro-5H-benzocyclohepten-l-yloxy)-acetic acid tert-Butyl Ester
Figure imgf000084_0001
A mixture of {5-[5-(3-trifluoromethyl-phenyl)-pyridine-2-sulfonylamino]-6,7,8,9- tetrahydro-5H-benzocyclohepten-l-yloxy}-acetic acid tert-butyl ester (which may be prepared as described for Intermediate 2.19; 120 mg, 0.21 mmol), methyl iodide (33 mg, 0.23 mmol), and K2CO3 (32 mg, 0.23 mmol) in DMF (2 mL) was stirred at room temperature overnight. The reaction mixture was then partitioned between EtOAc and H2O. The organic layer was concentrated and purified by column chromatography to give (5-{methyl-[5-(3-trifluoromethyl-phenyl)-pyridine-2-sulfonyl]-amino}-6,7,8,9- tetrahydro-5H-benzocyclohepten-l-yloxy)-acetic acid tert-butyl ester (75 mg, 61%). lU NMR (400 MHz, DMSO- ) δ: 9.22 (d, .7=1.5 Hz, 1 H), 8.50 (dd, 7=8.1 , 2.0 Hz, 1 H), 8.22 (s, 1 H), 8.18 (d, 7=7.6 Hz, 1 H), 8.07 (d, 7=8.1 Hz, 1 H), 7.85-7.90 (m, 1 H), 7.78-7.83 (m, 1 H), 7.12 (t, 7=7.9 Hz, 1 H), 6.87 (d, 7=7.8 Hz, 1 H), 6.74 (d, 7=8.3 Hz, 1 H), 5.28 (d, 7=10.3 Hz, 1 H), 4.64 (s, 2 H), 3.49 (dd, 7=13.8, 6.5 Hz, 1 H), 2.97 (s, 3 H), 2.67 (br. s., 1 H), 2.25-2.34 (m, 2 H), 1.57-1.91 (m, 4 H), 1.42 (s, 9 H), 1.21- 1.37 (m, 2 H), 1.04- 1.11 (m, 1 H).
Intermediate 3.15
(5-{ [5-(3-tert-Butyl-5-methyl-phenyl)-pyridine-2-sulfonyl]-methyl-amino}-6,7,8,9- tetrahydro-5H-benzocyclohepten-l-yloxy)-acetic acid tert-butyl ester
Figure imgf000085_0001
Using the conditions described for the preparation of Intermediate 3.14, {5-[5-(3-tert- butyl-5-methyl-phenyl)-pyridine-2-sulfonylamino]-6,7,8,9-tetrahydro-5H- benzocyclohepten-l-yloxy} -acetic acid tert-butyl ester (which may be prepared as described for Intermediate 2.20; 200 mg, 0.35 mmol) was reacted with methyl iodide (54 mg, 0.38 mmol) in the presence of K2C03 (52.5 mg, 0.38 mmol) in DMF (3 mL) to give (5-{ [5-(3-tert-butyl-5-methyl-phenyl)-pyridine-2-sulfonyl]-methyl-amino}- 6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy)-acetic acid tert-butyl ester (150 mg, 73%). 1H NMR (400 MHz, DMSO-d6) δ: 9.11 (s, 1 H), 8.33-8.42 (m, 1 H), 8.02 (d, 7=8.3 Hz, 1 H), 7.59 (s, 1 H), 7.46 (s, 1 H), 7.35 (s, 1 H), 7.12 (t, .7=7.9 Hz, 1 H), 6.87 (d, 7=7.8 Hz, 1 H), 6.74 (d, 7=8.1 Hz, 1 H), 5.27 (d, 7=10.3 Hz, 1 H), 4.64 (s, 2 H), 3.49 (dd, 7=13.8, 6.7 Hz, 1 H), 2.96 (s, 3 H), 2.41 (s, 3 H), 2.21-2.35 (m, 1 H), 1.55- 1.91 (m, 4 H), 1.42 (s, 9 H), 1.35 (s, 9 H), 1.03-1.12 (m, 2 H).
Intermediate 3.16
[5-({5-[3-(2-Hydroxy-ethyl)-phenyl]-pyridine-2-sulfonyl}-methyl-amino)-6,7,8,9- tetrahydro-5H-benzocyclohepten-l-yloxy] -acetic acid tert-butyl ester
Figure imgf000085_0002
Using the conditions described for the preparation of Intermediate 3.14, {5-[5-(3-tert- butyl-5-methyl-phenyl)-pyridine-2-sulfonylamino]-6,7,8,9-tetrahydro-5H- benzocyclohepten-l-yloxy} -acetic acid tert-butyl ester (which may be prepared as described for Intermediate 2.21; 200 mg, 0.36 mmol) was reacted with methyl iodide (57 mg, 0.4 mmol) in the presence of K2C03 (55 mg, 0.4 mmol) in DMF (3 mL) to give [5-({5-[3-(2-hydroxy-ethyl)-phenyl]-pyridine-2-sulfonyl}-methyl-amino)- 6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy]-acetic acid tert-butyl ester (100 mg, 49%). 1H NMR (400 MHz, DMSO-de) δ: 9.12 (d, 7=1.7 Hz, 1 H), 8.37 (dd, 7=8.2, 2.1 Hz, 1 H), 8.04 (d, 7=8.1 Hz, 1 H), 7.62-7.74 (m, 2 H), 7.46 (t, 7=7.7 Hz, 1 H), 7.36 (d, 7=7.6 Hz, 1 H), 7.12 (t, 7=8.1 Hz, 1 H), 6.87 (d, 7=7.8 Hz, 1 H), 6.74 (d, 7=8.3 Hz, 1
H), 5.26 (d, 7=10.0 Hz, 1 H), 4.69 (t, 7=5.1 Hz, 1 H), 4.64 (s, 2 H), 3.63-3.73 (m, 2 H), 3.49 (dd, 7=13.9, 6.8 Hz, 1 H), 2.96 (s, 3 H), 2.83 (t, 7=6.8 Hz, 2 H), 2.22-2.36 (m, 1 H), 1.55-1.92 (m, 4 H), 1.42 (s, 9 H), 1.21-1.28 (m, 2 H), 1.00-1.13 (m, 1 H).
Intermediate 3.17
{5-[Methyl-(4'-methyl-biphenyl-3-sulfonyl)-amino]-6,7,8,9-tetrahydro- benzoc clohepten-l-yloxy}-acetic acid tert-butyl ester
Figure imgf000086_0001
Using the conditions of General Procedure 3, {5-[methyl-(4'-methyl-biphenyl-3- sulfonyl)-amino]-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy}-acetic acid tert- butyl ester (which may be prepared as described for Intermediate 2.22; 150 mg, 0.29 mmol) was reacted with methyl iodide (82 mg, 0.58 mmol) in the presence of K2CO3 (80 mg, 0.58 mmol) in DMF (2 mL) to give {5-[methyl-(4'-methyl-biphenyl-3- sulfonyl)-amino]-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy}-acetic acid tert- butyl ester (100 mg, 65%).
Intermediate 3.18 {5-[(3'-Isopropyl-biphenyl-3-sulfonyl)-methyl-amino]-6,7,8,9-tetrahydro benzoc clohepten- l-yloxy}-acetic acid tert-butyl ester
Figure imgf000087_0001
Using the conditions of General Procedure 3, { 5-[(3'-isopropyl-biphenyl-3-sulfonyl)- methyl-amino]-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy}-acetic acid tert- butyl ester (which may be prepared as described for Intermediate 2.23; 100 mg, 0.18 mmol) was reacted with methyl iodide (29 mg, 0.2 mmol) in the presence of K2CO3 (28 mg, 0.2 mmol) in DMF (2 mL) to give {5-[(3'-isopropyl-biphenyl-3-sulfonyl)- methyl-amino]-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy}-acetic acid tert- butyl ester (70 mg, 72%). lU NMR (400 MHz, DMSO- ) δ: 7.97-8.07 (m, 2 H), 7.89 (d, 7=7.8 Hz, 1 H), 7.69-7.80 (m, 1 H), 7.49-7.60 (m, 2 H), 7.40-7.48 (m, 1 H), 7.33 (d, /=7.8 Hz, 1 H), 7.10 (t, /=7.8 Hz, 1 H), 6.83 (d, .7=7.8 Hz, 1 H), 6.74 (d, /=8.3 Hz, 1 H), 5.21 (br. s., 1 H), 4.63 (s, 2 H), 3.44-3.50 (m, 1 H), 2.95-3.09 (m, 1 H), 2.87 (s, 3 H), 2.67 (br. s., 1 H), 1.47- 1.85 (m, 1 H), 1.42 (s, 9 H), 1.27 (d, /=6.8 Hz, 6 H), 1.01- 1.10 (m, 1 H).
Intermediate 3.19
{ 5-[(3-Isopropyl-5-trifluoromethyl-benzenesulfonyl)-methyl-amino]-6,7,8,9- tetrahydro-5H-benzocyclohepten-l-yloxy}-acetic acid tert-butyl ester
Figure imgf000087_0002
A mixture of [5-(3-isopropyl-5-trifluoromethyl-benzenesulfonylamino)-6,7,8,9- tetrahydro-5H-benzocyclohepten-l-yloxy] -acetic acid tert-butyl ester (which may be prepared as described for Intermediate 2.24; 100 mg, 0.18 mmol), K2CO3 (53 mg, 0.38 mmol), and methyl iodide (81 mg, 0.57 mmol) in CH2CI2 (5 mL) was stirred at room temperature for 16 h. The reaction mixture was concentrated and diluted with EtOAc (10 mL). The mixture was washed with water (3 x 10 mL). The organic layer was concentrated under reduced pressure to give crude {5-[(3-isopropyl-5- trifluoromethyl-benzenesulfonyl)-methyl-amino]-6,7,8,9-tetrahydro-5H- benzocyclohepten-l-yloxy} -acetic acid tert-butyl ester (120 mg, 117% crude yield) as a yellow solid, which was used directly in the next step without further purification.
Intermediate 3.20
{5-[(4-Iodo-benzenesulfonyl)-methyl-amino]-6,7,8,9-tetrahydro-5H- benzocyclohepten-l-yloxy}-acetic acid tert-butyl ester
Figure imgf000088_0001
A mixture of [5-(4-iodo-benzenesulfonylammo)-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy] -acetic acid tert-butyl ester (which may be prepared as described for Intermediate 1.08; 250 mg, 0.45 mmol), methyl iodide (0.06 mL, 0.96 mmol), and K2CO3 (138 mg, 1 mmol) in DMF (2 mL) was stirred overnight at room temperature. The reaction mixture was partitioned between EtOAc and ¾0. The organic layers were combined, washed with water and brine, dried over MgSC>4, filtered, and concentrated to give {5-[(4-iodo-benzenesulfonyl)-methyl-amino]- 6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy}-acetic acid tert-butyl ester (210 mg,
82%). 1H NMR (400 MHz, DMSO-d6) δ: 8.03 (d, 7=8.3 Hz, 2 H), 7.65 (d, 7=8.3 Hz, 2 H), 7.06-7.16 (m, 1 H), 6.81 (d, /=7.8 Hz, 1 H), 6.74 (d, 7=8.1 Hz, 1 H), 5.08 (d, /=9.0 Hz, 1 H), 4.64 (s, 2 H), 3.46 (dd, 7=14.2, 6.8 Hz, 1 H), 2.82 (s, 3 H), 2.33 (t, 7=12.8 Hz, 1 H), 1.73-1.85 (m, 2 H), 1.49-1.60 (m, 1 H), 1.42 (s, 9 H), 1.22-1.35 (m, 2 H), 1.04 (q, 7=11.5 Hz, 1 H). PART III: PREPARATION OF COMPOUNDS OF INTEREST
Example 1
[5-(3,5-Bis-trifluoromethyl-benzenesulfonylamino)-6,7,8,9-tetrahydro-5H- ten- 1 -yloxy] -acetic acid
Figure imgf000089_0001
A solution of lithium hydroxide monohydrate (19 mg, 0.45 mmol) in water (2 mL) was added to a solution of [5-(3,5-bis-trifiuoromethyl-benzenesulfonylamino)-6,7,8,9- tetrahydro-5H-benzocyclohepten-l -yloxy] -acetic acid tert-butyl ester (which may be prepared as described for Intermediate 2.01; 85 mg, 0.15 mmol) in THF (8 mL) at room temperature. The reaction mixture was stirred for 48 h at room temperature. TLC showed that the reaction was not complete so a second portion of lithium hydroxide monohydrate (19 mg, 0.45 mmol) in water (1 mL) was added and the reaction mixture was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure. ¾0 (2 mL) was added and the mixture was extracted with ethyl acetate (3 mL). The aqueous layer was acidified using dilute aq. HC1. The resulting mixture was extracted with EtOAc (3 x 10 mL). The organic extracts were combined, dried over anhydrous Na2S04, filtered, and evaporated to give [5-(3,5-bis-trifluoromethyl-benzenesulfonylamino)-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy] -acetic acid (45 mg, 59%) as a white solid. 1H NMR (400 MHz, DMSO- ) δ: 12.95 (br. s., 1 H), 8.52 (d, /=7.8 Hz, 1 H), 8.32 (s, 1 H), 8.19 (s, 2 H), 6.87 (t, J=7.8 Hz, 1 H), 6.66 (d, 7=7.6 Hz, 1 H), 6.57 (d, J=8.3 Hz, 1 H), 4.56- 4.65 (m, 1 H), 4.40-4.54 (m, 2 H), 2.81 (br. s., 2 H), 1.71-1.93 (m, 2 H), 1.59 (br. s., 2 H), 1.11-1.51 (m, 2 H).
Example 2
[5-(3,5-Dichloro-benzenesulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l- yloxy] -acetic acid
Figure imgf000090_0001
Using the conditions described for the preparation of Example 4, a solution of [5-(3,5- dichloro-benzenesulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy]- acetic acid tert-butyl ester (which may be prepared as described for Intermediate 2.02; 180 mg, 0.36 mmol) in THF (4 mL) was reacted with a solution of lithium hydroxide monohydrate (75 mg, 1.8 mmol) in water (2 mL) and MeOH (1 mL) to give [5-(3,5- dichloro-benzenesulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy]- acetic acid (130 mg, 81%) as a white solid. XH NMR (300 MHz, DMSO-i¾) δ 12.95 (br s, 1 H), 8.37 (d, J = 7.8 Hz, 1 H), 7.85 (t, J = 1.8 Hz, 1 H), 6.97 (t, J = 7.8 Hz, 1 H), 6.73 (d, J = 7.6 Hz, 1 H), 6.67 (d, J = 7.5 Hz, 1 H), 4.55 (s, 2 H), 4.49-4.54 (m, 1 H), 2.93-3.01 (m, 1 H), 2.64-2.74 (m, 1 H), 1.33-1.86 (m, 6 H). HRMS [M-H ] observed: 442.0287, calculated for
Figure imgf000090_0002
442.0288.
Example 3
[5-(Biphenyl-3-sulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy]- acetic acid
Figure imgf000090_0003
Using the conditions described for the preparation of Example 4, a solution of [5- (biphenyl-3-sulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy]-acetic acid tert-butyl ester (which may be prepared as described for Intermediate 2.03; 160 mg, 0.32 mmol) in THF (4 mL) was reacted with a solution of lithium hydroxide monohydrate (66 mg, 1.6 mmol) in water (2 mL) and MeOH (1 mL) to give [5- (biphenyl-3-sulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy]-acetic acid (120 mg, 84%) as an off-white solid. lU NMR (300 MHz, DMSO-d6) δ 12.93 (br s, 1 H), 8.20 (d, J = 8.1 Hz, 1 H), 7.98-7.99 (m, 1 H), 7.86-7.89 (m, 1 H), 7.75-7.79 (m, 1 H), 7.59-7.64 (m, 3 H), 7.47-7.52 (m, 2 H), 7.39-7.44 (m, 1 H), 6.95 (t, J = 8.0 Hz, 1 H), 6.81 (d, J = 7.8 Hz, 1 H), 6.65 (d, J = 8.1 Hz, 1 H), 4.55 (s, 2 H), 4.44-4.51 (m, 1 H), 3.11-3.20 (m, 1 H), 2.55-2.60 (m, 1 H), 1.65-1.76 (m, 1 H), 1.44-1.59 (m, 4 H), 1.16-1.28 (m, 1 H)
Example 4
[5-(Biphenyl-4-sulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy]- acetic acid
Figure imgf000091_0001
A solution of lithium hydroxide monohydrate (70 mg, 1.67 mmol) in water (2 mL) and MeOH (1 mL) was added to a solution of [5-(biphenyl-4-sulfonylamino)-6,7,8,9- tetrahydro-5H-benzocyclohepten-l-yloxy] -acetic acid tert-butyl ester (which may be prepared as described for Intermediate 2.04; 170 mg, 0.33 mmol) in THF (4 mL) at room temperature. The reaction mixture was stirred for 6 h at room temperature. The reaction mixture was concentrated under reduced pressure. H20 (5 mL) was added and the mixture was acidified to pH ~3 using 50% aq. HCl. The mixture was extracted with EtOAc (3 x 10 mL). The organic extracts were combined, washed with water (5 mL) and brine (5 mL), dried over anhydrous Na2S04, filtered, and evaporated. The product was recrystallized from hexane to give [5-(biphenyl-4-sulfonylamino)- 6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy]-acetic acid (100 mg, 66%) as an off-white solid. 1H NMR (300 MHz, DMSO-ifc) δ 12.92 (br s, 1 H), 8.20 (d, J = 7.8 Hz, 1 H), 7.82-7.86 (m, 3 H), 7.70-7.74 (m, 2 H), 7.52-7.38 (m, 3 H), 6.95 (t, J = 7.9 Hz, 1 H), 6.84 (d, J = 7.5 Hz, 1 H), 6.68 (d, J = 7.5 Hz, 1 H), 4.57 (s, 2 H), 4.45 (br t, 1 H), 3.14-3.22 (m, 1 H), 1.44-1.74 (m, 6 H). HRMS [M+H+] observed: 452.1532, calculated for C25H26NO5S: 452.1526. Example 5
[5-(3-Methanesulfonyl-benzenesulfonylamino)-6,7,8,9-tetrahydro- benzoc clohepten- 1 -yloxy] -acetic acid
Figure imgf000092_0001
Using the conditions described for the preparation of Example 4, [5-(3- methanesulfonyl-benzenesulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l- yloxy]-acetic acid tert-butyl ester (which may be prepared as described for
Intermediate 2.05; 185 mg, 0.36 mmol) in THF (4 mL) was reacted with a solution of lithium hydroxide monohydrate (61 mg, 1.5 mmol) in water (2 mL) and MeOH (1 mL) to give [5-(3-methanesulfonyl-benzenesulfonylamino)-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy] -acetic acid (85 mg, 52%) as an off-white solid. 1H NMR (300 MHz, DMSO-i¾) δ 12.95 (br s, 1 H), 8.42 (d, J = 7.8 Hz, 1 H), 8.24 (t, J = 1.8 Hz, 1 H), 8.08-8.11 (m, 1 H), 8.05-8.01 (m, 1 H), 7.77 (t, J = 7.8 Hz, 1 H), 6.92 (t, J = 7.9 Hz, 1 H), 6.71 (d, J = 7.8 Hz, 1 H), 6.63 (d, J = 7.8 Hz, 1 H), 4.55 (s, 2 H), 4.45-4.52 (m, 1 H), 3.22 (s, 3 H), 3.02-3.11 (m, 1 H), 2.54-2.64 (m, 1 H), 1.78-1.24 (m, 6 H). HRMS [M+H+] observed: 454.0994, calculated for C20H24NO7S2: 454.0989.
Example 6
[5-(3-Fluoro-5-trifluoromethyl-benzenesulfonylamino)-6,7,8,9-tetrahydro
benzocyclohepten- 1 -yloxy] -acetic acid
Figure imgf000092_0002
A mixture of [5-(3-fluoro-5-trifluoromethyl-benzenesulfonylamino)-6,7,8,9- tetrahydro-5H-benzocyclohepten- l-yloxy] -acetic acid tert-butyl ester (which may be prepared as described for Intermediate 2.06; 70 mg, 0.14 mmol) and 2 N NaOH solution (1.35 mL, 2.7 mmol) in THF (1 mL) was stirred at room temperature for 20 h. The reaction mixture was concentrated under reduced pressure and the residue was washed with ether (2 x 2 mL), diluted with EtOAc (10 mL) and acidified with 2 N HC1 solution. The layers were separated and the aqueous layer was extracted with EtOAc (2 x 5 mL). The organic layers were combined, dried over anhydrous Na2S04, filtered, and evaporated to give [5-(3-fluoro-5-trifluoromethyl- benzenesulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten- 1-yloxy] -acetic acid (40 mg, 64%). lU NMR (400 MHz, DMSO-de) δ: 8.48 (d, .7=7.6 Hz, 1 H), 7.96 (d, 7=8.1 Hz, 1 H), 7.73-7.88 (m, 2 H), 6.94 (t, 7=7.9 Hz, 1 H), 6.72 (d, J=7.3 Hz, 1 H), 6.66 (d, 7=8.3 Hz, 1 H), 4.53-4.60 (m, 3 H), 2.89-3.05 (m, 1 H), 2.61-2.81 (m, 1 H), 1.75-1.86 (m, 1 H), 1.05- 1.73 (m, 6 H). HRMS [M+Na] observed: 484.0812, calculated for
Figure imgf000093_0001
484.0812.
Example 7
{ 5-[(3-Fluoro-5-trifluoromethyl-benzenesulfonyl)-methyl-amino]-6,7,8,9-tetrahydro- 5H-benzocyclohepten- 1 -yloxy } -acetic acid
Figure imgf000093_0002
Using the conditions of General Procedure 7, { 5-[(3-fluoro-5-trifluoromethyl- benzenesulfonyl)-methyl-amino]-6,7,8,9-tetrahydro-5H-benzocyclohepten- 1-yloxy }- acetic acid tert-butyl ester (which may be prepared as described for Intermediate 3.01 ; 60 mg, 0.11 mmol) was hydrolyzed using 2 N NaOH solution (1.13 mL, 2.3 mmol) to give { 5-[(3-fluoro-5-trifluoromethyl-benzenesulfonyl)-methyl-amino]-6,7,8,9- tetrahydro-5H-benzocyclohepten- l-yloxy}-acetic acid (20 mg, 37%). 1H NMR (400 MHz, DMSO-de) δ: 8.15 (apparent t, .7=7.7 Hz, 2 H), 7.99 (s, 1 H), 7.04 (t, 7=8.1 Hz, 1 H), 6.70 (d, =8.1 Hz, 2 H), 5.19 (d, .7=9.3 Hz, 1 H), 4.36 (br. s., 2 H), 3.43-3.51 (m, 1 H), 2.88 (s, 3 H), 2.67 (br. s., 1 H), 2.29-2.45 (m, 2 H), 1.72-1.86 (m, 2 H), 1.56- 1.63 (m, 1 H), 1.19-1.46 (m, 3 H), 0.99-1.10 (m, 1 H). HRMS [M+Na] observed: 498.0968, calculated for CiiHz^NNaOsS: 498.0969.
Example 8
[5-(3-Bromo-5-trifluoromethyl-benzenesulfonylamino)-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy] -acetic acid
Figure imgf000094_0001
Using the conditions described for the preparation of Example 23, [5-(3-bromo-5- trifluoromethyl-benzenesulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l- yloxy]-acetic acid tert-butyl ester (which may be prepared as described for
Intermediate 2.07; 100 mg, 0.17 mmol) was hydrolyzed using 2 N NaOH solution (1.73 mL, 3.5 mmol) to give [5-(3-bromo-5-trifluoromethyl-benzenesulfonylamino)- 6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy]-acetic acid (60 mg, 66% yield). !H NMR (300 MHz, DMSO-i¾) δ 12.93 (br s, 1 H), 8.42 (d, J = 7.8 Hz, 1 H), 8.18 (s, 1 H), 8.02 (s, 1 H), 7.94 (d, J = 0.6 Hz, 1 H), 6.92 (t, J = 8.0 Hz, 1 H), 6.68 (d, J = 7.6 Hz, 1 H), 6.63 (d, J = 7.5 Hz, 1 H), 4.53-4.60 (m, 1 H), 4.51 (d, J = 7.5 Hz, 2 H), 2.70- 2.93 (m, 2 H), 1.33-1.88 (m, 6 H).
Example 9
{5-[(3-Bromo-5-trifluoromethyl-benzenesulfonyl)-methyl-amino]-6,7,8,9-tetrahydro- 5H-benzocyclohepten- 1 -yloxy } -acetic acid
Figure imgf000095_0001
Using the conditions described for the preparation of Example 23, {5-[(3-bromo-5- trifluoromethyl-benzenesulfonyl)-methyl-amino]-6,7,8,9-tetrahydro-5H- benzocyclohepten-l-yloxy} -acetic acid tert-butyl ester (which may be prepared as described for Intermediate 3.02; 150 mg, 0.25 mmol) was hydrolyzed using 2 N NaOH solution (1.73 mL, 3.5 mmol) to give {5-[(3-bromo-5-trifluoromethyl- benzenesulfonyl)-methyl-amino]-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy}- acetic acid (60 mg, 44% yield). !H NMR (400 MHz, DMSO-de) δ: 12.95 (br. s., 1 H), 8.39 (s, 1 H), 8.14 (s, 1 H), 7.08 (t, J = 8.2 Hz, 1 H), 6.72-6.77 (m, 1 H), 5.24 (d, /=8.8 Hz, 1 H), 4.63-4.67 (m, 2 H), 3.46 (dd, 7=13.9, 6.8 Hz, 1 H), 2.87 (s, 3 H), 2.37-2.46 (m, 1 H), 1.54-1.95 (m, 3 H), 1.19-1.48 (m, 4 H), 1.00-1.08 (m, 1 H). HRMS [M-H ] observed: 520.0043, calculated for CioHigBrFsNOsS: 520.0047.
Example 10
[5-(3,5-Bis-methanesulfonyl-benzenesulfonylamino)-6,7,8,9-tetrahydro-5H- benzoc clohepten- 1 -yloxy] -acetic acid
Figure imgf000095_0002
Using the conditions of General Procedure 7, [5-(3,5-bis-methanesulfonyl- benzenesulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy]-acetic acid tert-butyl ester (which may be prepared as described for Intermediate 2.08; 100 mg, 0.17 mmol) was hydrolyzed using 2 N NaOH solution (1.7 mL, 3.4 mmol) to give [5- (3,5-bis-methanesulfonyl-benzenesulfonylamino)-6,7,8,9-tetrahydro-5H- benzocyclohepten-l-yloxy] -acetic acid (55 mg, 61% yield). XH NMR (400 MHz, DMSO- ) δ: 8.59 (d, 7=7.8 Hz, 1 H), 8.51 (s, 1 H), 8.45 (s, 2 H), 6.85-6.92 (m, 1 H), 6.66 (d, 7=7.3 Hz, 1 H), 6.58 (d, 7=8.3 Hz, 1 H), 4.60 (t, 7=7.3 Hz, 1 H), 4.52 (s, 2 H), 1.52-1.93 (m, 4 H), 1.35-1.45 (m, 1 H). HRMS [M+Na] observed: 554.0583, calculated for C22H27NNa09S3 : 554.0583.
Example 11
{5-[(3,5-Bis-methanesulfonyl-benzenesulfonyl)-methyl-amino]-6,7,8,9-tetrahydro- 5H-benzocyclohepten-l-yloxy}-acetic acid
Figure imgf000096_0001
Using the conditions of General Procedure 7, {5-[(3,5-bis-methanesulfonyl- benzenesulfonyl)-methyl-amino]-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy}- acetic acid tert-butyl ester (which may be prepared as described for Intermediate 3.03; 100 mg, 0.17 mmol) was hydrolyzed using 2 N NaOH solution (1.65 mL, 3.3 mmol) to give {5-[(3,5-bis-methanesulfonyl-benzenesulfonyl)-methyl-amino]-6,7,8,9- tetrahydro-5H-benzocyclohepten-l-yloxy}-acetic acid (45 mg, 50% yield). XH NMR (400 MHz, DMSC e) δ: 8.66 (s, 1 H), 8.63 (s, 2 H), 7.08 (t, 7=7.8 Hz, 1 H), 6.73- 6.78 (m, 2 H), 5.30 (d, 7=8.8 Hz, 1 H), 4.66 (s, 2 H), 3.46 (s, 6 H), 2.91 (s, 3 H), 2.31- 2.44 (m, 1 H), 1.63-1.91 (m, 2 H), 1.32-1.54 (m, 3 H), 0.93-1.11 (m, 1 H). HRMS [M+Na] observed: 568.0740, calculated for C2iH25NNa09S3: 568.0740.
Example 12
{5-[(Biphenyl-4-sulfonyl)-methyl-amino]-6,7,8,9-tetrahydro-5H-benzocyclohepten-l- yloxy}-acetic acid
Figure imgf000097_0001
Using the conditions of General Procedure 7, {5-[(biphenyl-4-sulfonyl)-methyl- amino]-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy}-acetic acid tert-butyl ester (which may be prepared as described for Intermediate 3.04; 90 mg, 0.17 mmol) was hydrolyzed using 2 N NaOH solution (1.7 mL, 3.4 mmol) to give {5-[(biphenyl-4- sulfonyl)-methyl-amino]-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy} -acetic acid (50 mg, 62% yield). 1H NMR (DMSO-d6) δ: 8.02 (s, 4 H), 7.84 (d, I = 7.3 Hz, 2 H), 7.56-7.63 (m, 2 H), 7.49-7.56 (m, 1 H), 7.12-7.23 (m, 1 H), 6.91 (d, I = 7.8 Hz, 1 H), 6.84 (d, I = 8.3 Hz, 1 H), 5.17-5.25 (m, 1 H), 4.72 (s, 2 H), 3.55 (dd, J = 13.9, 6.9 Hz, 1 H), 2.92 (s, 3 H), 2.41 (t, J = 12.7 Hz, 1 H), 1.76-1.95 (m, 2 H), 1.63 (d, J = 11.3 Hz, 1 H), 1.35-1.49 (m, 2 H), 1.11 (q, J = 11.8 Hz, 1 H). HRMS [M+Na] observed: 488.1499, calculated for C26H27NNa05S: 488.1502.
Example 13
[5-(3-Methoxy-5-trifluoromethyl-benzenesulfonylamino)-6,7,8,9-tetrahydro
- 1 -yloxy] -acetic acid
Figure imgf000097_0002
A mixture of [5-(3-fluoro-5-trifluoromethyl-benzenesulfonylamino)-6,7,8,9- tetrahydro-5H-benzocyclohepten-l -yloxy] -acetic acid tert-butyl ester (which may be prepared as described for Intermediate 2.06; 100 mg, 0.19 mmol) and NaOMe (52 mg, 0.96 mmol) in MeOH/DMF (1:1; 4 mL) was heated at 150 °C in a microwave reactor for 45 min. MeOH was removed by evaporation under reduced pressure and water was added. The mixture was stirred for 15 min and extracted with ether. The aqueous layer was acidified with 1 N HCl and extracted with ethyl acetate. The EtOAc extracts were combined, washed with water and brine, dried over anhydrous Na2S04, filtered, and evaporated to give [5-(3-methoxy-5-trifluoromethyl-benzenesulfonylamino)-
6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy]-acetic acid (60 mg, 66%).1H NMR (DMSO-d6) δ: 8.37 (d, J = 7.0 Hz, 1 H), 7.57 (s, 1 H), 7.46 (d, J = 11.3 Hz, 2 H), 6.89- 7.00 (m, 1 H), 6.61-6.78 (m, 2 H), 4.45-4.61 (m, 3 H), 3.85 (s, 2 H), 3.05 (br. s., 1 H), 2.67 (br. s., 1 H), 1.12-1.90 (m, 6 H). HRMS [M+Na] observed: 496.1012, calculated for C2iH22F3NNa06S: 496.1012.
Example 14
{5-[(3-Methoxy-5-trifluoromethyl-benzenesulfonyl)-methyl-amino]-6,7,8,9- -5H-benzocyclohepten-l-yloxy}-acetic acid
Figure imgf000098_0001
A mixture of {5-[(3-fluoro-5-trifluoromethyl-benzenesulfonyl)-methyl-amino]- 6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy}-acetic acid tert-butyl ester (which may be prepared as described for Intermediate 3.01 ; 60 mg, 0.11 mmol) and NaOMe (30.5 mg, 0.56 mmol) in MeOH/DMF (1:1; 2 mL) was heated at 150 °C in a microwave reactor for 45 min. MeOH was removed by evaporation under reduced pressure and water was added. The mixture was stirred for 15 min and extracted with ether. The aqueous layer was acidified with 1 N HCl and extracted with ethyl acetate. The EtOAc extracts were combined, washed with water and brine, dried over anhydrous Na2S04, filtered, and evaporated to give {5-[(3-methoxy-5-trifluoromethyl- benzenesulfonyl)-methyl-amino]-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy}- acetic acid (20 mg, 36%). XH NMR (DMSO-d6) δ: 7.68 (s, 1 H), 7.62 (s, 2 H), 7.06- 7.13 (m, 1 H), 6.77 (d, J = 8.3 Hz, 2 H), 5.20 (d, J = 9.0 Hz, 1 H), 4.65 (s, 2 H), 3.94 (s, 3 H), 3.47 (dd, J = 14.2, 6.7 Hz, 1 H), 2.86 (s, 3 H), 2.32-2.45 (m, 1 H), 0.94-1.90 (m, 6 H). HRMS [M+Na] observed 510.1170, calculated for C22H24F3NNa06S: 510.1168.
Example 15
[5-(3-Acetyl-5-trifluoromethyl-benzenesulfonylamino)-6,7,8,9-tetrahydro
- 1 -yloxy] -acetic acid
Figure imgf000099_0001
Using the conditions of General Procedure 7, [5-(3-acetyl-5-trifluoromethyl- benzenesulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy]-acetic acid tert-butyl ester (which may be prepared as described for Intermediate 2.10; 70 mg,
0.13 mmol) was hydrolyzed using 2 N NaOH solution (1.3 mL, 2.6 mmol) to give [5- (3-acetyl-5-trifluoromethyl-benzenesulfonylamino)-6,7,8,9-tetrahydro-5H- benzocyclohepten-1 -yloxy] -acetic acid (35 mg, 56% yield). XH NMR (DMSO-<¾ δ: 8.48 (d, J = 6.8 Hz, 1 H), 8.36 (s, 1 H), 8.32 (s, 1 H), 8.16 (s, 1 H), 6.83-6.93 (m, 1 H), 6.68 (d, J = 7.5 Hz, 1 H), 6.58 (d, J = 8.3 Hz, 1 H), 4.54 (d, J = 10.0 Hz, 1 H), 4.42- 4.50 (m, 2 H), 2.88 (br. s., 1 H), 2.73 (d, J = 13.1 Hz, 1 H), 2.61-2.68 (m, 3 H), 1.66- 1.90 (m, 2 H), 1.58 (d, J = 10.3 Hz, 2 H), 1.40 (br. s., 2 H). HRMS [M+Na] observed: 508.1015, calculated for C22H22F3NNa06S: 508.1012.
Example 16
{5-[(3-Acetyl-5-trifluoromethyl-benzenesulfonyl)-methyl-amino]-6,7,8,9-tetrahydro- 5H-benzocyclohepten- 1 -yloxy } -acetic acid
Figure imgf000100_0001
Using the conditions of General Procedure 7, {5-[(3-acetyl-5-trifluoromethyl- benzenesulfonyl)-methyl-amino]-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy}- acetic acid tert-butyl ester (which may be prepared as described for Intermediate 3.05; 150 mg, 0.27 mmol) was hydrolyzed using 2 N NaOH solution (2.9 mL, 5.8 mmol) to give {5-[(3-acetyl-5-trifluoromethyl-benzenesulfonyl)-methyl-amino]-6,7,8,9- tetrahydro-5H-benzocyclohepten-l-yloxy}-acetic acid (70 mg, 52% yield). XH NMR (400 MHz, DMSC 6) δ: 8.50 (s, 2 H), 8.39 (s, 1 H), 7.07 (t, .7=8.0 Hz, 1 H), 6.75 (t, 7=8.5 Hz, 2 H), 5.23-5.33 (m, 1 H), 4.65 (s, 2 H), 3.47 (dd, 7=14.2, 6.9 Hz, 1 H), 2.37- 2.47 (m, 1 H), 1.54-1.88 (m, 3 H), 1.21-1.44 (m, 4 H), 0.98-1.10 (m, 1 H). HRMS [M+H+] observed: 500.1355, calculated for C23H25F3NO6S: 500.1349.
Example 17
[5-(3-Methanesulfonyl-5-trifluoromethyl-benzenesulfonylamino)-6,7,8,9-tetrahydro- H-benzocyclohepten- 1 -yloxy] -acetic acid
Figure imgf000100_0002
Using the conditions of General Procedure 7, [5-(3-methanesulfonyl-5- trifluoromethyl-benzenesulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l- yloxy]-acetic acid tert-butyl ester (which may be prepared as described for Intermediate 2.11; 20 mg, 0.035 mmol) was hydrolyzed using 2 N NaOH solution (0.2 mL, 0.4 mmol) to give [5-(3-methanesulfonyl-5-trifluoromethyl- benzenesulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy]-acetic acid (5 mg, 28% yield). 1H NMR (400 MHz, DMSO-d6) δ: 8.62 (d, =7.8 Hz, 1 H), 8.50 (s, 1 H), 8.46 (s, 1 H), 8.25 (s, 1 H), 6.89-6.97 (m, 1 H), 6.72 (d, /=7.8 Hz, 1 H), 6.63 (d, /=8.3 Hz, 1 H), 4.66 (t, /=6.9 Hz, 1 H), 4.53 (d, J=2.8 Hz, 2 H), 2.84-2.93 (m, 2 H), 2.61 (s, 3 H), 1.26-1.96 (m, 9 H). HRMS [M-H ] observed: 520.0713, calculated for C21H21NO7S2: 520.0717.
Example 18
{5-[(3-Methanesulfonyl-5-trifluoromethyl-benzenesulfonyl)-methyl-amino]-6,7,8,9- tetrah dro-5H-benzocyclohepten-l-yloxy}-acetic acid
Figure imgf000101_0001
Using conditions similar to those described for Example 43, {5-[(3-methanesulfonyl- 5-trifluoromethyl-benzenesulfonyl)-methyl-amino]-6,7,8,9-tetrahydro-5H- benzocyclohepten-l-yloxy} -acetic acid tert-butyl ester (which may be prepared as described for Intermediate 3.06; 80 mg, 0.13 mmol) was hydrolyzed using a solution of lithium hydroxide monohydrate (18 mg, 0.4 mmol) in H20/MeOH (2: 1; 3 mL) to give {5-[(3-methanesulfonyl-5-trifluoromethyl-benzenesulfonyl)-methyl-amino]- 6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy}-acetic acid (15 mg, 21% yield). 1H NMR (400 MHz, DMSO- ) δ: 8.58 (s, 1 H), 8.56 (s, 1 H), 8.51 (s, 1 H), 7.05 (t, 7=8.0 Hz, 1 H), 6.68-6.76 (m, 2 H), 5.28-5.31 (m, 1 H), 4.53 (s, 2 H), 3.46 (s, 3 H), 2.90 (s, 3 H), 2.37-2.47 (m, 1 H), 1.59-1.93 (m, 2 H), 0.95-1.53 (m, 4 H).
Example 19
[5-(3'-Isopropyl-biphenyl-4-sulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-
1-yloxy] -acetic acid
Figure imgf000102_0001
Using the conditions of General Procedure 7, [5-(3'-isopropyl-biphenyl-4- sulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy] -acetic acid tert- butyl ester (which may be prepared as described for Intermediate 2.12; 80 mg, 0.15 mmol) was hydrolyzed using 2 N NaOH solution (1.4 mL, 2.8 mmol) to give [5-(3'- isopropyl-biphenyl-4-sulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten- l- yloxy]-acetic acid (28 mg, 39% yield). lU NMR (DMSO-d6) δ: 8.22 (d, J = 7.8 Hz, 1 H), 7.80-7.94 (m, 4 H), 7.59 (s, 1 H), 7.53 (d, J = 7.8 Hz, 1 H), 7.42 (t, J = 7.5 Hz, 1 H), 7.32 (d, J = 7.5 Hz, 1 H), 6.95-7.05 (m, 1 H), 6.86 (d, J = 7.5 Hz, 1 H), 6.69 (d, J = 8.3 Hz, 1 H), 4.57 (s, 2 H), 4.46 (br. s., 1 H), 3.14-3.25 (m, 1 H), 2.99 (dt, J = 13.7, 7.0 Hz, 1 H), 1.72 (br. s., 1 H), 1.52 (br. s., 4 H), 1.18-1.30 (m, 8H). HRMS [M+Na] observed: 516.1815, calculated for Czs^NNaOsS: 516.1815.
Example 20
{5-[(3'-Isopropyl-biphenyl-4-sulfonyl)-methyl-amino]-6,7,8,9-tetrahydro- benzoc clohepten- 1 -yloxy } -acetic acid
Figure imgf000102_0002
Using the conditions of General Procedure 7, { 5-[(3'-isopropyl-biphenyl-4-sulfonyl) methyl-amino]-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy}-acetic acid tert- butyl ester (which may be prepared as described for Intermediate 3.07; 50 mg, 0.09 mmol) was hydrolyzed using 2 N NaOH solution (0.9 mL, 1.8 mmol) to give {5-[(3'- isopropyl-biphenyl-4-sulfonyl)-methyl-amino]-6,7,8,9-tetrahydro-5H- benzocyclohepten-l-yloxy} -acetic acid (28 mg, 62% yield). 1H NMR (400 MHz, DMSO- e) δ: 7.95 (s, 4 H), 7.62 (s, 1 H), 7.57 (d, 7=7.8 Hz, 1 H), 7.44 (t, J=l .1 Hz, 1 H), 7.34 (d, 7=7.8 Hz, 1 H), 7.04-7.19 (m, 1 H), 6.85 (d, .7=7.8 Hz, 1 H), 6.77 (d, /=8.3 Hz, 1 H), 5.08-5.20 (m, 1 H), 4.62 (s, 2 H), 3.48 (dd, .7=14.1, 7.0 Hz, 1 H), 3.00 (dt, 7=13.8, 6.9 Hz, 1 H), 2.86 (s, 3 H), 2.28-2.43 (m, 1 H), 1.69-1.90 (m, 2 H), 1.48- 1.66 (m, 1 H), 1.33-1.40 (m, 2 H), 1.27 (d, /=6.8 Hz, 6 H), 1.05 (q, .7=11.5 Hz, 1 H). HRMS [M+H] observed: 508.2156, calculated for C29H34NO5S: 508.2152.
Example 21
[5-(3'-tert-Butyl-5'-methyl-biphenyl-4-sulfonylamino)-6,7,8,9-tetrahydro-5H- benzoc clohepten- 1 -yloxy] -acetic acid
Figure imgf000103_0001
Using the conditions of General Procedure 7, [5-(3'-tert-butyl-5'-methyl-biphenyl-4- sulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy] -acetic acid tert- butyl ester (which may be prepared as described for Intermediate 2.13; 80 mg, 0.14 mmol) was hydrolyzed using 2 N NaOH solution (1.4 mL, 2.8 mmol) to give [5-(3'- tert-butyl-5'-methyl-biphenyl-4-sulfonylamino)-6,7,8,9-tetrahydro-5H- benzocyclohepten-1 -yloxy] -acetic acid (13 mg, 18% yield). XH NMR (400 MHz, DMSO- ) δ: 8.19 (d, .7=6.78 Hz, 1 H). 7.80-7.88 (m, 4 H), 7.48 (s, 1 H), 7.35 (s, 1 H), 7.28 (s, 1 H), 6.91-7.04 (m, 1 H), 6.81 (d, 7=7.53 Hz, 1 H), 6.64 (d, 7=8.03 Hz, 1 H), 4.45 (br. s., 1 H), 4.34 (s, 2 H), 2.38 (s, 3 H), 1.37-1.57 (m, 6 H), 1.33 (s., 9 H), 1.17- 1.27 (m, 3 H). Example 22
{5-[(3'-tert-Butyl-5'-methyl-biphenyl-4-sulfonyl)-methyl-amino]-6,7,8,9-tetrahydro- 5H-benzoc clohepten- 1 -yloxy } -acetic acid
Figure imgf000104_0001
Using the conditions of General Procedure 7, {5-[(3'-tert-butyl-5'-mefhyl-biphenyl-4- sulfonyl)-methyl-amino]-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy} -acetic acid tert-butyl ester (which may be prepared as described for Intermediate 3.08; 40 mg, 0.07 mmol) was hydrolyzed using 2 N NaOH solution (0.7 mL, 1.4 mmol) to give {5- [(3'-tert-butyl-5'-methyl-biphenyl-4-sulfonyl)-methyl-amino]-6,7,8,9-tetrahydro-5H- benzocyclohepten-1 -yloxy} -acetic acid (20 mg, 55% yield). XH NMR (400 MHz, DMSO- ) δ: 8.00 (s, 4 H), 7.58 (s, 1 H), 7.45 (s, 1 H), 7.36 (s, 1 H), 7.18 (t, .7=8.0 Hz, 1 H), 6.91 (d, /=7.8 Hz, 1 H), 6.83 (d, .7=8.3 Hz, 1 H), 5.19-5.24 (m, 1 H), 4.69 (s, 2 H), 3.55 (dd, 7=13.8, 6.8 Hz, 1 H), 2.92 (s, 3 H), 2.35-2.50 (m, 4 H), 1.52-1.97 (m, 3 H), 1.38-1.45 (m, 11 H), 1.00-1.21 (m, 1 H).
Example 23
[5-(4'-Hydroxy-biphenyl-4-sulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-
1 -yloxy] -acetic acid
Figure imgf000105_0001
A mixture of [5-(4'-hydroxy-biphenyl-4-sulfonylamino)-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy] -acetic acid tert-butyl ester (which may be prepared as described for Intermediate 2.14; 100 mg, 0.19 mmol) and 2 N NaOH solution (1.45 mL, 2.9 mmol) in THF (1 mL) was stirred at room temperature overnight. The THF was removed under reduced pressure and water was added. The mixture was washed with ether. The aqueous layer was acidified to approximately pH 2 by the addition of dilute HC1 and the mixture was extracted three times with EtOAc. The organic layers were dried over Na2S04, filtered, and evaporated to give [5-(4'-hydroxy-biphenyl-4- sulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy]-acetic acid (45 mg, 50% yield). XH NMR (300 MHz, DMSO-J6) δ: 9.71 (s, 1 H), 8.13 (d, J = 7.8 Hz, 1 H), 7.79 (d, J = 9.1 Hz, 2 H), 7.73 (d, J = 8.8 Hz, 2 H), 7.56 (d, J = 8.8 Hz, 2 H), 6.98 (t, J = 7.8 Hz, 1 H), 6.82-6.88 (m, 3 H), 6.67 (d, J = 8.2 Hz, 1 H), 4.56 (s, 2 H), 4.42 (br t, 1 H), 3.14-3.23 (m, 1 H), 1.42-1.76 (m, 6 H). HRMS [M+H] observed: 468.1480, calculated for C25H26N06S: 468.1475.
Example 24
{5-[(4'-Hydroxy-biphenyl-4-sulfonyl)-methyl-amino]-6,7,8,9-tetrahydro
benzocyclohepten- 1 -yloxy } -acetic acid
Figure imgf000106_0001
Using the conditions described for the preparation of Example 23, { 5-[(4'-hydroxy- biphenyl-4-sulfonyl)-methyl-amino]-6,7,8,9-tetrahydro-5H-benzocyclohepten- l- yloxy} -acetic acid tert-butyl ester (which may be prepared as described for
Intermediate 3.09; 100 mg, 0.19 mmol) was hydrolyzed using 2 N NaOH solution ( 1.85 mL, 3.7 mmol) to give { 5-[(4'-hydroxy-biphenyl-4-sulfonyl)-methyl-amino]- 6,7,8,9-tetrahydro-5H-benzocyclohepten- l-yloxy}-acetic acid (45 mg, 50% yield). 1H NMR (300 MHz, DMSO-t¾) δ: 9.76 (br s, 1 H), 7.88 (d, J = 8.8 Hz, 2 H), 7.84 (d, J = 8.8 Hz, 2 H), 7.60 (d, J = 8.8 Hz, 2 H), 7.10 (t, J = 8 Hz, 1 H), 6.88 (d, J = 8.5 Hz, 2 H), 6.84 (d, J = 8.2 Hz, 1 H), 6.75 (d, J = 8.5 Hz, 1 H), 5.09-5.12 (m, 1 H), 4.63 (s, 2 H), 3.43-3.50 (m, 1 H), 2.82 (s, 3 H), 2.32 (t, J = 12.7 Hz, 1 H), 12.95 (br s, 1 H), 1.66-1.86 (m, 2 H), 1.47- 1.61 (m, 1 H), 1.25- 1.38 (m, 2 H), 0.95- 1.13 (m, 1 H). HRMS [M+H] observed: 482.1640, calculated for C26H2gN06S: 482.1632.
Example 25
{ 5-[4-(5-Methyl-pyridin-3-yl)-benzenesulfonylamino] -6,7,8,9-tetrahydro- benzocyclohepten- 1 -yloxy } -acetic acid
Figure imgf000106_0002
Using the conditions of General Procedure 7, {5-[4-(5-methyl-pyridin-3-yl)- benzenesulfonylamino]-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy}-acetic acid tert-butyl ester (which may be prepared as described for Intermediate 2.15; 100 mg, 0.19 mmol) was hydrolyzed using 2 N NaOH solution (1.9 mL, 3.8 mmol) to give {5- [4-(5-methyl-pyridin-3-yl)-benzenesulfonylamino]-6,7,8,9-tetrahydro-5H- benzocyclohepten-l-yloxy} -acetic acid (65 mg, 73% yield). 1H NMR (DMSO-d6) δ: 13.00 (br. s., 1 H), 8.82 (d, J = 2.0 Hz, 1 H), 8.54 (s, 1 H), 8.32 (d, J = 7.8 Hz, 1 H), 8.05 (s, 1 H), 7.87-7.99 (m, 4 H), 7.02-7.17 (m, 1 H), 6.92 (d, J = 7.8 Hz, 1 H), 6.76 (d, J = 8.0 Hz, 1 H), 4.66 (s, 2 H), 4.54 (br. s., 1 H), 3.24 (br. s., 1 H), 2.61 (s, 1 H), 2.46 (s, 3 H), 1.80 (br. s., 1 H), 1.60 (d, J = 7.3 Hz, 4 H), 1.30 (br. s., 1 H). HRMS [M+H] observed: 467.1632, calculated for C25H26N2Na05S: 467.1635.
Example 26
(5-{Methyl-[4-(5-methyl-pyridin-3-yl)-benzenesulfonyl]-amino}-6,7,8,9-tetrahydro- 5H-benzoc clohepten-l-yloxy)-acetic acid
Figure imgf000107_0001
Using conditions similar to those described for Example 43, (5-{methyl-[4-(5-methyl- pyridin-3-yl)-benzenesulfonyl]-amino}-6,7,8,9-tetrahydro-5H-benzocyclohepten-l- yloxy)-acetic acid tert-butyl ester (which may be prepared as described for
Intermediate 3.10; 45 mg, 0.08 mmol) was hydrolyzed using lithium hydroxide monohydrate (10 mg, 0.24 mmol) to give (5- {methyl- [4-(5-methyl-p yridin-3-yl)- benzenesulfonyl]-amino}-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy)-acetic acid (20 mg, 50%). !H NMR (400 MHz, DMSO- e) δ: 8.79 (s, 1 H), 8.50 (s, 1 H), 7.97-8.03 (m, 5 H), 7.11 (t, .7=8.1 Hz, 1 H), 6.84 (d, 7=7.8 Hz, 1 H), 6.77 (d, 7=8.3 Hz, 1 H), 5.15 (d, 7=8.3 Hz, 1 H), 4.64 (s, 2 H), 3.44-3.53 (m, 1 H), 2.86 (s, 3 H), 2.40 (s, 3 H), 1.73-1.85 (m, 2 H), 1.55-1.61 (m, 1 H), 1.33-1.39 (m, 2 H), 0.95-1.13 (m, 1 H). Example 27
[5-(3'-Methylsulfanyl-biphenyl-4-sulfonylamino)-6,7,8,9-tetrahydro-5H- benzoc clohepten- 1 -yloxy] -acetic acid
Figure imgf000108_0001
Using the conditions of General Procedure 7, [5-(3'-methylsulfanyl-biphenyl-4- sulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy] -acetic acid tert- butyl ester (which may be prepared as described for Intermediate 2.16; 50 mg, 0.09 mmol) was hydrolyzed using 2 N NaOH solution (0.9 mL, 1.8 mmol) to give [5-(3'- methylsulfanyl-biphenyl-4-sulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten- 1 -yloxy] -acetic acid (18 mg, 40% yield) as an off-white solid. HPLC indicated that the purity of this sample was 81%. Impurities are visible in the NMR at δ 8.06-8.08, 7.96- 8.00, and 7.76-7.84 ppm. 1H NMR (400 MHz, DMSO-ife) δ: 8.24-8.37 (m, 1 H), 7.93 (s, 4 H), 7.63 (s, 1 H), 7.54-7.58 (m, 1 H), 7.51 (t, J=7.5 Hz, 1 H), 7.39 (d, J=7.8 Hz, 1 H), 7.05 (t, J=8.0 Hz, 1 H), 6.91 (d, J=7.5 Hz, 1 H), 6.74 (d, J=8.3 Hz, 1 H), 4.49-4.63 (m, 3 H), 3.21-3.29 (m, 1 H), 2.74 (s, 1 H), 2.39 (s, 1 H), 1.78-1.83 (m, 1 H), 1.52- 1.66 (m, 3 H), 1.25-1.35 (m, 2 H).
Example 28
{5-[Methyl-(3'-methylsulfanyl-biphenyl-4-sulfonyl)-amino]-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy } -acetic acid
Figure imgf000109_0001
Using the conditions of General Procedure 7, {5-[methyl-(3'-methylsulfanyl-biphenyl- 4-sulfonyl)-amino]-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy}-acetic acid tert- butyl ester (which may be prepared as described for Intermediate 3.11 ; 40 mg, 0.07 mmol) was hydrolyzed using 2 N NaOH solution (0.7 mL, 1.4 mmol) to give {5- [methyl-(3'-methylsulfanyl-biphenyl-4-sulfonyl)-amino]-6,7,8,9-tetrahydro-5H- benzocyclohepten-l-yloxy} -acetic acid (25 mg, 69% yield) as a white solid. HPLC indicated that the purity of this sample was 82.5%. Impurities are visible in the NMR at δ 7.40, 7.09, 4.48, 2.80, and 1.25 ppm. 1H NMR (400 MHz, CDC13) δ: 7.89 (d, 7=8.3 Hz, 2 H), 7.69 (d, 7=8.3 Hz, 2 H), 7.47 (s, 1 H), 7.35-7.38 (m, 2 H), 7.30 (d, 7=7.3 Hz, 1 H), 7.89 (d, 7=8.3 Hz, 1 H), 6.91 (d, 7=7.3 Hz, 1 H), 6.69 (d, 7=7.8 Hz, 1 H), 5.30 (d, 7=9.8 Hz, 1 H), 4.63 (s, 2 H), 3.49 (dd, 7=14.2, 7.3 Hz, 1 H), 2.93 (s, 3 H), 2.55 (s, 3 H), 2.45 (t, 7=13.0 Hz, 1 H), 1.55-1.96 (m, 7 H).
Example 29
[5-(3'-Methanesulfonyl-biphenyl-4-sulfonylamino)-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy] -acetic acid
Figure imgf000109_0002
Using the conditions of General Procedure 7, [5-(3'-methanesulfonyl-biphenyl-4- sulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy] -acetic acid tert- butyl ester (which may be prepared as described for Intermediate 2.17; 100 mg, 0.17 mmol) was hydrolyzed using 2 N NaOH solution (1.66 mL, 3.3 mmol) to give [5-(3'- methanesulfonyl-biphenyl-4-sulfonylamino)-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy] -acetic acid (75 mg, 83% yield) as an off-white solid. XH NMR (DMSO-d6) δ: 8.28 (d, J = 7.8 Hz, 1 H), 8.23 (s, 1 H), 8.10 (d, J = 8.0 Hz, 1 H), 7.99 (s, 1 H), 7.95 (s, 2 H), 7.88-7.93 (m, 2 H), 7.76-7.83 (m, 1 H), 6.96-7.04 (m, 1 H), 6.86 (d, J = 7.8 Hz, 1 H), 6.70 (d, J = 8.3 Hz, 1 H), 4.59 (s, 2 H), 4.48 (br. s., 1 H), 3.33 (s, 3 H), 3.12-3.25 (m, 1 H), 2.54 (s, 1 H), 1.73 (d, J = 4.5 Hz, 1 H), 1.54 (d, J = 8.8 Hz, 4 H), 1.23 (br. s., 1 H). HRMS [M+Na] observed: 552.1117, calculated for C26H27NNa07S2: 552.1121.
Example 30
{5-[(3'-Methanesulfonyl-biphenyl-4-sulfonyl)-methyl-amino]-6,7,8,9-tetrahydro-5H- benzoc clohepten- 1 -yloxy } -acetic acid
Figure imgf000110_0001
Using the conditions of General Procedure 7, {5-[(3'-methanesulfonyl-biphenyl-4- sulfonyl)-methyl-amino]-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy} -acetic acid tert-butyl ester (which may be prepared as described for Intermediate 3.12; 100 mg, 0.17 mmol) was hydrolyzed using 2 N NaOH solution (1.66 mL, 3.3 mmol) to give {5-[(3'-methanesulfonyl-biphenyl-4-sulfonyl)-methyl-amino]-6,7,8,9-tetrahydro- 5H-benzocyclohepten- 1 -yloxy} -acetic acid (30 mg, 33% yield) as a brown solid.
1H NMR (400 MHz, DMSO- ) δ: 8.27 (s, 1 H), 8.15 (d, .7=8.0 Hz, 1 H), 7.97-8.09 (m, 5 H), 7.81 (t, .7=7.8 Hz, 1 H), 7.12 (t, .7=8.2 Hz, 1 H), 6.85 (d, 7=7.8 Hz, 1 H), 6.77 (d, 7=8.3 Hz, 1 H), 5.12-5.20 (m, 1 H), 4.65 (s, 2 H), 3.48 (dd, 7=14.05, 6.78 Hz, 1 H), 2.87 (s, 3 H), 2.54 (s, 3 H), 2.29-2.43 (m, 1 H), 1.71-1.90 (m, 2 H), 1.58 (d, 7=11.8 Hz, 1 H), 1.18-1.46 (m, 3 H), 0.95-1.13 (m, 1 H). HRMS [M+H+] observed: 544.1465, calculated for C27H30NO7S2: 544.1458.
Example 31
{5-[5-(3-Isopropyl-phenyl)-pyridine-2-sulfonylamino]-6,7,8,9-tetrahydro-5H- benzoc clohepten- 1 -yloxy } -acetic acid
Figure imgf000111_0001
Using the conditions described for the preparation of Example 23, { 5-[5-(3-isopropyl- phenyl)-pyridine-2-sulfonylamino]-6,7,8,9-tetrahydro-5H-benzocyclohepten-l- yloxy} -acetic acid tert-butyl ester (which may be prepared as described for
Intermediate 2.18; 100 mg, 0.18 mmol) was hydrolyzed using 2 N NaOH solution (1.8 mL, 3.6 mmol) to give { 5-[5-(3-isopropyl-phenyl)-pyridine-2-sulfonylamino]-6,7,8,9- tetrahydro-5H-benzocyclohepten-l-yloxy}-acetic acid (55 mg, 61% yield). 1H NMR (300 MHz, OMSO-d6) δ: 12.92 (br s, 1 H), 9.00 (d, J = 1.8 Hz, 1 H), 8.43 (d, J = 8.2 Hz, 1 H), 8.26 (dd, J = 2.4, 8.2 Hz, 1 H), 7.90 (d, J = 8.5 Hz, 1 H), 7.64 (s, 1 H), 7.59 (d, J = 7.8 Hz, 1 H), 7.45 (t, J = 7.5 Hz, 1 H), 7.36 (d, J = 7.8 Hz, 1 H), 6.98 (t, J = 7.8 Hz, 1 H), 6.90 (d, J = 7.5 Hz, 1 H), 6.66 (d, J = 7.5 Hz, 1 H), 4.68 (t, J = 7.8 Hz, 1 H), 4.55 (s, 2 H), 3.20-3.28 (m, 1 H), 2.99 (p, J - 6.9 Hz, 1 H), 1.46-1.78 (m, 6 H), 1.26 (d, J = 6.9 Hz, 6 H). HRMS [M+H+] observed: 495.1959, calculated for C27H31N2O5S: 495.1948.
Example 32
(5-{ [5-(3-Isopropyl-phenyl)-pyridine-2-sulfonyl]-methyl-amino}-6,7,8,9-tetrahydro- 5H-benzocyclohepten-l-yloxy)-acetic acid
Figure imgf000112_0001
Using the conditions described for the preparation of Example 23, (5-{ [5-(3- isopropyl-phenyl)-pyridine-2-sulfonyl]-methyl-amino}-6,7,8,9-tetrahydro-5H- benzocyclohepten-l-yloxy)-acetic acid tert-butyl ester (which may be prepared as described for Intermediate 3.13; 90 mg, 0.16 mmol) was hydrolyzed using 2 N NaOH solution (1.7 mL, 3.4 mmol) to give (5-{ [5-(3-isopropyl-phenyl)-pyridine-2-sulfonyl]- methyl-amino}-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy)-acetic acid (40 mg, 49% yield). XH NMR (DMSO-d6) δ: 9.13 (d, J = 1.8 Hz, 1 H), 8.39 (dd, J = 8.3, 2.3 Hz, 1 H), 8.03 (d, J = 8.3 Hz, 1 H), 7.71 (s, 1 H), 7.65 (d, J = 7.5 Hz, 1 H), 7.48 (t, J = 7.7 Hz, 1 H), 7.39 (d, J = 7.5 Hz, 1 H), 7.10 (t, J = 8.0 Hz, 1 H), 6.85 (d, J = 7.8 Hz, 1 H), 6.74 (d, I = 8.3 Hz, 1 H), 5.26 (d, J = 10.3 Hz, 1 H), 4.54 (br. s., 2 H), 3.50 (dd, J = 14.2, 6.7 Hz, 1 H), 2.88-3.07 (m, 4 H), 2.26 (br. s., 1 H), 1.37-1.91 (m, 5 H), 1.28 (d, J=7.0 Hz, 6 H), 1.00-1.14 (m, 1 H). HRMS [M+Na] observed: 531.1925, calculated for C28H32N2Na05S: 531.1924.
Example 33
{5-[5-(3-Trifluoromethyl-phenyl)-pyridine-2-sulfonylamino]-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy } -acetic acid
Figure imgf000112_0002
- I l l -
Using the conditions described for the preparation of Example 23, {5-[5-(3- trifluoromethyl-phenyl)-pyridine-2-sulfonylamino]-6,7,8,9-tetrahydro-5H- benzocyclohepten-l-yloxy} -acetic acid tert-butyl ester (which may be prepared as described for Intermediate 2.19; 50 mg, 0.09 mmol) was hydrolyzed using 2 N NaOH solution (0.8 mL, 1.6 mmol) to give {5-[5-(3-trifluoromethyl-phenyl)-pyridine-2- sulfonylamino]-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy}-acetic acid (30 mg, 66% yield). 1H NMR (300 MHz, DMSO-rf6) δ 12.94 (br s, 1 H), 9.10 (d, J = 2.1 Hz, 1 H), 8.49 (d, J = 7.8 Hz, 1 H), 8.38 (dd, J = 2.3, 8.3 Hz, 1 H), 8.15 (s, 1 H), 8.12 (d, J = 7.8 Hz, 1 H), 7.93 (d, J = 8.2 Hz, 1 H), 7.85 (d, I = 8.1 Hz, 1 H), 7.77 (t, J = 7.5 Hz, 1 H), 6.98 (t, J = 8.0 Hz, 1 H), 6.90 (d, I = 7.5 Hz, 1 H), 6.66 (d, J = 8.1 Hz, 1 H), 4.69 (t, J = 8.5 Hz, 1 H), 4.55 (s, 2 H), 3.20-3.26 (m, 1 H), 1.50-1.78 (m, 5 H), 1.15-1.26 (m, 1 H). HRMS [M+H+] observed: 521.1360, calculated for CisH^FsNzOsS:
521.1353.
Example 34
(5- { Methyl- [5-(3-trifluoromethyl-phenyl)-pyridine-2-sulfonyl]-amino }
tetrah dro-5H-benzocyclohepten- l-yloxy)-acetic acid
Figure imgf000113_0001
Using the conditions of General Procedure 7, (5-{methyl-[5-(3-trifluoromethyl- phenyl)-pyridine-2-sulfonyl]-amino}-6,7,8,9-tetrahydro-5H-benzocyclohepten-l- yloxy)-acetic acid tert-butyl ester (which may be prepared as described for
Intermediate 3.14; 40 mg, 0.07 mmol) was hydrolyzed using 2 N NaOH solution (0.7 mL, 1.4 mmol) to give (5- {methyl- [5-(3-trifluoromethyl-phenyl)-pyridine-2-sulfonyl]- amino}-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy)-acetic acid (23 mg, 64% yield). H NMR (300 MHz, DMSO-cfe) δ 8.20 (d, J = 2.1 Hz, 1 H), 8.48 (dd, J = 2.4, 8.1 Hz, 1 H), 8.20 (s, 1 H), 8.16 (d, I = 8.4 Hz, 1 H), 8.05 (d, I = 8.2 Hz, 1 H), 7.84- 7.87 (m, 1 H), 7.78 (t, J = 7.7 Hz, 1 H), 7.07 (t, I = 8.0 Hz, 1 H), 6.82 (d, I = 7.8 Hz, 1 H), 6.71 (d, J = 8.1 Hz, 1 H), 5.25 (d, J = 10.3 Hz, 1 H), 4.48 (s, 2 H), 3.52-3.44 (m, 1 H), 2.21-2.30 (m, 1 H), 1.88- 1.44 (m, 5 H), 1.04-1.12 (m, 1 H). HRMS [M+H+] observed: 535.1514, calculated for C26H26F3N2O5S: 535.1509. Example 35
{5-[5-(3-tert-Butyl-5-methyl-phenyl)-pyridine-2-sulfonylamino]-6,7,8,9-tetrahydro- 5H-benzoc clohepten- 1 -yloxy } -acetic acid
Figure imgf000114_0001
Using the conditions described for the preparation of Example 23, { 5-[5-(3-tert-butyl- 5-methyl-phenyl)-pyridine-2-sulfonylamino]-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy} -acetic acid tert-butyl ester (which may be prepared as described for Intermediate 2.20; 100 mg, 0.17 mmol) was hydrolyzed using 2 N NaOH solution (1.7 mL, 3.4 mmol) to give { 5-[5-(3-tert-butyl-5-methyl-phenyl)- pyridine-2-sulfonylamino]-6,7,8,9-tetrahydro-5H-benzocyclohepten- l-yloxy}-acetic acid (40 mg, 44% yield). 1H NMR (300 MHz, OMSO-d6) δ: 12.96 (br s, 1 H), 8.98 (d, J = 1.5 Hz, 1 H), 8.43 (d, J = 7.8 Hz, 1 H), 8.25 (dd, J = 2.4, 8.2 Hz, 1 H), 7.89 (d, J = 8.2 Hz, 1 H), 7.52 (s, 1 H), 7.40 (s, 1 H), 7.32 (s, 1 H), 6.97 (t, J = 7.8 Hz, 1 H), 6.90 (d, J = 7.8 Hz, 1 H), 6.65 (d, J = 7.8 Hz, 1 H), 4.68 (t, 1 H), 4.52 (s, 2 H), 3.20-3.28 (m, 1 H), 2.38 (s, 3 H), 1.50- 1.80 (m, 5 H), 1.32 (s, 9 H), 1.15-1.25 (m, 1 H). HRMS
[M+H+] observed: 523.2270, calculated for C29H35N2O5S: 523.2261.
Example 36
(5- { [5 - (3-tert-Butyl- 5 -methyl-phenyl)-pyridine-2- sulf onyl] -methyl- amino }
tetrahydro-5H-benzocyclohepten- l-yloxy)-acetic acid
Figure imgf000115_0001
Using the conditions of General Procedure 7, (5-{ [5-(3-tert-butyl-5-methyl-phenyl)- pyridine-2-sulfonyl]-methyl-amino}-6,7,8,9-tetrahydro-5H-benzocyclohepten-l- yloxy)-acetic acid tert-butyl ester (which may be prepared as described for
Intermediate 3.15; 150 mg, 0.25 mmol) was hydrolyzed using 2 N NaOH solution (2.6 mL, 5.2 mmol) to give (5-{ [5-(3-tert-butyl-5-methyl-phenyl)-pyridine-2-sulfonyl]- methyl-amino}-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy)-acetic acid (50 mg, 37% yield). XH NMR (DMSO-d6) δ: 9.11 (d, J = 1.8 Hz, 1 H), 8.37 (dd, J = 8.2, 2.1 Hz, 1 H), 8.02 (d, J = 8.0 Hz, 1 H), 7.59 (s, 1 H), 7.47 (s, 1 H), 7.34 (s, 1 H), 7.07 (t, J = 8.0 Hz, 1 H), 6.82 (d, J = 7.8 Hz, 1 H), 6.71 (d, J = 8.3 Hz, 1 H), 5.25 (d, J = 10.0 Hz, 1 H), 4.35-4.75 (m, 2 H), 3.50 (dd, J = 13.9, 6.9 Hz, 1 H), 2.96 (s, 3 H), 2.40 (s, 3 H), 2.28 (s, 1 H), 0.84-1.99 (m, 15 H). HRMS [M+H] observed: 537.2415, calculated for C30H37N2O5S: 537.2418.
Example 37
(5-{5-[3-(2-Hydroxy-ethyl)-phenyl]-pyridine-2-sulfonylamino}-6,7,8,9-tetrahydro- 5H-benzocyclohepten-l-yloxy)-acetic acid
Figure imgf000115_0002
Using the conditions described for the preparation of Example 23, (5-{ 5-[3-(2- hydroxy-ethyl)-phenyl]-pyridine-2-sulfonylamino}-6,7,8,9-tetrahydro-5H- benzocyclohepten-l-yloxy)-acetic acid tert-butyl ester (which may be prepared as described for Intermediate 2.21; 100 mg, 0.18 mmol) was hydrolyzed using 2 N NaOH solution (1.8 mL, 3.6 mmol) to give (5-{5-[3-(2-hydroxy-ethyl)-phenyl]- pyridine-2-sulfonylamino}-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy)-acetic acid (52 mg, 58% yield). 1H NMR (300 MHz, OMSO-d6) δ: 8.99 (d, J = 1.8 Hz, 1 H), 8.43 (d, J = 7.8 Hz, 1 H), 8.25 (dd, J = 2.4, 8.2 Hz, 1 H), 7.90 (d, J = 7.5 Hz, 1 H), 7.64 (s, 1 H), 7.60 (d, J = 7.8 Hz, 1 H), 7.43 (t, I = 7.7 Hz, 1 H), 7.32 (d, J = 7.8 Hz, 1 H), 6.97 (t, J = 7.8 Hz, 1 H), 6.89 (d, J = 7.3 Hz, 1 H), 6.66 (d, J = 7.8 Hz, 1 H), 4.67 (br t, 2 H), 4.54 (s, 2 H), 3.66 (t, J = 6.9 Hz, 2 H), 3.20-3.28 (m, 1 H), 2.81 (t, J = 6.9 Hz, 2 H), 1.78- 1.46 (m, 6 H). HRMS [M+H+] observed: 497.1748, calculated for C26H29N2O6S: 497.1741.
Example 38
[5-({ 5-[3-(2-Hydroxy-ethyl)-phenyl]-pyridine-2-sulfonyl}-methyl-amino)- tetrah dro-5H-benzocyclohepten-l-yloxy]-acetic acid
Figure imgf000116_0001
Using the conditions of General Procedure 7, [5-({5-[3-(2-hydroxy-ethyl)-phenyl]- pyridine-2-sulfonyl}-methyl-amino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l- yloxy]-acetic acid tert-butyl ester (which may be prepared as described for
Intermediate 3.16; 100 mg, 0.17 mmol) was hydrolyzed using 2 N NaOH solution (1.8 mL, 3.6 mmol) to give [5-({ 5-[3-(2-hydroxy-ethyl)-phenyl]-pyridine-2-sulfonyl}- methyl-amino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy]-acetic acid (20 mg, 22% yield). 1H NMR (DMSO-d6) δ: 9.12 (d, J = 1.8 Hz, 1 H), 8.37 (dd, J = 8.3, 2.3 Hz, 1 H), 8.04 (d, J = 8.3 Hz, 1 H), 7.63-7.72 (m, 2 H), 7.46 (t, J = 7.7 Hz, 1 H), 7.36 (d, J = 7.8 Hz, 1 H), 7.07-7.16 (m, 1 H), 6.86 (d, J = 7.8 Hz, 1 H), 6.76 (d, J = 8.3 Hz, 1 H), 5.26 (d, J = 10.3 Hz, 1 H), 4.62 (br. s., 2 H), 3.68 (t, J = 6.9 Hz, 2 H), 3.50 (dd, J = 13.9, 6.7 Hz, 1 H), 2.96 (s, 3 H), 2.83 (s, 2 H), 2.21-2.36 (m, 1 H), 0.93-1.92 (m, 6 H). HRMS [M+Na] observed: 533.1717, calculated for
Figure imgf000117_0001
533.1717.
Example 39
[5-(4'-Methyl-biphenyl-3-sulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l- loxy] -acetic acid
Figure imgf000117_0002
Using the conditions of General Procedure 7, [5-(4'-methyl-biphenyl-3- sulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy] -acetic acid tert- butyl ester (which may be prepared as described for Intermediate 2.22; 125 mg, 0.23 mmol) was hydrolyzed using 2 N NaOH solution (2.8 mL, 5.6 mmol). The product was purified by preparative TLC to give [5-(4'-methyl-biphenyl-3-sulfonylamino)- 6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy]-acetic acid (15 mg, 13% yield). !H NMR (300 MHz, DMSO-i¾) δ: 12.93 (br. s., 1 H), 8.21 (d, J=7.8 Hz, 1 H), 7.99 (s, 1 H), 7.88 (d, J=7.8 Hz, 1 H), 7.77 (d, J=7.8 Hz, 1 H), 7.57-7.67 (m, 3 H), 7.46-7.54 (m, 2 H), 7.42 (d, J=7.2 Hz, 1 H), 6.90-7.00 (m, 1 H), 6.81 (d, J=7.5 Hz, 1 H), 6.66 (d, J=8.2 Hz, 1 H), 4.55 (s, 2 H), 4.40-4.52 (m, 1 H), 3.16 (dd, J=13.9, 7.2 Hz, 1 H), 1.67- 1.76 (m, 1 H), 1.44-1.56 (m, 3 H), 1.16-1.28 (m, 1 H). HRMS [M+Na] observed: 452.1531, calculated for CzeHzsNOgS: 452.1526.
Example 40
{5-[Methyl-(4'-methyl-biphenyl-3-sulfonyl)-amino]-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy } -acetic acid
Figure imgf000117_0003
Using the conditions of General Procedure 7, {5-[methyl-(4'-methyl-biphenyl-3- sulfonyl)-amino]-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy}-acetic acid tert- butyl ester (which may be prepared as described for Intermediate 3.17; 100 mg, 0.19 mmol) was hydrolyzed using 2 N NaOH solution (1.86 mL, 3.7 mmol) to give {5- [methyl-(4'-methyl-biphenyl-3-sulfonyl)-amino]-6,7,8,9-tetrahydro-5H- benzocyclohepten-l-yloxy} -acetic acid (30 mg, 34% yield). 1H NMR (400 MHz, DMSO- ) δ: 7.96-8.04 (m, 2 H), 7.87 (d, 7=7.8 Hz, 1 H), 7.69-7.78 (m, 1 H), 7.63 (d, 7=7.8 Hz, 2 H), 7.33 (d, 7=7.3 Hz, 2 H), 7.10 (t, 7=8.1 Hz, 1 H), 6.83 (d, 7=8.3 Hz, 1 H), 6.76 (d, 7=7.8 Hz, 1 H), 5.18 (d, 7=8.3 Hz, 1 H), 4.63 (br. s., 2 H), 3.43-3.54 (m, 1 H), 2.87 (s, 3 H), 2.37 (s, 3 H), 1.70-1.84 (m, 2 H), 1.14-1.58 (m, 4 H), 0.99-1.09 (m, 1 H). HRMS [M+H+] observed: 480.1847, calculated for C27H30NO5S: 480.1839.
Example 41
[5-(3'-Isopropyl-biphenyl-3-sulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-
1- loxy] -acetic acid
Figure imgf000119_0001
Using the conditions of General Procedure 7, [5-(3'-isopropyl-biphenyl-3- sulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy] -acetic acid tert- butyl ester (which may be prepared as described for Intermediate 2.23; 25 mg, 0.05 mmol) was hydrolyzed using 2 N NaOH solution (1 mL, 2 mmol) to give [5-(3'- isopropyl-biphenyl-3-sulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten- l- yloxy]-acetic acid (18 mg, 80% yield). lU NMR (400 MHz, CDC13) δ: 7.97 (s, 1 H), 7.70 (d, 7=7.9 Hz, 2 H), 7.42-7.48 (m, 1 H), 7.30-7.40 (m, 3 H), 6.85 (t, 7=7.9 Hz, 1 H), 6.63 (d, 7=8.5 Hz, 1 H), 6.58 (d, 7=7.3 Hz, 1 H), 5.00 (d, 7=6.1 Hz, 1 H), 4.53- 4.61 (m, 1 H), 4.38 (br. s., 2 H), 3.47 (q, 7=7.3 Hz, 1 H), 2.91-2.99 (m, 1 H), 2.80-2.88 (m, 1 H), 1.43- 1.93 (m, 5 H), 1.23- 1.32 (m, 6 H).
Example 42
{5-[(3'-Isopropyl-biphenyl-3-sulfonyl)-methyl-amino]-6,7,8,9-tetrahydro- benzoc clohepten- 1 -yloxy } -acetic acid
Figure imgf000119_0002
Using the conditions of General Procedure 7, { 5-[(3'-isopropyl-biphenyl-3-sulfonyl) methyl-amino]-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy}-acetic acid tert- butyl ester (which may be prepared as described for Intermediate 3.18; 80 mg, 0.14 mmol) was hydrolyzed using 2 N NaOH solution (1.4 mL, 2.8 mmol) to give { 5-[(3' isopropyl-biphenyl-3-sulfonyl)-methyl-amino]-6,7,8,9-tetrahydro-5H- benzocyclohepten-l-yloxy} -acetic acid (30 mg, 42% yield). 1H NMR (400 MHz, DMSO- ) δ: 12.97 (br. s., 1 H), 7.98-8.06 (m, 2 H), 7.89 (d, .7=7.8 Hz, 1 H), 7.71- 7.78 (m, 1 H), 7.56 (s, 1 H), 7.53 (d, 7=7.8 Hz, 1 H), 7.44 (t, 7=7.6 Hz, 1 H), 7.33 (d, 7=7.3 Hz, 1 H), 7.10 (t, 7=8.1 Hz, 1 H), 6.83 (d, .7=7.8 Hz, 1 H), 6.77 (d, .7=8.3 Hz, 1 H), 5.20 (d, 7=7.8 Hz, 1 H), 4.66 (s, 2 H), 3.45-3.54 (m, 1 H), 2.96-3.06 (m, 1 H), 2.87 (s, 3 H), 2.31-2.43 (m, 1 H), 1.72-1.85 (m, 2 H), 1.51-1.61 (m, 1 H), 1.33-1.40 (m, 2 H), 1.27 (d, 7=6.8 Hz, 6 H), 0.98-1.10 (m, 1 H). HRMS [M+H+] observed: 508.2159, calculated for C29H34NO5S: 508.2152.
Example 43
[5-(3-Isopropyl-5-trifluoromethyl-benzenesulfonylamino)-6,7,8,9-tetrahydro- benzoc clohepten- 1 -yloxy] -acetic acid
Figure imgf000120_0001
Lithium hydroxide monohydrate (8 mg, 0.19 mmol) was added to a mixture of [5-(3- isopropyl-5-trifluoromethyl-benzenesulfonylamino)-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy] -acetic acid tert-butyl ester (which may be prepared as described for Intermediate 2.24; 30 mg, 0.06 mmol), THF (4 mL), MeOH (1 mL) and water (1 mL). The mixture was stirred for 16 h, then concentrated and diluted with water (10 mL). The pH of the mixture was adjusted to ~4 by adding 2N HC1 and the mixture was then extracted with EtOAc. The EtOAc was evaporated and the residue was washed with pentane to give [5-(3-isopropyl-5-trifluoromethyl- benzenesulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy]-acetic acid
(23 mg, 86%) as an off-white solid. lH NMR (400 MHz, DMSO- e) δ: 8.35 (d, 7=8.0 Hz, 1 H), 7.89 (s, 1 H), 7.79 (s, 2 H), 6.84-6.97 (m, 1 H), 6.70 (d, 7=7.5 Hz, 1 H), 6.63 (d, 7=8.3 Hz, 1 H), 4.46-4.54 (m, 3 H), 3.06 (dt, 7=13.7, 6.7 Hz, 2 H), 2.66 (d, 7=11.8 Hz, 1 H), 2.54 (s, 5 H), 2.33 (s, 1 H), 1.77 (br. s., 1 H), 1.43-1.62 (m, 4 H), 1.27-1.39 (m, 1 H), 1.20 (dd, 7=7.0, 4.5 Hz, 6 H). Example 44
{5-[(3-Isopropyl-5-trifluoromethyl-benzenesulfonyl)-methyl-amino]-6,7,8,9- tetrahydro- 5H-benzocyclohepten- 1-yloxy} - acetic acid
Figure imgf000121_0001
Using conditions similar to those described for Example 43, {5-[(3-isopropyl-5- trifluoromethyl-benzenesulfonyl)-methyl-amino]-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1-yloxy} -acetic acid tert-butyl ester (which was prepared as described for Intermediate 3.19; 120 mg of crude material, -0.18 mmol) was hydrolyzed using lithium hydroxide monohydrate (0.64 mmol), to give {5-[(3- isopropyl-5-trifluoromethyl-benzenesulfonyl)-methyl-amino]-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1-yloxy} -acetic acid (60 mg, 65%) as a pale yellow solid. 1H NMR (400 MHz, DMSO-de) δ: 12.97 (br. s., 1 H), 8.04 (s, 1 H), 7.97 (s, 1 H), 7.94 (s, 1 H), 7.08 (t, .7=8.0 Hz, 1 H), 6.77 (d, 7=8.0 Hz, 2 H), 5.20 (d, 7=10.0 Hz, 1 H), 4.65 (s, 2 H), 3.47 (dd, 7=14.2, 6.9 Hz, 1 H), 3.19 (dt, 7=13.8, 6.9 Hz, 1 H), 2.84 (s, 3 H), 2.39 (t, 7=12.8 Hz, 1 H), 1.72-1.86 (m, 2 H), 1.58 (q, 7=12.5 Hz, 1 H), 1.32-1.44 (m, 1 H), 1.27 (dd, 7=6.8, 4.5 Hz, 6 H), 1.03 (q, 7=11.5 Hz, 1 H). HRMS [M+H+] observed: 500.1719, calculated for C24H29F3NO5S: 500.1713. Examples 45 and 46
Chiral separation of [5-(3,5-Bis-trifluoromethyl-benzenesulfonylamino)-6,7,8,9- tetrahydro-5H-benzocyclohepten- 1-yloxy] -acetic acid to give Enantiomer A and
Enantiomer B
Figure imgf000122_0001
A sample of [5-(3,5-bis-trifluoromethyl-benzenesulfonylamino)-6,7,8,9-tetrahydro- 5H-benzocyclohepten-l-yloxy] -acetic acid (which may be prepared as described in Example 1; 50 mg) was separated by supercritical fluid chromatography (SFC) using a Multigram® III instrument (from Thar Technologies, Inc.), using a Daicel OJ 3 x 25 cm column, and eluting with 8% MeOH/C02 at a flow rate of 70 mL/min at 100 bar back-pressure, with monitoring at 220 nm. 42 mg of this material was purified using 10 injections of 5 mg each to give [5-(3,5-Bis-trifluoromethyl- benzenesulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy]-acetic acid Enantiomer A (Example 45, 8.6 mg, Retention Time: 3.46 min) and [5-(3,5-Bis- trifluoromethyl-benzenesulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l- yloxy]-acetic acid Enantiomer B (Example 46, 11.1 mg, Retention Time: 4.26 min).
Example 47
Human CRTH2 Receptor Binding Assay
A whole cell receptor binding assay using [3H]ramatroban as the competing radioactive ligand was employed to evaluate the compound binding activity to human CRTH2. The radioactive ligand [3H]ramatroban was synthesized according to Sugimoto et. al. {Eur. J. Pharmacol. 2005, 524, 30-37) to a specific activity of 42 Ci/mmol.
A cell line stably expressing human CRTH2 was established by transfecting CHO-K1 cells with two mammalian expression vectors that harbored human CRTH2 and G- alphal6 cDNAs, respectively, using FuGene® 6 transfection reagent (from Roche). Stable clones expressing CRTH2 were selected by staining each clone with BM16 (BD Pharmingen™ from BD Biosciences, a division of Becton, Dickinson and Company), which is a rat monoclonal antibody to human CRTH2. The cells were maintained as monolayer cultures in Ham's F-12 medium containing 10% fetal bovine serum, 100 units/mL penicillin, 100 μg/mL streptomycin, 2 mM glutamine, 0.5 mg/mL G418 (geneticin) for CRTH2, and 0.2 mg/mL hygromycin-B (for G-alpha 16). For whole cell receptor binding assay, the monolayer cells were rinsed once with PBS (phosphate buffered saline), dissociated using ethylenediaminetetraacetate (Versene™ EDTA from Lonza Inc.), and suspended in PBS containing 10 mM MgCl2 and 0.06% BSA (bovine serum albumin) at 1.5 x 106 cells/mL.
The binding reactions (0.2 mL) were performed in 96-well plates at room temperature in PBS containing 1.5 x 10s cells, 10 mM MgCl2, 0.06% BSA, 20 nM [3H]ramatroban, and test compound at various concentrations. After 1 hour of binding reactions, the cells were harvested on GF™/B filter microplates (microtiter plates with embedded glass fiber from PerkinElmer, Inc.) and washed 5 times with PBS using a Filtermate™ Harvester (a cell harvester that harvests and washes cells from microplates from PerkinElmer, Inc.). The radioactivities bound to the cells were determined using a microplate scintillation counter (TopCount® NXT, from PerkinElmer, Inc.) after adding 50 μΐ^ of Microscint™ 20 scintillation fluid (from PerkinElmer, Inc.) to each well of the filter plates. The radioactivity from non-specific binding was determined by replacing compound with 10 μΜ of 15(R)-15-methyl PGD2 (from Cayman
Chemical Company) in the reaction mixtures. The radioactivity bound to the cells in the absence of compound (total binding) was determined by replacing compound with 0.25% of DMSO (dimethyl sulfoxide) in the reaction mixture. Specific binding data were obtained by subtracting the radioactivity of non-specific binding from each binding data.
The IC50 value is defined as the concentration of the tested compound that is required for 50% inhibition of total specific binding. In order to calculate the IC50 value, the percent inhibition data were determined for 7 concentrations for each compound. The percent inhibition for a compound at each concentration was calculated according to the following formula, [1 -(specific binding in the presence of compound)/(total specific binding)]xl00. The IC50 value was then obtained by fitting the percent inhibition data to a sigmoidal dose-response (4 parameter logistic) model in the
XLfit® software Excel add-in program [from ID Business Solutions Ltd., model 205, where F(x) = (A+(B-A)/(l+((C/x)AD)))].
The acid compounds of the foregoing examples were tested using the above Human CRTH2 Receptor Binding Assay. The results of the assay showed that all of these compounds have binding activity exhibiting IC50 values ranging from 0.0033 μΜ to 2.61 μΜ. For instance, the following table shows the specific IC50 values for these compounds:
Human CRTH2 Binding
Example No. IC50 (μΜ)
1 0.0089
2 0.0584
3 2.6069
4 0.0336
5 0.9525
6 0.1713
7 0.0646
8 0.047
9 0.0574
10 0.0503
11 0.0334
12 0.7502
13 0.1579
14 0.1057
15 0.0033
16 0.0059
17 0.0114
18 0.0114
19 0.013
20 0.1058
21 0.0347
22 0.1894
23 0.1031
24 0.9871
25 0.0337
26 1.4961 Human CRTH2 Binding
Example No. ICso (μΜ)
27 0.0243
28 0.6035
29 0.0091
30 0.189
31 0.0267
32 0.123
33 0.1775
34 0.4567
35 0.0179
36 0.1643
37 0.017
38 2.1203
39 0.5143
40 0.5548
41 0.2262
42 0.8453
43 0.2978
44 0.1992
45 1.4931
46 0.0245
Example 48
Calcium Flux Assay Using Fluorometric Imaging Plate Reader
Cell Culture Conditions:
CHO-K1 cells previously transfected with G-alpha 16 were subsequently transfected with the human CRTH2 receptor and the neomycin resistance gene. Following selection in 800 μg/mL G418 (geneticin), individual clones were assayed for their receptor expression based on staining with an anti human CRTH2 IgG, followed by assaying for their response to 13, 14-dihydro- 15-keto Prostaglandin D2 (DK-PDG2) (ligand) in the Ca2+ Flux assay. Positive clones were then cloned by limiting dilution cloning. The transfected cells were cultured in Ham's F- 12 medium supplemented with 10% fetal bovine serum, 2 mM glutamine , 100 U/mL penicillin/ 100 μg/mL streptomycin, 200 μg/mL hygromycin B, and 800 μg/mL G418 (geneticin). Cells were harvested with trypsin-EDTA (trypsin-ethylenediaminetetraacetic acid) and counted using ViaCount® reagent (from Guava Technologies, Inc. which contains two DNA-binding dyes that enable the reagent user to distinguish between viable and nonviable cells). The cell suspension volume was adjusted to 2.5 xlO5 cells /mL with complete growth media. Aliquots of 50
Figure imgf000126_0001
were dispensed into BD Falcon™ 384 well black/clear microplates (from BD Biosciences, a division of Becton, Dickinson and Company) and the microplates were placed in a 37 °C CO2 incubator overnight. The following day, the microplates were used in the assay.
Dye Loading and Assay:
Loading Buffer containing dye (from the FLIPR® Calcium 3 Assay Kit from
Molecular Devices, a division of MDS Analytical Technologies and MDS Inc.) was prepared by dissolving the contents of one bottle into 200 mL Hank' s Balanced Salt Solution containing 20 mM HEPES (4-(2-hydroxyethyl)-l-piperazineethanesulfonic acid) and 2.5 mM probenecid. Growth media was removed from the cell plates and 25 μΐ. of Hank' s Balanced Salt Solution (HBSS) containing 20 mM HEPES, 0.05% BSA and 2.5 mM probenecid was added to each well followed by 25 μL· of diluted dye using a Multidrop dispenser. The plates were then incubated for 1 hour at 37 C.
During the incubation, test compound plates were prepared by adding 90 μL· of HBSS/20 mM HEPES/0.005% BSA buffer to the 2 μΐ, of serial diluted compounds. To prepare serial diluted compounds, 20 mM stocks of compounds were dissolved in 100% DMSO. The compound dilution plate was set up as follows: well # 1 received 5 μL of compound plus 10 μL· of DMSO. Wells 2-10 received 10 μL of DMSO. 5 μL· was mixed and transferred from well #1 into well #2. 1:3 serial dilutions were continued out 10 steps. 2 pL of diluted compound was transferred into duplicate wells of a 384 well "assay plate" and then 90 μL· of buffer was added.
After incubation, both the cell and "assay plate" plates were brought to the fhiorometric imaging plate reader (FLIPR®) and 20 μΐ. of the diluted compounds were transferred to the cell plates by the FLIPR®. Plates were then incubated for 1 hour at room temperature. After the 1 hour incubation, plates were returned to the FLIPR® and 20 μL· of 4.5X concentrated ligand was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL· of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds. Responses (increase in peak fluorescence) in each well following agonist addition were determined. The initial fluorescence reading from each well, prior to ligand stimulation, was used as a zero baseline value for the data from that well. The responses were expressed as % inhibition of the buffer control. The IC50 value, defined as the concentration of a compound that was required for 50% inhibition of the buffer control, was calculated by fitting the percent inhibition data for 10 concentrations to a sigmoidal dose- response (4 parameter logistic) model using Genedata Screener® Condoseo software program [from Genedata AG, model 205, where F(x) = (A+(B-A)/(l+((C/x)AD)))]. Specific representative compounds tested in the binding assay were tested using the above FLIPR® assay. For instance, the following table shows the specific IC50 values for these compounds: Human CRTH2 FLIPR®
Example No.
ICso (μΜ)
1 0.114
2 0.3397
4 0.2548
5 0.581
8 0.0366
9 0.0061
23 0.0421
25 0.1232
29 0.0606
31 0.476
33 0.0292
34 4.3085
35 0.14
36 0.7835
37 0.214
41 >5
46 0.1877
Example 49
DK-PGD2-induced IL-13 production assay in Th2 cells
Inhibition of 13,14-dihydro-15-keto Prostaglandin D2 (DK-PGD2)-induced IL-13 production in T helper type 2 (Th2) cells was applied to evaluate compound cellular potency.
Cultures of Th2 cells were established from blood of healthy human volunteers according to the following procedure. Peripheral blood mononuclear cells (PBMC) were first isolated from 50 mL of fresh blood by Ficoll-Hypaque density gradient centrifugation, followed by CD4+ cell purification using a CD4+ T Cell Isolation Kit II (from Miltenyi Biotec Inc.). The CD4+ T cells were then differentiated to Th2 cells by culturing the cells in X-VIVO 15® medium (from Cambrex BioScience Walkersville Inc.) containing 10% human AB serum (serum of blood type AB from Invitrogen Corporation), 50 U/mL of recombinant human interleukin-2 (rhIL-2) (from PeproTech Inc.) and 100 ng/mL of recombinant human interleukin-4 (rhIL-4) (from PeproTech Inc.) for 7 days. The Th2 cells were isolated using a CD294 (CRTH2) MicroBead Kit (from Miltenyi Biotec Inc.) and amplified in X-VIVO 15® medium containing 10% human AB serum and 50 U/mL of rhIL-2 for 2 to 5 weeks. In general, 70% to 80% of the Th2 cells used in the assay are CRTH2-positive when analyzed by fluorescence- activated cell sorting using the BM16 antibody (as previously described) conjugated to phycoerythrin (PE). To determine cellular inhibitory potency, compounds at various concentrations were incubated with 2.5 x 104 Th2 cells and 500 nM DK-PGD2 for 4 hrs at 37 °C in 200 of X-VIVO 15® medium containing 10% human AB serum. IL-13 production to the medium was detected by ELISA (enzyme-linked immunosorbent assay) using an "Instant ELISA™" kit (from Bender MedSystems Inc.) according to the procedure suggested by the vendor. The spontaneous production of IL-13 by Th2 cells was determined in the absence of DK-PGD2 stimulation and the value was subtracted from that in the presence of each compound for percent inhibition and IC50
calculations. The percent inhibition of interleukin 13 (IL-13) production for a compound at various concentrations was calculated according to the following formula, [1 -(IL-13 production in the presence of compound)/(IL-13 production in the presence of 0.15% DMSO)]xl00. The IC50 value, defined as the concentration of a compound that is required for 50% inhibition of IL-13 production, was calculated by fitting the percent inhibition data for 7 concentrations to a sigmoidal dose-response (4 parameter logistic) model in the XLfit® software Excel add-in program [ID Business Solutions Ltd., model 205, where F(x) = (A+(B-A)/(l+((C/x)AD)))].
Representative compounds tested in the binding assay were tested using the foregoing DK-PGD2-induced IL-13 production assay (examples 1-1 to 1-9, 2-1, 3-1 to 3-3, 4-1 to 4-3, 5-1, 6-1, 7-1, 8-1, 9-1 to 9-3, 10-2, 10-5, and 10-6). The results of the DK- PGD2-induced IL-13 production assay showed that, with the exception of examples 1- 8 and 1-9 (which exhibited IC50 values greater than 10), the compounds tested in this assay exhibited activity in inhibiting IL-13 production, with IC50 values ranging from 0.0032 μΜ to 6.428 μΜ. Thus, the compounds of the present invention possess a specific, substantial and credible utility since the compounds tested show some activity in at least one of the above three assays (i.e., binding at the CRTH2 receptor), and therefore may be useful as antagonists in treating diseases and disorders associated with this receptor such as asthma.
Example 50
Human Thromboxane A2 Receptor Binding Assay The thromboxane A2 receptor (TP) plays a key role in hemostasis as its abnormality leads to bleeding disorders. To avoid the potential liability of bleeding disorders, the binding activity of certain compounds of the present invention against TP was monitored by a receptor binding assay using human platelets as the source of the receptor and [3H]SQ29548 (generically named (5Z)-[5,6-3H]-7-[(lS,2R,3R,4R)-3-[[2- [(phenylamino)carbonyl]hydrazinyl]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5- heptenoic acid, from PerkinElmer Inc.) as the competing radioactive ligand.
The TP binding reactions (0.2 mL) were performed in 96-well plates at room temperature in PBS containing 5 x 107 platelets, 10 mM MgCl2, 0.06% BSA, 10 nM [3H]SQ29548, and the test compound at various concentrations. After 1 hour of binding reactions, the platelets were harvested on GF/B filter plates (as previously described from PerkinElmer Inc.) and washed 5 times with PBS using a Filtermate™ Harvester (as previously described from PerkinElmer Inc.). The radioactivities bound to the platelets were determined using a microplate scintillation counter (TopCount® NXT, from PerkinElmer Inc.) after adding 50 of Micro scint™ 20 scintillation fluid (from PerkinElmer Inc.) to each well of the filter plates. The radioactivity from nonspecific binding was determined by replacing the compound with 10 μΜ of ramatroban (BAY-u3405, from Cayman Chemical Company) in the reaction mixtures. The radioactivity bound to the platelets in the absence of compound (total binding) was determined by replacing the compound with 0.25% of DMSO in the reaction mixture. Specific binding data were obtained by subtracting the radioactivity of nonspecific binding from each binding data.
The IC50 value is defined as the concentration of the tested compound that is required for 50% inhibition of total specific binding. In order to calculate the IC50 value, the percent inhibition data were determined for 7 concentrations for each compound. The percent inhibition for a compound at each concentration was calculated according to the following formula, [1 -(specific binding in the presence of compound)/(total specific binding)]xl00. The IC50 value was then obtained by fitting the percent inhibition data to a sigmoidal dose-response (4 parameter logistic) model in the
XLfit® software Excel add-in program [from ID Business Solutions Ltd., model 205, where F(x) - (A+(B-A)/(l+((C/x)AD)))].
The results of the thromboxane A2 receptor binding assay are summarized following table:
Figure imgf000131_0001
It is to be understood that the invention is not limited to the particular embodiments of the invention described above, as variations of the particular embodiments may be made and still fall within the scope of the appended claims.

Claims

Claims:
1. A compound of formula (I):
Figure imgf000132_0001
wherein:
Ar is: -phenyl, unsubstituted or mono- or bi-substituted independently with halogen, lower alkyl, -CF3, -SO2CH3, alkoxy, -C(0)CH3, unsubstituted heteroaryl or heteroaryl substituted with lower alkyl;
-biphenyl, unsubstituted or mono- or bi-substituted independently with -OH, lower alkyl, -SCH3 or -S02CH3; or
-pyridine, unsubstituted or substituted independently with unsubstituted phenyl or phenyl mono- or bi-substituted independently with lower alkyl, -CF3 or - CH2CH2OH; and
R1 is hydrogen or lower alkyl,
or a pharmaceutically acceptable salt thereof.
2. The compound according to claim 1, wherein Ar is phenyl, unsubstituted or mono- or bi-substituted independently with fluorine, chlorine, bromine, -CH(CH3)2, -CF3, - S02CH3, -OCH3, -C(0)CH3 or -pyridine-methyl.
3. The compound according to claim 1, wherein Ar is biphenyl, unsubstituted or mono- or bi-substituted independently with -CH3, -CH(CH3)2, -C(CH3)3, -OH, -SCH3 or - S02CH3.
4. The compound according to claim 1, wherein Ar is pyridine substituted independently with unsubstituted phenyl or phenyl mono- or bi-substituted independently with -CH3, -CH(CH3)2, -C(CH3)3, -CF3 or -CH2CH2OH.
5. The compound according to any one of claims 1 to 4, wherein R1 is hydrogen.
6. The compound according to any one of claims 1 to 4, wherein R1 is methyl.
7. The compound according to claim 1, wherein said compound is:
[5 - (3 , 5 -Bis -trifluoromethyl-benzenesulf onylamino) -6 ,7 , 8 ,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy] -acetic acid;
[5-(3,5-Dichloro-benzenesulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l- yloxy] -acetic acid;
[5-(Biphenyl-3-sulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy]-acetic acid;
[5-(Biphenyl-4-sulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l-yloxy]-acetic acid;
[5-(3-Methanesulfonyl-benzenesulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten- 1 -yloxy] -acetic acid;
[5-(3-Fluoro-5-trifluoromethyl-benzenesulfonylamino)-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy] -acetic acid;
{5-[(3-Fluoro-5-trifluoromethyl-benzenesulfonyl)-methyl-amino]-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy } -acetic acid;
[5-(3-Bromo-5-trifluoromethyl-benzenesulfonylamino)-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy] -acetic acid;
{5-[(3-Bromo-5-trifluoromethyl-benzenesulfonyl)-methyl-amino]-6,7,8,9-tetrahydro-5H- benzocyclohepten-l-yloxy}-acetic acid;
[5-(3,5-Bis-methanesulfonyl-benzenesulfonylamino)-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy] -acetic acid;
{5-[(3,5-Bis-methanesulfonyl-benzenesulfonyl)-methyl-amino]-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy } -acetic acid;
{5-[(Biphenyl-4-sulfonyl)-methyl-amino]-6,7,8,9-tetrahydro-5H-benzocyclohepten-l- yloxy} -acetic acid;
[5-(3-Methoxy-5-trifluoromethyl-benzenesulfonylamino)-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy] -acetic acid;
{5-[(3-Methoxy-5-trifiuoromethyl-benzenesulfonyl)-methyl-amino]-6,7,8,9-tetrahydro- 5H-benzocyclohepten- 1 -yloxy} -acetic acid;
[5-(3-Acetyl-5-trifluoromethyl-benzenesulfonylamino)-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy] -acetic acid;
{5-[(3-Acetyl-5-trifluoromethyl-benzenesulfonyl)-methyl-amino]-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy } -acetic acid;
[5-(3-Methanesulfonyl-5-trifluoromethyl-benzenesulfonylamino)-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy] -acetic acid;
{5-[(3-Methanesulfonyl-5-trifluoromethyl-benzenesulfonyl)-methyl-amino]-6,7,8,9- tetrahydro-5H-benzocyclohepten-l-yloxy}-acetic acid;
[5-(3'-Isopropyl-biphenyl-4-sulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l- yloxy] -acetic acid;
{5-[(3'-Isopropyl-biphenyl-4-sulfonyl)-methyl-amino]-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy } -acetic acid;
[5-(3'-tert-Butyl-5'-methyl-biphenyl-4-sulfonylamino)-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy] -acetic acid;
{5-[(3'-tert-Butyl-5'-methyl-biphenyl-4-sulfonyl)-methyl-amino]-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy } -acetic acid;
[5-(4'-Hydroxy-biphenyl-4-sulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l- yloxy] -acetic acid; {5-[(4'-Hydroxy-biphenyl-4-sulfonyl)-methyl-amino]-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy } -acetic acid;
{5-[4-(5-Methyl-pyridin-3-yl)-benzenesulfonylamino]-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy } -acetic acid;
(5-{Methyl-[4-(5-methyl-pyridin-3-yl)-benzenesulfonyl]-amino}-6,7,8,9-tetrahydro-5H- benzocyclohepten-l-yloxy)-acetic acid;
[5-(3'-Methylsulfanyl-biphenyl-4-sulfonylamino)-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy] -acetic acid;
{5-[Methyl-(3'-methylsulfanyl-biphenyl-4-sulfonyl)-amino]-6,7,8,9-tetrahydro-5H- benzocyclohepten-l-yloxy}-acetic acid;
[5-(3'-Methanesulfonyl-biphenyl-4-sulfonylamino)-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy] -acetic acid;
{5-[(3'-Methanesulfonyl-biphenyl-4-sulfonyl)-methyl-amino]-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy } -acetic acid;
{5-[5-(3-Isopropyl-phenyl)-pyridine-2-sulfonylamino]-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy } -acetic acid;
(5-{ [5-(3-Isopropyl-phenyl)-pyridine-2-sulfonyl]-methyl-amino}-6,7,8,9-tetrahydro-5H- benzocyclohepten-l-yloxy)-acetic acid;
{5-[5-(3-Trifluoromethyl-phenyl)-pyridine-2-sulfonylamino]-6,7,8,9-tetrahydro-5H- benzocyclohepten-l-yloxy}-acetic acid;
(5-{Methyl-[5-(3-trifluoromethyl-phenyl)-pyridine-2-sulfonyl]-amino}-6,7,8,9- tetrahydro-5H-benzocyclohepten- 1 -yloxy)-acetic acid;
{5-[5-(3-tert-Butyl-5-methyl-phenyl)-pyridine-2-sulfonylamino]-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy } -acetic acid;
(5-{ [5-(3-tert-Butyl-5-methyl-phenyl)-pyridine-2-sulfonyl]-methyl-amino}-6,7,8,9- tetrahydro-5H-benzocyclohepten- 1 -yloxy)-acetic acid;
(5-{5-[3-(2-Hydroxy-ethyl)-phenyl]-pyridine-2-sulfonylamino}-6,7,8,9-tetrahydro-5H- benzocyclohepten- l-yloxy)-acetic acid;
[5-({5-[3-(2-Hydroxy-ethyl)-phenyl]-pyridine-2-sulfonyl}-methyl-amino)-6,7,8,9- tetrahydro-5H-benzocyclohepten-l -yloxy] -acetic acid;
[5-(4'-Methyl-biphenyl-3-sulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l- yloxy] -acetic acid;
{5-[Methyl-(4'-methyl-biphenyl-3-sulfonyl)-amino]-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy } -acetic acid;
[5-(3'-Isopropyl-biphenyl-3-sulfonylamino)-6,7,8,9-tetrahydro-5H-benzocyclohepten-l- yloxy] -acetic acid;
{5-[(3'-Isopropyl-biphenyl-3-sulfonyl)-methyl-amino]-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy } -acetic acid;
[5-(3-Isopropyl-5-trifluoromethyl-benzenesulfonylamino)-6,7,8,9-tetrahydro-5H- benzocyclohepten- 1 -yloxy] -acetic acid; or
{5-[(3-Isopropyl-5-trifluoromethyl-benzenesulfonyl)-methyl-amino]-6,7,8,9-tetrahydro- 5H-benzocyclohepten- 1 -yloxy } -acetic acid.
8. A compound according to any one of claims 1 to 7 for use as a therapeutically active substance.
9. A pharmaceutical composition, comprising a therapeutically effective amount of a compound in accordance with any one of claims 1 to 7 and a therapeutically inert carrier.
10. The use of a compound according to any one of claims 1 to 7 for the treatment or prophylaxis of asthma or COPD.
11. The use of a compound according to any one of claims 1 to 7 for the preparation of a medicament for the treatment or prophylaxis of asthma or COPD.
12. A compound according to any one of claims 1 to 7 for the treatment or prophylaxis of asthma or COPD.
13. A method for the treatment or prophylaxis of asthma or COPD, which method comprises the step of administering an effective amount of a compound as defined in any one of claims 1 to 7 to a patient in need thereof.
14. The invention as hereinbefore described.
PCT/EP2012/060455 2011-06-06 2012-06-04 Benzocycloheptene acetic acids WO2012168162A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP2014514009A JP2014522407A (en) 2011-06-06 2012-06-04 Benzocycloheptene acetic acid
CA2837146A CA2837146A1 (en) 2011-06-06 2012-06-04 Benzocycloheptene acetic acids
EP12725741.8A EP2718264B1 (en) 2011-06-06 2012-06-04 Benzocycloheptene acetic acids
MX2013013849A MX2013013849A (en) 2011-06-06 2012-06-04 Benzocycloheptene acetic acids.
CN201280027840.6A CN103596925A (en) 2011-06-06 2012-06-04 Benzo cycloheptene acetic acids
RU2013154733/04A RU2013154733A (en) 2011-06-06 2012-06-04 DERIVATIVES OF BENZOCYCLOHEPTENE ACID ACID
KR1020137034448A KR20140041589A (en) 2011-06-06 2012-06-04 Benzocycloheptene acetic acids
BR112013030264A BR112013030264A2 (en) 2011-06-06 2012-06-04 benzocycloheptene acetic acids

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161493603P 2011-06-06 2011-06-06
US61/493,603 2011-06-06

Publications (1)

Publication Number Publication Date
WO2012168162A1 true WO2012168162A1 (en) 2012-12-13

Family

ID=46208519

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/060455 WO2012168162A1 (en) 2011-06-06 2012-06-04 Benzocycloheptene acetic acids

Country Status (10)

Country Link
US (1) US20120309796A1 (en)
EP (1) EP2718264B1 (en)
JP (1) JP2014522407A (en)
KR (1) KR20140041589A (en)
CN (1) CN103596925A (en)
BR (1) BR112013030264A2 (en)
CA (1) CA2837146A1 (en)
MX (1) MX2013013849A (en)
RU (1) RU2013154733A (en)
WO (1) WO2012168162A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6689821B2 (en) 2014-08-12 2020-04-28 シンジェンタ パーティシペーションズ アーゲー Pesticidally Active Heterocyclic Derivatives Bearing Sulfur-Containing Substituents
ES2806459T3 (en) 2015-04-24 2021-02-17 Syngenta Participations Ag Pesticidally active polycyclic derivatives with sulfur-substituted five-membered ring heterocycles
US10745396B2 (en) 2015-07-01 2020-08-18 Syngenta Participations Ag Pesticidally active polycyclic derivatives with sulfur containing substituents
US10202380B2 (en) 2015-07-01 2019-02-12 Syngenta Participations Ag Pesticidally active tetracyclic derivatives with sulfur containing substituents
WO2017201683A1 (en) 2016-05-25 2017-11-30 Merck Sharp & Dohme Corp. Substituted tetrahydroisoquinoline compounds useful as gpr120 agonists
WO2020011808A1 (en) 2018-07-13 2020-01-16 Syngenta Crop Protection Ag Pesticidally-active bicyclic heteroaromatic compounds
WO2020025658A1 (en) 2018-08-03 2020-02-06 Syngenta Crop Protection Ag Pesticidally-active bicyclic heteroaromatic compounds
AR118243A1 (en) 2019-03-07 2021-09-22 Pi Industries Ltd FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS PEST CONTROL AGENTS
AR120074A1 (en) 2019-08-20 2022-02-02 Pi Industries Ltd FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS PEST CONTROL AGENTS
WO2021144354A1 (en) 2020-01-15 2021-07-22 Syngenta Crop Protection Ag Pesticidally-active bicyclic heteroaromatic compounds

Citations (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3932440A (en) 1974-06-03 1976-01-13 American Cyanamid Company P-(1H-tetrazol-1-yl)-phenylcarbamates
US4454135A (en) 1983-01-04 1984-06-12 E. I. Du Pont De Nemours And Company Organotin insecticidal sulfonamides
US4521241A (en) 1983-09-19 1985-06-04 E. I. Du Pont De Nemours And Company Herbicidal benzenesulfonamides
US4857644A (en) 1988-06-09 1989-08-15 American Home Products Corporation Aryl sulfonopiperazines as anti-inflammatory agents
US4937350A (en) 1989-06-05 1990-06-26 The Dow Chemical Company Preparation of N-(-3(((aryl)amino)suldonyl)-1H-1,2,4-triazol-5-yl)amines
US4948827A (en) 1988-11-08 1990-08-14 Societe Francaise Hoechst Methyl-2-tertiary butyl-5-thiophenol, its preparation process and its use
US5072023A (en) 1990-02-15 1991-12-10 E. R. Squibb & Sons, Inc. Process for preparing highly substituted phenyls
US5436370A (en) 1990-03-03 1995-07-25 Hoechst Ag Process for the preparation of 3-nitrobenzenesulfonyl chloride
EP0861836A1 (en) * 1997-02-26 1998-09-02 Hoechst Aktiengesellschaft Sulfonamido substituted condensed, seven-membered ring compounds with potassium channel blocking activity
US6103708A (en) 1998-05-12 2000-08-15 American Home Products Corporation Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia
US6140505A (en) 1995-03-10 2000-10-31 G. D. Searle & Co. Synthesis of benzo fused heterocyclic sulfonyl chlorides
US6248766B1 (en) 1996-09-25 2001-06-19 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
US6355640B1 (en) 1993-12-29 2002-03-12 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine adenosine antagonists
US20020099035A1 (en) 2001-01-24 2002-07-25 Sandanayaka Vincent P. Method for preparing alpha-sulfonyl hydroxamic acid derivatives
US6433169B1 (en) 2000-09-26 2002-08-13 Dow Agrosciences Llc Process for the preparation of 2-alkoxy-6-trifluoromethyl-N-([1,2,4]triazolo[1,5-c]pyrimidin-2-yl) benzenesulfonamides
US6482824B1 (en) 1998-11-02 2002-11-19 Eli Lilly And Company Use of n-substituted (3,6-dihydro)-2h-1,2-oxazine derivatives as selective mglur1 antagonists
US20020198251A1 (en) 1999-08-09 2002-12-26 Bernd Sundermann Substituted 2-dialkylaminoalkylbiphenyl derivatives
WO2003002546A1 (en) 2001-06-29 2003-01-09 Bayer Chemicals Ag Supported condensation reactants and method for the production thereof
US6531605B1 (en) 1997-03-07 2003-03-11 Zeneca Limited Process for the manufacture of arylsulfonyl chloride
US20040019190A1 (en) 2000-05-25 2004-01-29 Erickson-Miller Connie J Thrombopoietin mimetics
US20050043354A1 (en) 2003-06-19 2005-02-24 Pfizer Inc NK1 antagonist
US20050234029A1 (en) 2002-07-31 2005-10-20 Nerina Dodic Compounds
WO2006013085A1 (en) 2004-08-06 2006-02-09 Roberto Pellicciari 4-sulfonyl-substituted benzoylalanine derivates useful as kynurenine-aminotransferase inhibitors
US7001917B2 (en) 2002-04-12 2006-02-21 Warner Lambert Company Llc Pyrazole compounds as anti-inflammatory and analgesic agents
JP2006063064A (en) 2004-07-27 2006-03-09 Takeda Chem Ind Ltd Receptor agonist
US7019175B2 (en) 2001-06-12 2006-03-28 Imperial Chemical Industries Plc Catalytic oxidation process
US20070027184A1 (en) 2005-07-29 2007-02-01 Kalypsys, Inc. Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
WO2007039578A1 (en) 2005-10-05 2007-04-12 Nycomed Gmbh Imidazolyl-substituted azabenzophenone compounds
WO2007057775A1 (en) 2005-11-21 2007-05-24 Pfizer Limited Spiropiperidine derivatives
US7288651B2 (en) 2003-08-08 2007-10-30 Janssen Pharmaceutica N.V. Preparation of quinoxaline compounds
WO2008030520A1 (en) 2006-09-07 2008-03-13 Amgen Inc. Heterocyclic gpr40 modulators
US20080146612A1 (en) 2005-01-27 2008-06-19 Astrazeneca Ab Novel Biaromatic Compounds, Inhibitors of the P2X7-Receptor
US20080153850A1 (en) 2004-08-30 2008-06-26 Astrazeneca Ab Adamantyl Derivates as P2x7 Receptor Antagonists
WO2008124524A2 (en) 2007-04-03 2008-10-16 Janssen Pharmaceutica N.V. Aryl sulfonamide compounds as modulators of the cck2 receptor
US7462617B2 (en) 2003-09-09 2008-12-09 Hoffmann-La Roche Inc. Substituted acylpiperazine derivatives
WO2008157751A2 (en) 2007-06-21 2008-12-24 Cara Therapeutics, Inc. Substituted imidazoheterocycles
WO2009023757A1 (en) 2007-08-15 2009-02-19 Allergan, Inc. Therapeutic compounds
WO2009071504A1 (en) 2007-12-03 2009-06-11 Smithkline Beecham Corporation 2,6-disubstituted pyridines as soluble guanylate cyclase activators
US20090203910A1 (en) 2007-12-14 2009-08-13 Roch Palo Alto Llc Deprotection of N-BOC compounds
US7579368B2 (en) 2005-03-16 2009-08-25 Hoffman-La Roche Inc. Cis-imidazolines
US20090270367A1 (en) 2004-03-09 2009-10-29 Elan Pharmaceuticals, Inc. Substituted hydroxyethylamine aspartyl protease inhibitors
WO2009147167A1 (en) 2008-06-06 2009-12-10 N.V. Organon Indane derivatives as ampa receptor modulators
WO2009158467A2 (en) 2008-06-25 2009-12-30 Envivo Pharmaceuticals, Inc. Di-substituted phenyl compounds
US20100029772A1 (en) 2005-10-21 2010-02-04 Stephan Bartel Dicarboxylic Acid Derivatives and their Use
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US20100041760A1 (en) 2008-08-15 2010-02-18 Jean-Baptiste Blanc Monoaryl aminotetralines
US20100041713A1 (en) 2008-08-15 2010-02-18 Fariborz Firooznia Substituted aminotetralines
WO2010018113A2 (en) * 2008-08-15 2010-02-18 F. Hoffmann-La Roche Ag Bi-aryl aminotetralines
US20100063281A1 (en) 2008-09-05 2010-03-11 So Ha Lee Diphenyl amine derivatives having luminescence property
US20100062465A1 (en) 2006-04-21 2010-03-11 Ronen Sabrina M Detection of Histone Deacetylase Inhibition
WO2010042475A1 (en) 2008-10-07 2010-04-15 Schering Corporation Spiroaminooxazoline analogues as alpha2c adrenergic receptor modulators
US7700625B2 (en) 2005-04-13 2010-04-20 Astex Therapeutics Ltd. Hydroxybenzamide derivatives and their use as inhibitors of Hsp90
WO2010048170A2 (en) 2008-10-21 2010-04-29 Board Of Regents Of The University Of Nebraska Fluorination of aromatic ring systems
WO2010059943A2 (en) 2008-11-20 2010-05-27 President And Fellows Of Harvard College Fluorination of organic compounds
US7737167B2 (en) 2004-08-05 2010-06-15 Neurosearch A/S 2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels
US20100184809A1 (en) 2006-08-29 2010-07-22 Phenex Pharmaceuticals Ag Heterocyclic FXR Binding Compounds
US20100210680A1 (en) 2007-09-17 2010-08-19 N.V. Organon Tricyclic heterocyclic derivatives
WO2010104818A1 (en) 2009-03-09 2010-09-16 Bristol-Myers Squibb Company Aza pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0372419A (en) * 1989-05-16 1991-03-27 Tanabe Seiyaku Co Ltd Reversal agent against thromboxane a2
IL104567A (en) * 1992-02-03 1997-03-18 Fujisawa Pharmaceutical Co Ethanolamine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
PE20020870A1 (en) * 2001-02-13 2002-11-18 Aventis Pharma Gmbh 6,7,8,9-TETRAHYDRO-5H-BENZOCYCLOHEPTENYL ACILATED AMINES
WO2008061006A1 (en) * 2006-11-10 2008-05-22 Wyeth Substituted indan-2-yl, tetrahydronaphthalen-2-yl, or dihydr0-2h-chr0men-3-yl arylsulfonamides and methods of their use

Patent Citations (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3932440A (en) 1974-06-03 1976-01-13 American Cyanamid Company P-(1H-tetrazol-1-yl)-phenylcarbamates
US4454135A (en) 1983-01-04 1984-06-12 E. I. Du Pont De Nemours And Company Organotin insecticidal sulfonamides
US4521241A (en) 1983-09-19 1985-06-04 E. I. Du Pont De Nemours And Company Herbicidal benzenesulfonamides
US4857644A (en) 1988-06-09 1989-08-15 American Home Products Corporation Aryl sulfonopiperazines as anti-inflammatory agents
US4948827A (en) 1988-11-08 1990-08-14 Societe Francaise Hoechst Methyl-2-tertiary butyl-5-thiophenol, its preparation process and its use
US4937350A (en) 1989-06-05 1990-06-26 The Dow Chemical Company Preparation of N-(-3(((aryl)amino)suldonyl)-1H-1,2,4-triazol-5-yl)amines
US5072023A (en) 1990-02-15 1991-12-10 E. R. Squibb & Sons, Inc. Process for preparing highly substituted phenyls
US5436370A (en) 1990-03-03 1995-07-25 Hoechst Ag Process for the preparation of 3-nitrobenzenesulfonyl chloride
US6355640B1 (en) 1993-12-29 2002-03-12 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine adenosine antagonists
US6140505A (en) 1995-03-10 2000-10-31 G. D. Searle & Co. Synthesis of benzo fused heterocyclic sulfonyl chlorides
US6248766B1 (en) 1996-09-25 2001-06-19 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
EP0861836A1 (en) * 1997-02-26 1998-09-02 Hoechst Aktiengesellschaft Sulfonamido substituted condensed, seven-membered ring compounds with potassium channel blocking activity
US6531605B1 (en) 1997-03-07 2003-03-11 Zeneca Limited Process for the manufacture of arylsulfonyl chloride
US6103708A (en) 1998-05-12 2000-08-15 American Home Products Corporation Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia
US6482824B1 (en) 1998-11-02 2002-11-19 Eli Lilly And Company Use of n-substituted (3,6-dihydro)-2h-1,2-oxazine derivatives as selective mglur1 antagonists
US20020198251A1 (en) 1999-08-09 2002-12-26 Bernd Sundermann Substituted 2-dialkylaminoalkylbiphenyl derivatives
US20040019190A1 (en) 2000-05-25 2004-01-29 Erickson-Miller Connie J Thrombopoietin mimetics
US6433169B1 (en) 2000-09-26 2002-08-13 Dow Agrosciences Llc Process for the preparation of 2-alkoxy-6-trifluoromethyl-N-([1,2,4]triazolo[1,5-c]pyrimidin-2-yl) benzenesulfonamides
US20020099035A1 (en) 2001-01-24 2002-07-25 Sandanayaka Vincent P. Method for preparing alpha-sulfonyl hydroxamic acid derivatives
US7019175B2 (en) 2001-06-12 2006-03-28 Imperial Chemical Industries Plc Catalytic oxidation process
WO2003002546A1 (en) 2001-06-29 2003-01-09 Bayer Chemicals Ag Supported condensation reactants and method for the production thereof
US7001917B2 (en) 2002-04-12 2006-02-21 Warner Lambert Company Llc Pyrazole compounds as anti-inflammatory and analgesic agents
US20050234029A1 (en) 2002-07-31 2005-10-20 Nerina Dodic Compounds
US20050043354A1 (en) 2003-06-19 2005-02-24 Pfizer Inc NK1 antagonist
US7288651B2 (en) 2003-08-08 2007-10-30 Janssen Pharmaceutica N.V. Preparation of quinoxaline compounds
US7462617B2 (en) 2003-09-09 2008-12-09 Hoffmann-La Roche Inc. Substituted acylpiperazine derivatives
US20090270367A1 (en) 2004-03-09 2009-10-29 Elan Pharmaceuticals, Inc. Substituted hydroxyethylamine aspartyl protease inhibitors
JP2006063064A (en) 2004-07-27 2006-03-09 Takeda Chem Ind Ltd Receptor agonist
US7737167B2 (en) 2004-08-05 2010-06-15 Neurosearch A/S 2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels
WO2006013085A1 (en) 2004-08-06 2006-02-09 Roberto Pellicciari 4-sulfonyl-substituted benzoylalanine derivates useful as kynurenine-aminotransferase inhibitors
US20080153850A1 (en) 2004-08-30 2008-06-26 Astrazeneca Ab Adamantyl Derivates as P2x7 Receptor Antagonists
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US20080146612A1 (en) 2005-01-27 2008-06-19 Astrazeneca Ab Novel Biaromatic Compounds, Inhibitors of the P2X7-Receptor
US7579368B2 (en) 2005-03-16 2009-08-25 Hoffman-La Roche Inc. Cis-imidazolines
US7700625B2 (en) 2005-04-13 2010-04-20 Astex Therapeutics Ltd. Hydroxybenzamide derivatives and their use as inhibitors of Hsp90
US20070027184A1 (en) 2005-07-29 2007-02-01 Kalypsys, Inc. Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
WO2007039578A1 (en) 2005-10-05 2007-04-12 Nycomed Gmbh Imidazolyl-substituted azabenzophenone compounds
US20100029772A1 (en) 2005-10-21 2010-02-04 Stephan Bartel Dicarboxylic Acid Derivatives and their Use
WO2007057775A1 (en) 2005-11-21 2007-05-24 Pfizer Limited Spiropiperidine derivatives
US20100062465A1 (en) 2006-04-21 2010-03-11 Ronen Sabrina M Detection of Histone Deacetylase Inhibition
US20100184809A1 (en) 2006-08-29 2010-07-22 Phenex Pharmaceuticals Ag Heterocyclic FXR Binding Compounds
WO2008030520A1 (en) 2006-09-07 2008-03-13 Amgen Inc. Heterocyclic gpr40 modulators
WO2008124524A2 (en) 2007-04-03 2008-10-16 Janssen Pharmaceutica N.V. Aryl sulfonamide compounds as modulators of the cck2 receptor
WO2008157751A2 (en) 2007-06-21 2008-12-24 Cara Therapeutics, Inc. Substituted imidazoheterocycles
WO2009023757A1 (en) 2007-08-15 2009-02-19 Allergan, Inc. Therapeutic compounds
US20100210680A1 (en) 2007-09-17 2010-08-19 N.V. Organon Tricyclic heterocyclic derivatives
WO2009071504A1 (en) 2007-12-03 2009-06-11 Smithkline Beecham Corporation 2,6-disubstituted pyridines as soluble guanylate cyclase activators
US20090203910A1 (en) 2007-12-14 2009-08-13 Roch Palo Alto Llc Deprotection of N-BOC compounds
WO2009147167A1 (en) 2008-06-06 2009-12-10 N.V. Organon Indane derivatives as ampa receptor modulators
WO2009158467A2 (en) 2008-06-25 2009-12-30 Envivo Pharmaceuticals, Inc. Di-substituted phenyl compounds
US20100041713A1 (en) 2008-08-15 2010-02-18 Fariborz Firooznia Substituted aminotetralines
US20100041714A1 (en) 2008-08-15 2010-02-18 Jean-Baptiste Blanc Bi-aryl aminotetralines
WO2010018112A2 (en) * 2008-08-15 2010-02-18 F. Hoffmann-La Roche Ag Monoaryl aminotetralines
WO2010018113A2 (en) * 2008-08-15 2010-02-18 F. Hoffmann-La Roche Ag Bi-aryl aminotetralines
US20100041760A1 (en) 2008-08-15 2010-02-18 Jean-Baptiste Blanc Monoaryl aminotetralines
US20100063281A1 (en) 2008-09-05 2010-03-11 So Ha Lee Diphenyl amine derivatives having luminescence property
WO2010042475A1 (en) 2008-10-07 2010-04-15 Schering Corporation Spiroaminooxazoline analogues as alpha2c adrenergic receptor modulators
WO2010048170A2 (en) 2008-10-21 2010-04-29 Board Of Regents Of The University Of Nebraska Fluorination of aromatic ring systems
WO2010059943A2 (en) 2008-11-20 2010-05-27 President And Fellows Of Harvard College Fluorination of organic compounds
WO2010104818A1 (en) 2009-03-09 2010-09-16 Bristol-Myers Squibb Company Aza pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists

Non-Patent Citations (63)

* Cited by examiner, † Cited by third party
Title
ALONSO, F.; BELETSKAYA, I. P.; YUS, M., TETRAHEDRON, vol. 64, 2008, pages 3047 - 3101
ANDERSON, K. ET AL., J. AM. CHEM. SOC., vol. 128, 2006, pages 10694 - 10695
ANDREWS, S. P.; LADLOW, M., J. ORG. CHEM., vol. 68, 2003, pages 5525 - 5533
ARDUINI, A. ET AL., TETRAHEDRON LETT., vol. 44, 2003, pages 5755 - 5757
BAKER, R. H. ET AL., J. AM. CHEM. SOC., vol. 68, 1946, pages 2636 - 2639
BARRY, W. J.; FINAR, I. L., J. CHEM. SOC., 1954, pages 138 - 140
BAUDOIN, O. ET AL., J. ORG. CHEM., vol. 65, 2000, pages 9268 - 9271
BAUM, J. C. ET AL., CAN. J. CHEM., vol. 68, 1990, pages 1450 - 1455
BHANDARI, K. ET AL., BIOORG. MED. CHEM., vol. 12, 2004, pages 4189 - 4196
C. BINISTI, C. ET AL., EUR. J. MED. CHEM., vol. 36, 2001, pages 809 - 828
CHAN, M. F. ET AL., BIOORG. MED. CHEM., vol. 6, 1998, pages 2301 - 2316
CHERNEY, R. J. ET AL., J. MED. CHEM., vol. 46, 2003, pages 1811 - 1823
CLAWSON, R. W., JR. ET AL., TETRAHEDRON, vol. 65, 2009, pages 8786 - 8793
CONCEICAO, C. M. M. ET AL., J. CHEM. RES., 1995, pages 347
CORNELIUS, L. A. M.; COMBS, D. W., SYNTH. COMMUN., vol. 24, 1994, pages 2777 - 2788
COSMI, L. ET AL., EUR J IMMUNOL, vol. 30, 2000, pages 2972 - 2979
CRICH, D.; SHARMA, I., ANGEW. CHEM. INTL. EDN., vol. 121, 2009, pages 7727 - 7730
DERDAU, V. ET AL., J. ORG. CHEM., vol. 68, 2003, pages 5168 - 5173
EWING, W. R. ET AL., J. MED. CHEM., vol. 42, 1999, pages 3557 - 3571
FARINA, V. ET AL., ORG. REACTIONS, vol. 50, 1997, pages 1 - 652
GERVAIS, F. G. J., ALLERGY CLIN. IMMUNOL., vol. 108, 2001, pages 982 - 988
GIMENO, N. ET AL., ANGEW. CHEM. INT. EDN., vol. 43, 2004, pages 5235 - 5238
GOODACRE, S. C. ET AL., J. MED. CHEM., vol. 49, 2006, pages 35 - 38
GROSS, M. F. ET AL., BIOORG. MED. CHEM. LETT., vol. 19, 2009, pages 3063 - 3066
GRUBER, R. ET AL., BULL. CHEM. SOC. FRANCE, 1983, pages 96 - 104
GUIANVARC'H, D. ET AL., J. MED. CHEM., vol. 47, 2004, pages 2365 - 2374
GWALTNEY, S. L. ET AL., BIOORG. MED. CHEM. LETT., vol. 11, 2001, pages 871 - 874
HAMADA, T.; YONEMITSU, O., SYNTHESIS, 1986, pages 852 - 854
HIRAI, H. ET AL., J. EXP. MED., vol. 193, 2001, pages 255 - 26 1
HIRASHIMA, S. ET AL., J. MED. CHEM., vol. 49, 2006, pages 4721 - 4736
HOWBERT, J. J.; CROWELL, T. A., SYNTHETIC COMMUN., vol. 20, 1990, pages 3193 - 3195
HUANG, J.-L. ET AL., HUM. MOL. GENET., vol. 13, 2004, pages 2691 - 2697
ISAAD, J. ET AL., EUR. J. ORG. CHEM., 2009, pages 2748 - 2764
IVACHTCHENKO, A. V. ET AL., EUR. J. MED. CHEM., vol. 45, 2010, pages 782 - 789
LIMA, L. M. ET AL., BIOORG. MED. CHEM., vol. 10, 2002, pages 3067 - 3073
LITTKE, A. F. ET AL., J. AM. CHEM. SOC., vol. 124, 2002, pages 5343 - 6348
MAILYAN, A. K. ET AL., J. ORG. CHEM., vol. 74, 2009, pages 8444 - 8447
MATSUMOTO, T. ET AL., CHEM. LETT., 1988, pages 1399 - 1402
MIYAURA, N.; SUZUKI, A., CHEM. REV., vol. 95, 1995, pages 2457 - 2483
MORIKAWA, A. ET AL., J. MED. CHEM., vol. 32, 1989, pages 42 - 46
N. IKEMOTO, N. ET AL., TETRAHEDRON, vol. 59, 2003, pages 1317 - 1325
NAGATA, K. ET AL., FEBS LETT., vol. 459, 1999, pages 195 - 199
PAL, M. ET AL., J. MED. CHEM., vol. 46, 2003, pages 3975 - 3984
PERCEC, V. ET AL., J. ORG. CHEM., vol. 66, 2001, pages 2104 - 2117
QIAN, X. ET AL., ACS MED. CHEM. LETT., vol. 1, 2010, pages 30 - 34
QIN, Z. ET AL., J. MED. CHEM., vol. 50, 2007, pages 2682 - 2692
RAETH, C., LIEBIGS ANN. CHEM., vol. 487, 1931, pages 105 - 119
RAJU, B. ET AL., BIOORG. MED. CHEM. LETT., vol. 7, 1997, pages 939 - 944
SCHMIDT, A.; RAHIMI, A., CHEM. COMMUN., vol. 46, 2010, pages 2995 - 2997
STURINO, C. F. ET AL., J. MED. CHEM., vol. 50, 2007, pages 794 - 806
SUGIMOTO, EUR. J. PHARMACOL., vol. 524, 2005, pages 30 - 37
T. W. GREENE; P. G. M. WUTS: "Protective Groups in Organic Synthesis, 2nd Edition,", 1991, JOHN WILEY & SONS
TAMURA, Y. ET AL., J. MED. CHEM., vol. 41, 1998, pages 640 - 649
TIEDE, S. ET AL., ANGEW. CHEM. INTL. EDN., vol. 49, 2010, pages 3972 - 3975
TOBISU, M. ET AL., J. ORG. CHEM., vol. 75, 2010, pages 4835 - 4840
VEDEJS, E. ET AL., J. ORG. CHEM., vol. 65, 2000, pages 2309 - 2318
WAGMAN, A. S. ET AL., J. ORG. CHEM., vol. 65, 2000, pages 9103 - 9113
WANG, X. ET AL., ORG. LETT., vol. 11, 2009, pages 5490 - 5493
WU, C., J. ORG. CHEM., vol. 63, 1998, pages 2348 - 2350
XUE, L. ET AL., J. IMMUNOL., vol. 175, 2005, pages 6531 - 6536
YATES, C. M. ET AL., J. MED. CHEM., vol. 53, 2010, pages 4531 - 4544
YOSHIMURA-UCHIYAMA, C. ET AL., CLIN. EXP. ALLERGY, vol. 34, 2004, pages 1283 - 1290
ZBRUYEV, A. I ET AL., TETRAHEDRON, vol. 63, 2007, pages 4297 - 4303

Also Published As

Publication number Publication date
KR20140041589A (en) 2014-04-04
MX2013013849A (en) 2014-01-20
BR112013030264A2 (en) 2018-08-28
EP2718264A1 (en) 2014-04-16
CA2837146A1 (en) 2012-12-13
US20120309796A1 (en) 2012-12-06
RU2013154733A (en) 2015-07-20
JP2014522407A (en) 2014-09-04
CN103596925A (en) 2014-02-19
EP2718264B1 (en) 2015-08-05

Similar Documents

Publication Publication Date Title
EP2718264B1 (en) Benzocycloheptene acetic acids
US8263656B2 (en) Substituted aminotetralines
US8163781B2 (en) Bi-aryl aminotetralines
CA2511214C (en) Asthma and allergic inflammation modulators
TWI409247B (en) 4-substituted phenoxyphenylacetic acid derivatives
ES2386948T3 (en) Aminotetrahydroindazoloacetic acids
US8642629B2 (en) Naphthylacetic acids
WO2000039088A1 (en) Glucagon antagonists/inverse agonists
EP2307382A1 (en) Aminotetrahydroindazoloacetic acids
TW201022197A (en) Naphthylacetic acids
Buckingham et al. Oxidative fluorination of N-arylsulfonamides
EP2231595B1 (en) Phenyl acetic acid derivatives as inflammation modulators
KR100929996B1 (en) Styrylsulfonamides, preparations thereof, and use as pharmaceutical preparations
US9000044B2 (en) Substituted naphthylacetic acids

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12725741

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2012725741

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2837146

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2013/013849

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2014514009

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20137034448

Country of ref document: KR

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013030264

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2013154733

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112013030264

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20131126